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 Abstract 
The aims of this study were firstly, to investigate the role of growth hormones: 
insulin-like growth factor (IGF-I), epidermal growth factor (EGF) and heregulin-1 
(HRG) on the anchorage-independent survival and migration of oestrogen non-
responsive breast cancer cells. Secondly, the effects of inhibition of the type I 
IGF receptor (IGF-IR), EGF receptor (EGFR) and human epidermal growth 
factor receptor 2 (HER-2) were studied. Thirdly, the expression of IGF-IR, 
EGFR, HER-2, TFF1 and TFF3 was assessed in oestrogen receptor-negative 
breast tumours and involved lymph node metastases, and associations with 
biomarkers of cell survival and proliferation analysed. 
IGFs and EGFs contribute to the growth, survival and metastasis of malignant 
cells and inhibitors of IGF-IR and EGFR are in clinical trials. IGF and EGF 
signal transduction pathways are proposed to be important in oestrogen non-
responsive, HER-2 positive and triple-negative breast cancers. The effects of 
IGF and EGF on anchorage-independent cell survival and cell migration have 
not been investigated thoroughly.  
An in vitro model of anoikis was developed for triple-negative MDA-MB-231, 
Hs578T and HER-2 positive SK-BR-3 breast cancer cells. For the first time, an 
anti-anoikis effect of IGF-1 was demonstrated in triple-negative breast cancer 
cells. The survival effect of IGF-1 was shown to be via activation of the IGF-IR. 
EGF and HRG were protective against anoikis in oestrogen receptor-negative 
breast cancer cells. The protective effect of EGF was mediated through EGFR. 
IGF-1, EGF and HRG demonstrated powerful migratory effects on oestrogen 
non-responsive breast cancer cells and the inhibition of IGF-IR and EGFR in 
these cells reduced the cell migration. The combination of IGF-1 and EGF 
induced more cell migration than either ligand alone. IGF-IR, EGFR and HER-2 
were expressed in oestrogen receptor-negative breast primary tumours, and 
expression of IGF-IR and EGFR was associated with biomarkers of cell survival 
and proliferation. Expression of TFF3 was detected at higher levels than TFF1 
in both in situ and invasive breast tumours and was associated significantly with 
expression of HER-2 in invasive breast tumours.  
ii 
 
Overall, these results demonstrated the importance of different growth factors 
alone and in combination in oestrogen non-responsive breast cancer. Further 
investigation of the potential of targeting the metastatic progression of 
oestrogen non-responsive breast cancer via the IGF and EGF signal 
transduction pathways is merited.  
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Chapter 1. Introduction 
 
1.1 Histology of the normal breast  
In the human, there is a single pair of mammary glands, one on the right and 
one on left side of the body situated anatomically over the pectoral muscles of 
the chest wall and suspended from the anterior chest wall with the help of the 
fibrous strands called cooper ligaments. Each mammary gland consists of one 
conical elevated area called the nipple which has small pores of 0.5 mm in 
diameter. The nipple is surrounded by moderately thin skin called areola which 
has more melanin than other parts of the breast. The structure of the breast is 
the same in males and females before puberty. After puberty the structure of 
female breast undergoes drastic changes due to an increase in the circulatory 
concentrations of ovarian hormones. This increases growth and development of 
the ductal-lobular system and the tendency of adipose tissue to accumulate in 
inter-lobular stroma of the breast (Luis Carlos Junqueira 2003).  
Each human breast consists of 15 to 25 lobes that encircle the nipple and are 
separated from each other by inter-lobar connective tissue. Each lobe 
comprises numerous smaller lobes, called lobules or terminal duct lobular units 
which are open to the nipple through their own lactiferous ducts that transport 
milk from the lobules to the nipple (Figure 1.1 A). The ducts are lined by two 
layers: an inner columnar or cuboidal epithelial layer and an outer contractile 
myoepithelial cell layer (Figure 1.1 C) (Robbins 2010).  
Throughout the menstrual cycle, the normal breast undergoes morphological 
changes. During the premenstrual phase, when oestrogen reaches to its peak 
level, the size of ductal epithelial cells increases and they become more 
columnar in shape. This growth is followed by swelling of the connective tissue 
and the breast become slightly larger than it is in the rest of the cycle (Robbins 
2010). The structure and function of the normal breast change dramatically 
throughout pregnancy and lactation. These variations stem from the synergic 
actions of the ovarian hormones, particularly oestrogen, progesterone, prolactin 
and human placental lactogen. The breast increases in size due to growth and 
proliferation of the lactiferous ducts and conversion of the blunt-ended lobules 
into secretory spherical alveoli. During lactation, the alveoli produces milk, 
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whereas with termination of breast-feeding, the majority of the alveoli 
degenerate and cells are eliminated through apoptosis. 
 
Figure 1.1: Structure of the human breast. The diagram represent that mammary gland 
contains numerous of lobes which formed a several smaller tubule-alveolar units called lobules. 
The lobes open separately to the nipple through lactiferous ducts that slightly widen to form 
lactiferous sinuses. Connective tissues called suspensory ligaments supports the breasts and 
connect the breast tissues to the dermis of the overlying skin (A). Haematoxylin and eosin 
stained section shows that the each lobule divided into several terminal ductules (B). The 
terminal ductules are lined by an inner columnar epithelium and an outer contractile 
myoepithelial cell layer (C). 
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1.2 Breast cancer  
1.2.1 Epidemiology of breast cancer   
Breast cancer is one of the most common cancers diagnosed amongst women 
and is the leading cause of female mortality worldwide. It is estimated that over 
1.7 million women were diagnosed with breast cancer and more than 520,000 
cases succumb in 2012 (GLOBOCON 2012). Breast cancer incidence and 
mortality rates are variable globally. The highest incidence rates are in 
developed countries, whereas lower rates are found in under-developed or 
developing countries (Figure 1.2) (Boyle and Ferlay 2005). It has been reported 
that, in recent years, the rate of breast cancer mortality has declined noticeably 
in developed countries (Jemal, Center et al. 2010). This decline could be due to 
an increase in awareness, improvements in treatment, more accurate and early 
diagnosis which includes implementation of screening programmes with 
mammography, development of adjuvant therapies and reduction in the use of 
hormonal replacement therapy (Glass, Lacey et al. 2007). 
 
Figure 1.2: Incident and mortality rates of breast cancers worldwide in 2012. Adapted from 
GLOBOCON 2012.  
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In the UK, breast cancer is the commonest female malignancy. It is estimated 
that the lifetime risk of developing breast cancer is 1 in 8 for women (CRUKa 
2012). The incidence of breast cancer in women has increased by 6% in the 
last ten years but the mortality rates have fallen by approximately a fifth in UK. 
In 2010, 49,961 new cases of breast cancer were diagnosed, which equals 136 
women each day. Almost 1,200 death cases of breast cancer were amongst 
women under age of 50 (Jemal, Center et al. 2010).  
1.2.2 Risk factors of breast cancer  
Epidemiologic studies have identified many risk factors that might be associated 
with developing breast cancer. Gender is one of the most important risk factors 
for breast cancer. The majority of people who develop this disease are women. 
Breast cancer risk is highly related to age. The risk of developing breast cancer 
is higher with increasing age. It is estimated that more than 75% of women who 
are diagnosed with breast cancer are above age 50 (Key, T. J. 2001)  
Women with early age at menarche, late menopause and delayed first 
pregnancy are more prone to develop breast cancer. It is estimated that the risk 
of developing breast cancer decreases by about 5% with every one year delay 
in menarche and increases by 3% for each year’s delay in menopause. Other 
variable menstrual factors, such as length or irregularity of the cycle do not have 
an influence on risk of breast cancer (CRUKa 2012, Key, T. J. 2001). 
Childbearing at early ages around 20 years or younger protects a woman 
against breast cancer. There is evidence that the risk of breast cancer 
increases by 3% for every one year delay in pregnancy. The risk of breast 
cancer in women, who breastfeed for longer duration is lower, compared to 
those who had shorter duration or who never breastfed (Key, T. J. 2001).  
There is an association between serum concentrations of endogenous 
hormones and risk of developing breast cancer. The higher the level of 
hormones, the higher the risk of breast cancer is. The risk of breast cancer is 
two times higher in postmenopausal women who have higher levels of 
oestrogen compared to those with a lower level of this hormone (Key, Appleby 
et al. 2002). The risk of breast cancer is relatively higher in women who are 
exposed to exogenous hormones including oral contraceptives and hormonal 
replacement therapy. The risk of breast cancer increases in current 
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contraceptive users by 24%, but this rate abates after cessation (Key, 
Verkasalo et al. 2001, Gierisch, Coeytaux et al. 2013). Hormonal replacement 
therapy increases the risk of breast cancer by 66% in women who are current 
users of hormonal replacement therapy. It has been reported that the risk is 
higher for users of combined oestrogen and progesterone therapy compared to 
oestrogen alone (Chlebowski, Manson et al. 2013). The majority of breast 
cancers are sporadic and only small percentage are caused by inherited 
mutations. Women who carry breast cancer associated susceptibility gene (1, 2) 
BRCA1 and BRCA2 mutant genes have a 45-56% increased risk of developing 
breast cancer by the age of 70 (Antoniou, Pharoah et al. 2003). Several studies 
on familial history of breast cancer show that the risk is approximately double in 
women with affected first-degree relatives, compared to those with no family 
background. However, over 85% of women with breast cancer do not have any 
hereditary predisposition, and more than 85% of women who have a familial 
history do not develop breast cancer (Key, T. J.2001,The lancet 2001).  
Epidemiological studies have shown that life style and environmental factors 
such as bodyweight, physical activity, consumption of alcohol or dietary intake 
have significant impact on breast cancer incidence. There is a strong 
association between consumption of alcohol and chance of developing breast 
cancer. Obesity is another risk factor for breast cancer. In postmenopausal 
women obesity is one of the risk factors that increases the chance of breast 
cancer development due to the endogenous synthesis of oestrogen hormone in 
fatty tissues (Key, Verkasalo et al. 2001). 
1.3 Different histological types of breast cancer  
The majority of malignant breast tumours are adenocarcinomas which arise 
from the epithelial lining of the mammary lobular and ductal system (Dreyer, 
Vandorpe et al. 2013). Breast tumours can be categorized as non-invasive or 
invasive carcinomas. Based on the histological morphology, both non-invasive 
and invasive carcinomas of the breast are further classified into ductal or lobular 
carcinomas.  
1.3.1 Non-invasive carcinoma (carcinoma in situ) 
If the malignant cells stay within the myoepithelial cells of the ductal or lobular 
system and do not invade the adjacent stroma, they are referred as non-
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invasive or in situ carcinomas. There is a chance of developing invasive breast 
carcinoma from non-invasive lesions if they are not treated. In general, non-
invasive carcinoma can be divided into two subgroups: ductal carcinoma in situ 
(DCIS) and lobular carcinoma in situ (LCIS) (Fabbri, Carcangiu et al. 2008). 
1.3.1.1 Ductal carcinoma in situ (DCIS) 
Ductal carcinoma in situ is reported as a heterogeneous lesion which is known 
as the most common type of non-invasive malignancy (Holland, Peterse et al. 
1994, Fabbri, Carcangiu et al. 2008). Ductal carcinoma in situ can be classifed 
on the basis of architectural characteristics into different types of comedo, 
cribriform, solid, papillary and micropapillary (Figure 1.3). According to the 
cytological pattern, it can be classified as a low, intermediate and high grade 
tumour. Comedo ductal carcinoma in situ is made up of large cells with irregular 
shapes and contains a high level of central necrosis and large numbers of the 
mitotic figures. Ductal carcinoma in situ comedo type is referred as a high grade 
tumour due to its poor differentiation and has a more aggressive nature (Figure 
1.3 A). If the tumour cells have a solid pattern sheet in appearance, they are 
called as solid ductal carcinoma in situ (Figure 1.3 C), whereas, if they have 
space in between the cells, they are referred to as cribriform ductal carcinoma 
in situ (Figure 1.3 B) and if they form a finger-like structure, they are termed 
micropapillary ductal carcinoma in situ (Figure 1.3 D, E) (Vinay Kumar 2004, 
Fabbri, Carcangiu et al. 2008).  
 
Figure 1.3: Histology of different types of ductal carcinoma in situ. High-grade comedo (A), 
low-grade cribriform (B), low-grade solid (C), low-grade micropapillary (D), low-grade papillary 
(E).  
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1.3.1.2 Lobular carcinoma in situ (LCIS) 
Lobular carcinoma in situ is a growth and division of malignant cells within the 
lobules which has not yet penetrated into the myoepithelial cells. Women with 
this type of carcinoma have an increased chance of developing invasive 
carcinoma. In lobular carcinoma in situ, affected lobules are enlarged and filled 
with small uniform cohesive cells that contain small round nuclei (Figure 1.4). 
Usually this type of carcinoma is oestrogen receptor and progesterone receptor 
positive (Vinay Kumar 2004, Fabbri, Carcangiu et al. 2008).  
 
Figure 1.4: Histology of lobular carcinoma in situ. The photo micrograph illustrates the 
growth of tumour cells inside the lobules without infiltration to outside the lobular wall. 
 
1.3.2 Invasive carcinoma 
When cancerous epithelial tumours break through the myoepithelial cells and 
invade into the surrounding normal stroma it is referred as invasive carcinoma. 
Invasive carcinoma can be subdivided into invasive ductal carcinoma and 
invasive lobular carcinoma (Vinay Kumar 2004, Fabbri, Carcangiu et al. 2008). 
1.3.2.1 Invasive ductal carcinoma (IDC)  
Invasive ductal carcinoma (IDC) of no specific type is the most prevalent type of 
breast cancer, and comprises 70% of all invasive breast carcinomas (Dreyer, 
Vandorpe et al. 2013). The tumours do not have any particular macroscopic 
characteristics to achieve a more specific histological classification. They arise 
from cells within the breast lobular and ductal system followed by penetration of 
myoepithelial cell layer and spread into the surrounding connective and fatty 
tissues (Figure 1.5).There is a chance that they will metastasise to different 
parts of the body via the lymphatic system or bloodstream. About 80% of 
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invasive ductal carcinomas are oestrogen receptor positive and around 15 to 
30% express HER-2 (Vinay Kumar 2004, Fabbri, Carcangiu et al. 2008). 
 
Figure 1.5: Histology of invasive ductal carcinoma. The image illustrates the infiltration of 
cancerous cells outside of the duct through the stroma.  
 
1.3.2.2 Invasive lobular carcinoma (ILC)  
Invasive lobular carcinoma is the second most prevalent malignancy after 
invasive ductal carcinoma. Morphologically, invasive lobular carcinoma cells 
have an unclear tumour margin. Their nuclei appear to be round or irregular 
ovoid (Figure 1.6). Approximately 70 to 90% of invasive lobular carcinomas are 
oestrogen and progesterone receptor positive (Vinay Kumar 2004, Fabbri, 
Carcangiu et al. 2008). 
 
Figure 1.6: Histology of invasive lobular carcinoma. Tumour cells can appear as single file 
linear pattern in fibrous stroma. 
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1.4 Molecular classification of breast cancer 
Breast cancer is a heterogeneous disease and exhibits diverse clinical and 
morphological characteristics. Molecular profiling of breast cancer based on the 
expression of the genes, has classified breast cancer into two main groups of 
oestrogen receptor-positive and oestrogen receptor-negative tumours. It can be 
sub-classified further into five different subtypes: luminal A, luminal B, HER-2 
positive, triple-negative or basal-like tumours and normal-like breast tumours 
(Figure 1.7) (Perou, Sorlie et al. 2000, Rakha, Reis-Filho et al. 2008). In 
addition, in more recent studies, a new subtype has been identified which is 
called the ‘‘claudin-low’’ subtype (Malhotra, Zhao et al. 2010, Prat, Parker et al. 
2010). Another recent study reported the 10 novel subgroups of breast cancer. 
In this study, breast cancer classification was based on the cluster analysis of 
genome and transcriptome expression (Curtis, Shah et al. 2012) and identified 
further molecular subgroups of breast cancer which are proposed to specify the 
therapeutic intervention for each breast cancer subtypes.  
 
Figure 1.7: Molecular classification of breast cancer. This classification is on the basis of 
cDNA expression microarray analysis. Taken from (Malhotra, Zhao et al. 2010). 
 
Luminal A tumours express an oestrogen receptor-related gene cluster, have a 
low proliferation rate, low expression level of Ki-67 protein and are negative for 
expression of HER-2 (Rakha, Reis-Filho et al. 2008). Luminal A tumours have 
the best prognosis. Tumours of the luminal B subtypes also express an 
oestrogen receptor-related gene cluster but have high proliferation rate, as have 
high level of expression of Ki-67 and are positive for expression of HER-2. 
HER-2 enriched subtype does not express the oestrogen receptor-related gene 
cluster, belongs to the luminal groups, but overexpresses HER-2. HER-2 
overexpression in tumour cells is identified as poor prognosis (Eroles, Bosch et 
9 
 
al. 2012). Basal-like tumours do not express luminal or HER-2 related genes, 
but express cytokeratin 5 and 6 (CK 5/6) and epidermal growth factor receptor 
(EGFR) (Nielsen, Hsu et al. 2004). They are categorised as triple-negative 
tumour subtype, as they do not express oestrogen receptor, progesterone 
receptors or HER-2. Triple-negative tumours and basal-like tumours are 
categorised as one group, due to many common characteristics shared 
between them. Data from immunohistochemical analysis, molecular features 
and prognosis suggests that all triple-negative tumours are not necessarily 
basal-like tumours or vice versa. A discordance of up to 30% has been reported 
and according to microarray-based expression analysis, up to 15-45% in basal-
like tumours express one of the oestrogen or progesterone receptors or HER-2 
(Rakha, Reis-Filho et al. 2008, O'Brien, Cole et al. 2010) 
Although relatively fewer patients have triple-negative breast cancer, it has the 
highest rate of mortality, particularly in younger women less than 50 years of 
age. Compared to other molecular subtypes, triple-negative breast cancer is 
more aggressive and more prevalent among black African American or British 
black women (Bowen, Duffy et al. 2008). This can be deduced from the 
observation that the risk of recurrence is more frequent during the first and third 
years and that the mortality rate is highest in the first five years of therapy. 
Recently, researches based on gene expression profiling, classified triple-
negative breast cancer in to six different subtypes; two basal-like BL1 and BL2 
subtypes, mesenchymal, M and mesenchymal-stem like subtype ML, an 
immunomodulatory and lastly a luminal androgen receptor-positive subgroup 
(Chen, Li et al. 2012).  The mainstay of triple-negative breast cancer treatment 
is conventional chemotherapy; therefore, identification of therapeutic target for 
these tumours is a priority.  
Based on the gene expression analysis, in year 2007,  a new claudin-low 
subgroup of tumours was identified (Herschkowitz, Simin et al. 2007). The 
majority of claudin-low tumours are identified as poor prognosis. On hierarchical 
clustering, claudin-low subtype is located close to the basal-like tumours, as 
they share expression profiles of some characteristic genes including low 
expression of oestrogen or progesterone receptors or HER-2 and luminal 
epithelial genes. Claudin-low tumours are also characterized by high expression 
of epithelial to mesenchymal transition markers, cancer stem cell-like features 
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and immune response genes (Prat, Parker et al. 2010). Histologically, claudin-
low tumours are high grade infiltrating ductal carcinomas with high proportion of 
metaplastic differentiation (Prat, Parker et al. 2010, Eroles, Bosch et al. 2012).  
Normal-like breast tumours express high level of gene characteristics of non-
epithelial cells such as adipose cells and express low level of luminal epithelial 
cell genes. Significantly these breast cancer subgroups have the best prognosis 
(Gluz, Liedtke et al. 2009). 
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1.5 Treatment options for breast cancer 
1.5.1 Surgical treatment for early breast cancer 
Surgery is the main treatment for breast cancer when the tumour is localized to 
the breast and local lymph nodes. The primary tumour is removed either by 
wide local excision (lumpectomy) or mastectomy. However, on some occasions 
prior to the lumpectomy, chemotherapy is administrated as neoadjuvant 
treatment to shrink larger tumours. The status of regional axillary lymph node is 
assessed by sentinel lymph node biopsy or lymph node dissection (MD 2009). 
Surgery is followed by systemic therapies called adjuvant therapies which aim 
to eliminate any residual malignant cells. These adjuvant therapies are: 
radiotherapy, adjuvant endocrine therapy, molecular targeted therapies such as 
trastuzumab and cytotoxic therapy.    
1.5.2 Radiotherapy 
Radiation therapy is one of the adjuvant treatments for patients who have 
undergone a lumpectomy or mastectomy operation. Radiotherapy involves the 
application of high energy X-rays or other types of irradiation to the chest wall or 
to the lymph node draining region. Post-mastectomy radiotherapy can decrease 
the risk of loco-regional recurrence in the affected breast through removing 
microscopic disease that remains in the breast after mastectomy. It helps in 
increasing the overall survival rate in patients with high risk breast cancer 
(Vilarino-Varela, Chin et al. 2009). It has been reported that oestrogen receptor-
positive patients benefit more from radiotherapy than oestrogen receptor-
negative and triple-negative breast cancer patients (NCI Cancer Bulletin). 
1.5.3 Systematic treatment of breast cancer  
The aim of systemic treatment is to eradicate metastatic disease. 
Chemotherapy and hormonal therapy and other targeted therapies are different 
types of systemic therapies. These systemic treatments can be applied to 
patient either as neoadjuvant therapy which is given prior to the surgery or as 
adjuvant therapy which is given to patient after the loco-regional surgery. Based 
on the biological subtypes of breast cancer, chemotherapy can be beneficial. 
Chemotherapeutic drugs prevent cell growth, cell division and induce cell death. 
The most common class of chemotherapy drugs used in breast cancer are the 
anthracyclines such as doxorubicin and epirubicin and the taxanes, docetaxal 
and paclitaxel. Chemotherapy regimens include one or a combination of these 
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classes of drugs. Oestrogen receptor negative or HER-2 positive patients 
benefit more from cytotoxic chemotherapy than other subgroups (Dixon 2012).  
1.5.4 Endocrine therapy  
Endocrine therapy has made an important impact in improving the overall 
survival for patients whose tumours express the oestrogen and or the 
progesterone receptor. The decision about which endocrine therapy is 
implemented is affected by the menopausal status of the patients and stage of 
the disease (Johnston and Yeo 2014).The majority of endocrine agents either 
block the circulating oestrogen production by aromatase inhibition or inhibit 
oestrogen action at the cellular level by the competitive inhibition of oestrogen 
binding to its receptor (Buzdar and Hortobagyi 1998, Ellis and Ma 2008, 
Osborne and Schiff 2011).  
1.5.4.1 Tamoxifen 
The non-steroidal anti-oestrogen drug tamoxifen is widely used for all the 
stages of breast cancer. Tamoxifen shows effectiveness in both premenopausal 
and postmenopausal patients. It improves disease-free survival and overall 
survival rates of hormone receptor-positive breast cancer patients. Tamoxifen 
given for 5 years as adjuvant therapy to patients reduces significantly breast 
cancer relapse and improves overall survival. Based on the positive effect of 5 
years usage of adjuvant endocrine treatments along with the knowledge that 
many relapses occur 5 years after initial surgery, different clinical trials studies 
reported an advantage of continuing the endocrine therapy for more than 5 
years  (Johnston and Yeo 2014). Tamoxifen binds to oestrogen receptor, 
induces conformational changes in the receptor and subsequently inhibits 
access to one of the co-activator interaction surfaces which in turn prevents 
oestrogen-regulated gene transcription and cellular proliferation (Johnston and 
Yeo 2014). 
1.5.4.2 Aromatase inhibitors 
Aromatase inhibitors improve outcomes either as an alternative to tamoxifen or 
in a sequential order after initial tamoxifen (Johnston and Yeo 2014). In 
postmenopausal women, ovarian oestrogen production stops due to complete 
loss of primordial follicles in the ovaries. However, oestrogens are produced 
from peripheral tissue like fat, muscles, or even breast tumours themselves 
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(Dowsett, Folkerd et al. 2005). Biosynthesis of oestrogen from androgen is 
catalysed by a cytochrome P450 enzyme complex called aromatase. 
(Brueggemeier, Hackett et al. 2005). Aromatase inhibitors decrease the level of 
circulating oestrogen by more than 80% in postmenopausal women (Geisler, 
Helle et al. 2008). 
Aromatase inhibitors such as non-steroidal inhibitors: anastrozole and letrozole 
and steroidal inhibitors: such as exemestane have been approved clinically as 
endocrine therapy in postmenopausal patients who had failed in anti-oestrogen 
therapy or in multiple hormonal therapies. Clinical studies have reported that 
these aromatase inhibitors have more potential in postmenopausal women with 
metastatic breast cancer than tamoxifen in both the neo-adjuvant and adjuvant 
settings (Brueggemeier, Hackett et al. 2005). Studies suggest that letrozole 
might be the most efficient aromatase inhibitor particularly in endocrine-
responsive postmenopausal women who have advanced or metastatic breast 
cancer in terms of significant overall response and reduction in times of disease 
progression. Furthermore, a recent study addressed the superior effect of 
combination of anastrozole and fulvestrant compared to anastrozole as an 
individual drug in treatment of postmenopausal oestrogen positive metastatic 
breast cancer patients (Mehta, Barlow et al. 2012). 
1.5.5 Other Molecular targeted therapy 
Molecular targeted therapy in breast cancer has significant impact on 
improvement and further treatment of breast cancer. Molecular-targeted therapy 
involves targeting the key molecules that are playing important roles in cellular 
processes which promote cancer progression such as cell growth, survival, 
migration, invasion and metastasis without any harm to other normal cells. 
Monoclonal antibodies and tyrosine kinase inhibitors are two types of targeted 
therapies. Targeted agents that have been approved for treatment of breast 
cancer include tyrosine kinase inhibitor lapatinib and monoclonal antibody 
trastuzumab, which are anti-HER-2 inhibitors and target the HER-2 receptor, 
and bevacizumab which is an inhibitor of vascular endothelial growth factor 
(VEGF). There are several other targeted agents that are under preclinical and 
clinical trials such as anti-EGFR which targets EGFR receptor, anti-IGF-IR that 
targets type I IGF receptor or agents that interfere with the important signal 
transduction pathways: PI3K/AKT/mTOR and Ras/MAPK pathways. Another 
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type of targeted therapy is using the PARP inhibitors that are being studied for 
treatment of triple-negative subtypes of breast cancer (Munagala, Aqil et al. 
2011). 
As mentioned previously, the only available systematic treatment for triple-
negative or basal-like breast tumours is conventional chemotherapy, due to 
their resistance to endocrine treatments. There are several compounds 
available for triple-negative breast cancer such as taxanes, platinating agents, 
and poly (ADP-ribose) polymerase inhibitors (PARP). Combination therapy of 
cytotoxic drugs such as: paclitaxel, doxorubicin and cyclophosphamide seem to 
be beneficial for triple-negative or even HER-2-positive patients (Schneider, 
Winer et al. 2008). Triple-negative or basal-like breast cancer shares various 
clinico-pathological features with BRCA1 and BRCA2 mutation in breast cancer, 
which followed by dysregulation in DNA repair mechanism. Poly (ADP ribose) 
polymerase (PARP) is a molecule involved in several cellular processes 
including non-homologous DNA repair mechanisms. It has been hypothesized 
that poly (ADP ribose) polymerase inhibitors either alone or in combination with 
chemotherapy or DNA damaging agents such as platinum drugs can result in 
cell death and could be beneficial as therapeutic agents in treatment of triple 
negative or basal-like breast cancer (Schneider, Winer et al. 2008, Gluz, Liedtke 
et al. 2009, Anders, Winer et al. 2010, O'Shaughnessy, Osborne et al. 2011). A 
clinical trial that evaluated the role of epidermal growth factor receptor inhibitors 
in triple-negative metastatic breast cancer suggested that patients are more 
responsive to anti-EGFR monoclonal antibody cetuximab in combination with 
carboplatin than cetuximab alone (Schneider, Winer et al. 2008). Other 
evidence reported the beneficial effect of combination of lapatinib and 
rapamycin in triple-negative breast cancer, suggesting that combination of 
EGFR and HER-2 inhibitor lapatinib with mTOR inhibitor rapamycin can 
increase the cell death in some of the triple-negative breast cancer cell lines 
(Liu, Yacoub et al. 2011).  
Some limited clinical data show sensitivity of triple-negative tumours to 
platinum-based chemotherapy. The rate of response to platinum-based 
chemotherapy was increased in triple-negative breast cancer. However, 
patients with an early stage of triple-negative breast cancer had worse survival 
rate while an improved survival was observed in patients with advanced triple 
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negative breast cancer (Sirohi, Arnedos et al. 2008). Therefore, there is an 
urgent need of new therapy for hormone receptor-negative patients.                   
1.6 Prognostic factors in breast cancer 
Prognostic factors are the informative markers that can predict the outcome and 
course of the disease. They provide the valuable information which can be 
helpful in treatment decisions particularly in patients with early stage of cancer.  
1.6.1 Hormonal receptor status 
Expression of oestrogen receptor (ER) and progesterone receptor (PgR) in 
breast cancer is one of the important well-established predictive markers in 
response to therapies. Oestrogen receptor and the oncogene ErbB-2/human 
epidermal growth factor receptor-2 (HER-2) play important roles in the 
development and progression of breast cancer (Gluz, Liedtke et al. 2009). The 
majority of breast tumours, around 80%, are hormone receptor-positive. 
Positive oestrogen receptor expression is more likely in tumours of 
postmenopausal women than in tumours of premenopausal women. Successful 
oestrogen targeted therapies such as the anti-oestrogen tamoxifen or 
aromatase inhibitors have been developed. These endocrine therapies are 
valuable for the treatment of breast cancer patients whose breast tumour cells 
express oestrogen and progesterone receptor in the nucleus. Tumours with 
HER-2 expression are treated with trastuzumab, which is an anti-HER-2 
monoclonal antibody (Reis-Filho and Tutt 2008).  
1.6.2 Nodal status  
Among prognostic factors in breast cancer, nodal status is one of the most 
important risk factors. The number of involved nodes is crucial for prognosis 
and treatment decisions. Patient survival is associated with the number and the 
level of the involved lymph node (Dixon 2012). Patients who have four or more 
nodes involved have a worse prognosis and are at higher risk of relapse, while 
those patients who have fewer involved nodes are characterised as being in an 
intermediate risk group. (Fitzgibbons, Page et al. 2000). 
1.6.3 Tumour size 
The size of the tumour is another important prognostic factor. Patients with a 
tumour larger than 2 cm have an intermediate prognosis, while those with 
tumours of less than 1 cm in diameter have better prognosis (Dixon 2012).  
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1.6.4 Histological grade  
There are different systems for evaluating the grade of breast cancer. Bloom 
and Richardson is one of the most common grading systems (Bloom and 
Richardson 1957). The grading is based on the three morphologic features of 
tumours: the degree of tubular formation, tumour mitotic activity and nuclear 
polymorphism of tumour cells. Based on this, tumours are classified into three 
grades of 1, 2, and 3; 1 is low grade, 2 is intermediate and 3 is referred to as 
high grade tumours. Low grade tumours tend to be less aggressive than high 
grade tumours. 
1.7 Importance of metastasis in breast cancer  
Metastasis at distant sites is the main cause of fatality in breast cancer patients, 
regardless of the breast cancer type. Despite the considerable progress in early 
diagnosis by mammographic screening and the implementation of systemic 
adjuvant therapies which have improved the survival rate of breast cancer 
patients, recurrence after surgery in breast cancer is continuous (Rugo 2008). 
Metastasis is a multiple step process which takes place through detachment of 
the cancer cells from the primary tumour, invasion through the myoepithelium 
and travel into blood or lymphatic stream and subsequently invade to other 
organs (Rabbani and Mazar 2007, Nguyen, Bos et al. 2009). Development of 
cancer first involves the formation of the premalignant lesions before formation 
of invasive tumours. The development of lesions might be due to genetic 
alterations which lead to monoclonal expansion of the tumour or it can be by 
environmental factors which results in polyclonal expansion of the tumour cells. 
Continuous modification in genetic alteration of premalignant lesions can trigger 
malignant clonal cells to produce the primary tumours. Only small numbers of 
cells in primary tumours have high potential to metastasis. Shift from non-motile 
epithelial-like state to the mesenchymal-like migratory state followed by loss of 
the cell-cell adhesion makes the metastatic tumours cells invade to other 
organs (Rabbani and Mazar 2007).  
Distant metastasis is one of the most frequent types of recurrence in breast 
cancer patients. Breast cancer forms as a local disease, but it can metastasize 
to the lymph nodes and any other distant organs. On the basis of the evidence 
in literature, metastasis to regional lymph nodes occurs in one third of breast 
cancer patients. The major sites of distant metastasis in breast cancer at first 
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recurrence are bone, lung or thorax, liver and the central nervous system. Bone 
is the most preferred site of metastasis in breast cancer (Figure 1.8).According 
to the prospective study in Strathfield Breast Cancer Centre, the five years 
disease-free survival rate in patients with local relapse was 41%, in patients 
with regional recurrence was 20% and in patients with distant metastasis was 
13%. Moreover the survival rate was varied in patients with different metastatic 
sites, for instance: the five years overall-survival rate in patients with bone 
metastasis was 16%, in lung metastasis patients, 12% and in patients who had 
liver metastasis was 0%, which suggests that patients who had first bone 
metastasis had better prognosis compared to those group who had first visceral 
metastases (Rabbani and Mazar 2007). According to many published studies, 
breast cancer patients with loco-regional recurrences are more likely to develop 
distant metastasis in 10 years as compared to those patients who had de novo 
second primary neoplasm.  
 
Figure 1.8: Most frequent sites of distant metastasis in breast cancer patients at autopsy. 
Primary breast cancer cells travel through the blood stream spread into various sites, most 
preferably they   metastasis to lung, bone and liver. Adapted from Nature Reviews (Weigelt, 
Peterse et al. 2005).    
                                                                                  
According to many studies, the earliest peak of recurrence risk is between 2 to 
3 years after the surgical treatment of primary disease in both oestrogen 
receptor-positive and negative breast cancer. It has been observed that after 
early diagnosis, the recurrence rate was higher in oestrogen receptor-negative 
tumours. However, according to Saphner et al, the chance of recurrence 
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irrespective to the oestrogen receptor status and chemotherapy treatment is 
higher in postmenopausal patients compare to premenopausal patients 
(Saphner, Tormey et al. 1996). Involvement of axillary lymph nodes and size of 
tumour has association with the risk of distant metastases. Patients who are 
positive for lymph node and have larger primary tumours are more prone to 
distant metastases. Despite this observation, it has been reported that in about 
one-third of patients with metastatic breast cancer, tumours have not invaded 
into lymph nodes, whereas in another cohort of patients with tumours positive to 
axillary lymph node, there was no evidence of metastases 10 years after initial 
treatment (Weigelt, Peterse et al. 2005). Moreover, circulating tumour cells has 
been reported to be found in bone marrow of both lymph node positive and 
lymph node negative breast cancer patients (Rabbani and Mazar 2007). 
Increase in the age of patient (above 40 years), larger tumour size, positivity of 
the axillary lymph nodes (>2), higher histopathological grade of the tumour, 
tumour stage (≥T3), invasion of lymphovascular system, poorly differentiated 
ductal carcinoma in situ and unknown oestrogen receptor status are the main 
independent risk factors for early breast cancer recurrence (Rabbani and Mazar 
2007, Rugo 2008).   
The combination of systemic therapy with localized treatments such as surgery 
and radiotherapy has been shown to be effective on treatment of the distance 
metastasis. Radiotherapy after mastectomy reduces both local recurrence and 
overall distant metastasis. Adjuvant chemotherapy and endocrine therapy 
improve distant disease-free survival and overall survival of breast cancer 
patients. Adjuvant endocrine therapy with tamoxifen has proven to have good 
impact on treatment of hormone-sensitive postmenopausal breast cancer 
patients. Aromatase inhibitors as initial adjuvant therapy are more effective in 
treatment of breast cancer patients than tamoxifen, in terms of reduction in the 
risk of relapse. Amongst aromatase inhibitors, letrozole is reported to be a more 
effective drug in reducing the risk of distant metastasis than anastrazole after 
two years of therapy (Rabbani and Mazar 2007). 
Identification and characterization of circulating tumour cells (CTC) provides 
new information regarding cancer dissemination. CTC count is a novel potential 
quantitative and qualitative biological tool to understand the metastatic process 
in breast cancer patients (Bidard, Fehm et al. 2013). Cristofanilli et al (2004) 
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addressed CTC count as an independent prognostic factor for metastatic breast 
cancer patients with progression-free and overall survival (Cristofanilli, Budd et 
al. 2004).   
One of the possibilities to identify the patients who are at higher risk of 
developing metastases is gene expression profiling. Studies reported the 
overexpression of diverse sets of genes which have important effects on 
promoting the metastasis of breast cancer to the bone (Rodenhiser, Andrews et 
al. 2011). Next generation sequencing could facilitate identification of patients 
who might be at risk of developing metastatic breast cancer and could have an 
effective role in individualized treatment decisions. Next generation sequencing 
could sequence the whole genome of a tumour and detect the mutations in 
tumour DNA or RNA (Rodenhiser, Andrews et al. 2011).  
1.8 In vitro assays with which to study metastatic potential    
1.8.1 Cell survival  
Survival of normal mammary epithelial cells depends on their attachment to the 
extracellular matrix (Davison, Durbin et al. 2013). Adhesion of cells to 
extracellular matrix involves interaction of integrin receptors, plasma membrane 
bound receptors with extracellular matrix components which initiate different 
signal transduction that mediates cellular differentiation, proliferation and 
migration. Appropriate adhesion of cells to extracellular matrix molecules is 
essential to determine the correct location of cells (Kim, Koo et al. 2012, Taddei, 
Giannoni et al. 2012). Frisch and Francis (1994) found that loss or inappropriate 
attachment of cells to extracellular matrix caused apoptosis. They named this 
particular type of programmed cell death as anoikis which means 
‘homelessness’ in Greek (Frisch and Francis 1994, Simpson, Anyiwe et al. 
2008, Taddei, Giannoni et al. 2012). Detached epithelial cells are eliminated 
through anoikis process to inhibit their reattachment to the new incorrect matrix, 
hence preventing dysplastic growth and proliferation of the cells (Kim, Koo et al. 
2012, Taddei, Giannoni et al. 2012). Anoikis has a significant role in the 
physiological induction of apoptosis for mediating tissue-haemostatic and 
developmental processes (Frisch and Screaton 2001, Grossmann 2002, Kim, 
Koo et al. 2012) Resistance of tumour cells against anoikis is one of the 
significant characteristics toward cancer progression and metastasis, because 
cancer cells may survive without attachment to the extracellular matrix while 
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travelling through the blood or lymphatic vessels. Understanding the molecular 
mechanisms that regulate anoikis resistance in cancer cells may lead towards 
the novel therapeutic approaches to prevent cancer progression and tumour 
dissemination (Davison, Durbin et al. 2013).   
Anoikis is initiated through two pathways: The intrinsic pathway, as a result of 
mitochondrial permeabilization and the extrinsic pathway induced by the cell 
surface death receptor (Figure 1.9) (Kim, Koo et al. 2012). Dysregulation in 
either pathway can trigger malignant cells, resistance to anoikis process. In the 
death receptor (extrinsic) pathway, ligation of extracellular death ligands such 
as Fas ligand (Fas L) or tumour necrosis factor-α (TNF-α) and their 
transmembrane receptors, Fas and TNFR results in development of the death-
inducing signalling complex (DISC) as it is illustrated in Figure 1.9. Cell 
detachments trigger upregulation of FasL and Fas receptor and downregulation 
of FLIP which is an antagonist of caspase-8. This results in activation of 
caspase-8 through Fas-associated death domain (FADD). The activation of 
caspase-8 induce activation of caspase-7 and subsequently caspase-3 which 
results in cleavage of cellular substrate and cell death. Blockage in signalling 
pathway of death receptor inhibits activity of death ligands to induce cell death, 
therefore leads to resistance to anoikis (Taddei, Giannoni et al. 2012, Simpson, 
Anyiwe et al. 2008 ).  
In the intrinsic pathway, caspase activation occurs as a result of mitochondrial 
permeabilization (Figure 1.9). Loss of cell attachment to the extracellular matrix 
activates proapoptotic family such as the BH3-only proteins Bid, Bad, Puma, 
Noxa, Bim, as well as Bok, Bax and Bak) which in turn deactivate the 
antiapoptotic proteins Bcl-2, Bcl-xL, Mcl-1. This process leads to translocation 
of Bax and Bak monomer from cytosol to outer mitochondrial membrane (OMM) 
and formation of oligomers, which create a channel that makes the 
mitochondrial membrane permeable. Due to perturbation of outer mitochondrial 
membrane, cytochrome C is released and forms the apoptosome with caspase 
9 and apoptosis protease activating factor (APAF), Subsequently caspase 3 
activates (Kim, Koo et al. 2012). Bcl-2 as an antiapoptotic protein binds to 
proapoptotic proteins Bax and Bad, inhibits their assembly and prevents 
formation of the pores in the mitochondrial membrane, hence prevents induction 
of apoptosis. In addition, BH-3 only proteins contribute to promote the apoptosis 
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by competition with Bcl-2 for binding to apoptotic activators. Loss of cellular 
adhesion prevents both extracellular signal regulated kinase (ERK) and 
phosphoinositide-3-kinase (PI3K)/AKT pathway which mediate the 
phosphorylation of Bim hence inhibit the Bim proteasomal degradation and 
sequestration by dynein cytoskeletal complexes, as a result, increase in 
accumulation of cytoplasmic Bim. Activation of Bim induces oligomerization of 
Bax/Bak on outer mitochondrial membrane (OMM) and promotes execution of 
the apoptotic process. Furthermore, upon loss of cellular adhesion, Bcl-2 
modifying factor (BMF) is released from the myosin V motor complex and 
deactivates antiapoptotic Bcl-2, which promotes anoikis (Kim, Koo et al. 2012). 
Suppression of BMF activity could results in anoikis resistance (Reginato, Mills 
et al. 2003).  
 
Figure 1.9: Caspase activation of anoikis pathways. Lack or inappropriate attachment of 
normal cells to the extracellular matrix induces anoikis through activation of intrinsic and 
extrinsic pathways. The extrinsic pathway is activated through increased expression of FAS and 
Fas ligand (FasL) and decreased expression of FLIP (FLICE inhibitory protein) which triggers 
subsequently the activation of caspase 8 (FLICE), caspase 7 and caspase 3, respectively. In 
intrinsic pathway, loss of cell adhesion induces the activation of proapoptotic Bcl-2 family 
proteins such as Bid, Puma, Bad, Noxa, Bmf, Bid, Bax and Bak, which neutralise the activation 
of antiapoptotic Bcl-2 molecules such as Bcl-2, Bcl-xL, Mcl-1, and makes the mitochondrial 
membrane permeabilize through assembly of Bax/Bak oligomers. These events promote the 
mitochondrial cytochrome c release and formation of apoptosome, followed by activation of 
caspase 9 and subsequently caspase 3. Conversely, in cancer cells increased in FLIP 
expression leads to inhibition of the extrinsic pathway and expression of some oncogenes such 
as EGFR and hypoxia decrease Bim and Bmf expression, hence prevents mitochondrial 
permeabilization and therefore causes cancer cells to be resistant to anoikis. Adapted from 
(Kim, Koo et al. 2012) 
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Anoikis prevents epithelial cells from colonising elsewhere other than the tissue 
in which they originated. Integrins are major regulators of cell-matrix adherence 
by transmission of signals from extracellular matrix ligands to the intracellular 
signal transduction pathways. Several studies have reported the impact of 
different types of integrins on cell survival in both normal and malignant cells 
(Giancotti 2000, Alahari, Reddig et al. 2002, Taddei, Giannoni et al. 2012). 
When tumour cells acquire resistance to anoikis, the expression pattern of 
integrins is altered.  One of the important players in anoikis resistance is a 
signal transduction molecule, focal adhesion kinase (FAK) that mediates signal 
transmission through integrins in cells. FAK transmits the cell-matrix adhesion-
induced survival signals through binding to the cytoplasmic tail of integrin and 
undergoes autophosphorylation which subsequently activates PI3K and AKT 
signal transduction pathway (Nagaprashantha, Vartak et al. 2012). It has been 
demonstrated that knocking down FAK by siRNA in anoikis-resistant pancreatic 
tumour cells increases their anoikis (Duxbury, Ito et al. 2004, Nagaprashantha, 
Vartak et al. 2012) 
Epithelial cancer cells that have undergone epithelial-mesenchymal transition 
(EMT) acquire resistance to anoikis. EMT is a process which is essential for 
tissue development and may occur in during tissue restitution and 
carcinogenesis. E-cadherin is an important protein in mediation of normal 
epithelial phenotype, its expression is lost during EMT process. Numerous in 
vitro and in vivo studies have been reported the importance of E-cadherin loss 
in metastasis (Hajra and Fearon 2002). Derksen, Liu et al (2006) has 
demonstrated in a mouse model that knock down of E-cadherin and p53 in 
mammary epithelial cells triggers tumour formation, resistance to anoikis and 
metastasis. Initiation of EMT also increase in expression of growth factors such 
as epidermal growth factors (EGF), fibroblast growth factor (FGF) and 
hepatocyte growth factor (HGF) which in turns enhance the activation of 
downstream survival cascades PI3K, MAPK and mTOR (Thiery 2002, Thiery 
and Sleeman 2006, Nagaprashantha, Vartak et al. 2012). Induction of molecular 
alterations during EMT increases the cancerous cells potential to gain anoikis 
resistance.  
Increase in expression of growth factor receptors such as epidermal growth 
factor receptor (EGFR) or their signal transduction molecules is reported to be 
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related to tumour progression through blockade of the apoptosis pathway 
(Sharma, Bell et al. 2007). In normal condition, cell detachment from the 
extracellular matrix induces decreased expression of EGFR and increased 
expression of Bim which is an essential component in anoikis, whereas 
Reginato et al (2003) illustrated in human mammary epithelial cells MCF-10A 
cells that when EGFR is overexpressed, it mediates ERK pathway activation 
which in turns blocks the anoikis process through suppression of Bim. In 
addition, in another study overexpression of HER-2 was shown to supress Bim 
expression through activation of MAPK pathway which subsequently conferring 
anoikis insensitivity (Haenssen, Caldwell et al. 2010). Among growth factors, 
insulin-like growth factor (IGF-1) is identified as master regulator of cell survival 
that induces activation of AKT in the process of cell detachment. Inhibition of 
anoikis by type I IGF receptor in human epithelial prostate cancer cell line 
LNCaP and mouse embryo fibroblasts has been reported (Kim, Koo et al. 2012). 
Furthermore, it has been demonstrated that blocking the IGF-1 receptor 
signalling pathway can increase the anoikis in metastatic variant of MDA-MB-
435 breast cancer cells and decrease the population of circulating tumour cells 
in the blood of tumour-bearing mice (Sachdev, Zhang et al. 2009).  
1.8.2 Cell migration 
Cell migration is a multistep process involved in embryonic morphogenesis, 
branching morphogenesis, development of the nervous system, tissue 
restitution, regeneration and immune cell trafficking. Migration plays a 
significant role in many pathological processes including development of 
diseases such as: cancer, rheumatoid arthritis, vascular disease, 
atherosclerosis and many others. Cell motility was first observed in early 1675 
by van Leeuwnhoek who observed cell movement across his microscope slides 
(Ananthakrishnan R, Ehrlicher A et al. 2007).        
As mentioned before, a key step in metastasis is invasion into the extracellular 
matrix, migration through the circulatory system and dissemination into distant 
organs (Schroeder, Heller et al. 2012). Regulation of cell adhesion and de-
adhesion is essential in cell migration and metastasis. There have been 
difficulties in clarification between migration and invasion terms in experimental 
cell biology. Migration is cellular movement on a substrate such as the 
extracellular matrix, without any disruption of the tissue, which leads to a 
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change in the location of cells within tissues or between organs. (Kramer, Walzl 
et al. 2013). Invasion involves break down of tissue barriers such as 
extracellular matrix, followed by diffusion into underlying tissues. Invasion 
requires adhesion, proteolysis of matrix components and migration towards 
different sites. To migrate through matrix, cells need to modify their shape and 
interact with the surrounding extracellular matrix. Migration is an essential 
component of invasion; cells are not capable to invade without migration, but 
they can travel to different sites without invasion (Kramer, Walzl et al. 2013). 
Cells have different modes of motility. Several in vitro and in vivo studies 
reported various pattern of tumour cells infiltration into adjacent tissue matrix. 
Tumour cells either disseminate as individual cells which is called as single cell 
migration, or they can grow in clusters, as files or as solid cell strands or sheets, 
sometimes called collective migration (Figure 1.10) (Friedl and Wolf 2003). 
Tumour cells may migrate as single cells and collective migration. Malignant 
cells of patients with leukemia, lymphoma and the majority of solid stromal 
tumours such as sarcomas migrate as single cells, whereas epithelial tumours 
tend to migrate by collective migration. In general, less well differentiated 
tumour cells migrate as individual cells (Friedl and Wolf 2003).  
Single cell migrations have different appearance depending on the cell type, 
integrin involvement, cytoskeletal structure and protease production. It can be 
subdivided into amoeboid and mesenchymal migration. Amoeboid migration is 
observed in certain types of cancer cells, in embryonic cells and leukocytes. In 
this type of migration, cells move as round and ellipsoid forms without 
contribution of focal adhesion molecules and cellular attachment.  This type of 
movement is also called as blebby migration because cells move with the help 
of the propulsive blebs. Cancer cells tend to detach and disseminate from 
primary tumours at early stages by amoeboid migration. In leukemias, 
lymphomas and small-cell lung carcinoma this type of migration is reported 
most frequently (Rintoul and Sethi 2001, Friedl and Wolf 2003). Mesenchymal 
migration comprises participation of focal adhesion to extracellular matrix, 
cytoskeletal contractility and cells move as elongated fibroblast-like needle-
shaped cell bodies. In this type of movement, high traction force is exerted at 
both cell poles. Highly dedifferentiated tumour cells that have undergone 
epithelial-mesenchymal transition move by mesenchymal migration mode for 
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their movement. Collective migration is described as the movement of groups of 
cells as a functional unit through the extracellular matrix while they are adhered 
physically to each other. Collective migration has been observed in highly 
differentiated tumours such as: epithelial prostate cancer, lobular breast 
carcinoma and large-cell lung cancer (Friedl and Wolf 2003). Hence, collective 
movement of cancerous cells can be an initial step towards invasion and 
metastasis. Dissemination of cancer cells from the primary tumour can be either 
through amoeboid or mesenchymal movement or by collective migration. It has 
been hypothesized that various environmental factors play role in different types 
of tumour-cell motility behaviours, hence participate in invasion (Friedl and Wolf 
2003, Bravo-Cordero, Hodgson et al. 2012). For instance; interaction of tumour 
cells with different growth factors such as epidermal growth factors (EGF), 
insulin-like growth factor (IGF-1) and chemoattractants can regulate the type of 
tumour cells motility. Many of these motility enhancing chemokines and growth 
factors can regulate the migration through transmission of pre-migratory signals 
through phosphatidyl inositol 3-kinase (PI3K), RAC and RHO signal 
transduction.   
 
Figure 1.10: Different modes of cell motility. Various molecules (shown in triangles) can 
regulate individual or collective migration of tumour cells. There is an increase in cell-matrix 
interactions by integrin and matrix-degrading protease from single cell to collective cell 
migration. Specific characteristics of collective migration are cell-cell adhesion via cadherins and 
other adhesion receptors, communication between cells through gap junctions. Amoeboid 
individual migration occurs in leukemias, lymphomas and small-cell lung cancers (SCLC), 
whereas sarcomas and glioblastoma tumours have been shown to move by mesenchymal type 
of individual migration for their movement. Highly differentiated epithelial cancer cells such as 
breast, colon, prostate cancer and melanoma cells are observed to move by collective 
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migration. Some epithelial cancer and vascular tumour cells that tend to move in multicellular 
strands or sheets. Taken from (Friedl and Wolf 2003) 
 
Cell migration is thought to be a continuous cyclical process (Ridley, Schwartz 
et al. 2003). It can be divided in to three phases: protrusion of the leading edge, 
assembly of the leading edge and disassembly of the cell body at the rear of the 
cell. The cell is pulled forward through contraction generated by cytoskeleton 
network. The protrusion occurs normally through polymerisation of actin. The 
leading edge of the motile cell can be morphologically large, needle-shape 
filopodia or extensive flat lamellipodia. These changes in morphology of the 
cells are controlled by small GTPase family proteins such as Rac1, RhoA and 
Cdc42. The protrusions can be supported by focal adhesion molecules and 
integrins which provide attachment of the cells to the extracellular matrix or to 
neighbouring cells through transmembrane receptors that are connected to the 
actin cytoskeleton. These attachments act as the starting point for forward 
migration of the cell, which leads to dismantling of the cell attachment at the 
rear to allow it to detach. The final step in movement of the cells is translocation 
of the cell body and the rear side of the cell. The acto-myosin network produces 
a contractile force by sliding of myosin motors and actin filaments in the cell 
body and rear of the cell which pushes the cell forward (Figure 1.11) 
(Ananthakrishnan R, Ehrlicher A et al. 2007). Integrins are the main 
transmembrane receptors in migration promotion in different cells. The activate 
migration-related signaling molecules has been described to act as ‘feet’ for the 
migrating cells by maintaining the adhesion to the extracellular matrix or other 
adjacent cells and by connecting through adaptors to the actin filaments inside 
the cells (Ridley, Schwartz et al. 2003).  
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 Figure 1.11: Diagram of cell migration. Cell migration depends on the dynamic interaction of 
cell-substrate adhesion at the leading edge of the cells in co-operation with the cell-substrate 
disassembly at the rear. Focal adhesion complexes facilitate the adhesive bond between the 
integrin receptor and intracellular actin cytoskeleton. To migrate, cells need to modify their 
shape which is often called polarization in response to migratory agents by developing the 
filopodia or lamellipodia structures at the leading edge. The morphological modification of cells 
is control by small GTPases family proteins such as Rac1, RhoA, Cdc42. At the leading edge of 
the cells, lamellipodia stabilised by adhering to the underlying substrate through formation of 
focal adhesion complex attachment which is called as ‘focal contacts’ as illustrated in the figure. 
Development of focal adhesions near the leading edge of the cells facilitates the traction which 
is necessary for pushing the cells forward. This is followed by disassembly of focal adhesion 
and detachment of cell-substrate at the rear of the cell and allows the tail retraction. Adapted 
from (Frame, Fincham et al. 2002). 
 
1.9 Insulin-like growth factor family  
1.9.1 IGF ligands and IGF receptors 
Insulin-like growth factors (IGFs) are the main regulators in post-natal and 
adolescent growth and energy metabolism. There are large bodies of evidence 
that support a significant role of insulin-like growth factors and their signaling 
networks in cancer progression (Pollak 2008, Sachdev, Zhang et al. 2009, 
Davison, de Blacquiere et al. 2011, Pollak 2012).  
The insulin-like growth factor system comprises three ligands; insulin-like 
growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2) and insulin, three 
transmembrane receptors namely, type I insulin-like growth factor receptor 
(IGF-IR), type II insulin-like growth factor (IGF-IIR) and insulin receptor (IR), six 
binding proteins (IGFBP-1 to IGFBP-6) and binding-protein proteases that 
control the availability of ligands (Firth and Baxter 2002, Renehan, Frystyk et al. 
2006). IGF ligands transduce their signals via two transmembrane receptors the 
type I IGF receptor and the insulin receptor. The two ligands IGF-1 and IGF-2 
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have higher binding affinity for the type I IGF receptor, whereas insulin has a 
higher binding affinity for the insulin receptor. Binding of IGF ligands to the 
extracellular domains of their receptors is followed by conformational changes 
in the receptors which induces phosphorylation of the receptors and in turn, 
enables phosphorylation of downstream adaptor molecules (Pollak 2012, 
Davison, de Blacquiere et al. 2011).  
The main site of IGFs expression is in liver. These growth factors regulate 
cellular growth, differentiation and transformation through autocrine, paracrine 
and endocrine manner. Insulin is responsible for glucose metabolism. It is 
expressed in pancreatic β-cells and its secretion is regulated acutely by the 
level of circulating glucose. Insulin can travel to the neoplastic tissues through 
circulation (Pollak 2008, Pollak 2012). IGFs action is regulated by insulin-like 
growth factor binding proteins (IGFBPs). IGFBPs have relatively high binding 
affinity for both IGF-1 and IGF-2 and moderate the interaction of IGF with the 
IGF-IR and hence control the bioactivity of these growth factors. Amongst 
IGFBPs, IGFBP-3 is the main binding protein for IGF-1. One speculation is that 
expression of high affinity IGFBPs can lead to increase in the concentration of 
IGF ligands in tumour microenvironment. Ligands can be released from the 
complex via the IGFBP protease family (Gunter, Hoover et al. 2009).   
Insulin and type I insulin-like growth factor receptor family are expressed on 
both normal and neoplastic tissues (Law, Habibi et al. 2008, Cox, Gleave et al. 
2009, Badzio, Wynes et al. 2010, Kim, Kim et al. 2012). Both types of these 
tyrosine kinase membrane receptors have a heterotetrameric structure and 
have two extracellular α-chains and two intracellular β-chains that contain the 
tyrosine kinase domain (Pollak 2008). In contrast, IGF-IIR does not have 
catalytic activity; it does not participate in downstream signal transduction. IGF-
IIR regulates the level of extracellular IGF-1 and IGF-2 via receptor-mediated 
endocytosis, which leads to lysosomal degradation of IGF-1 and IGF-2 (Zha and 
Lackner 2010).  The insulin receptor comprises two different isoforms, IR-A and 
IR-B, due to the presence of a 12 amino acid sequence at the carboxyl terminus 
of the α-chain in IR-B; IR-A lacks the corresponding sequence. This variation 
stems from differences in splicing of exon 11 (Siddle 2011). Isoform B has much 
higher affinity for insulin than IGF-1 and IGF-2 whereas the differences in 
affinities of these ligands for isoform A is less marked. It has been reported that 
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isoform A is expressed in tumours cells (Belfiore, Frasca et al. 2009). Hetero-
dimerization of both insulin receptor and type I IGF receptor arises from the 
dimerization of half receptors to create six potential different receptors (Figure 
1.12). 
 
Figure 1.12: The insulin and insulin-like growth factor receptor family.  The  insulin 
receptor exists as two isoforms: IR-A and IR-B. The half receptors can dimerize and generate 
six different types of hybrid receptors with different binding affinities for their ligands. Insulin 
binds with high affinity to IR and lower affinity with IGF-IR. IGF-I binds to IGF-IR and IR-A and 
hybrid receptors with higher affinity compared to IR. IGF-II binds IGF-IR, IR-A and a hybrid 
receptor Adapted from nature review (Pollak 2012).   
 
1.9.2 Activation of IGF pathway 
Binding of IGF-1 to IGF-IR induces autophosphorylation of β subunit tyrosine 
kinase, followed by phosphorylation of three different tyrosine residue on IGF-
IR; Y1131, Y1135 and Y1136 (Foulstone, Prince et al. 2005, Zha and Lackner 
2010). Phosphorylated IGF-IR recruits and activates the signalling adaptor 
proteins, such as insulin receptor substrates (IRS-1, IRS-2) and Src homology 2 
domain containing transforming protein (Shc) to the cell membrane which are 
phosphorylated in turn (Kuijjer, Peterse et al. 2013). Recruitment of IRS-1 is 
proposed to be essential for mitogenic signalling, while IRS-2 recruitment is 
involved in response to cellular motility (Byron, Horwitz et al. 2006). Upon 
activation of IRS-1 by IGF-IR, phosphorylated IRS-1 leads to activation of 
downstream signalling cascade through binding to the p85 regulatory subunit of 
phosphatidylinositol-3-kinase (PI3K). The PI3K is a dimeric enzyme that 
phosphorylates phosphatidylinositol 4, 5-biphosphate (PIP2) to 
phosphatidylinositol 3, 4, 5-triphosphate (PIP3). Akt undergoes phosphorylation 
and activation by phosphoinositide-dependent kinase-1 (PDK1), which 
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phosphorylates Akt on Thr 308  and by mammalian target of rapamycin 
(mTORC2) complex, which phosphorylates Akt on Ser 473 (Guertin and 
Sabatini 2005). Activation of Akt leads to an increase in cellular proliferation and 
survival and regulation of glucose metabolism (Figure 1.13), (Zha and Lackner 
2010). Through recruitment of growth factor receptor-bound protein 2 (Grb2) 
and son-of-sevenless (SOS) by Shc Ras-Raf-ERk pathway activates, which 
subsequently leads to cellular proliferation. 
 
Figure 1.13: Activation of IGF downstream signal transduction pathway. Binding of IGF to 
type I IGF receptor induces autophosphorylation of the receptor and subsequent 
phosphorylation of downstream adaptor proteins such as IRS-1, IRS-2 and Shc. This event 
leads to activation of two main downstream signaling cascades: Ras mitogen-activated protein 
kinase (MAPK) pathway, which is responsible for cellular proliferation and phosphatidylinositol 
3-kinase (PI3K) Akt pathway, which is important in cell survival. IGF binding proteins (IGFBPs) 
modify the bioavailability of both IGF ligands. Extracellular levels of IGF-1 are controlled by 
IGFBPs, whereas, IGF-2 availability is controlled by both IGFBPs and IGF-IIR. Upon binding 
IGF-1 and IGF-2 to IGF-IIR, this receptor sequesters the IGF-2 for lysosomal degradation. 
Adapted from (Zha and Lackner 2010).  
 
1.9.3 IGF action in breast cancer 
A large and growing body of literature has established the significant 
involvement of the insulin-like growth factor system in tumourigenesis, 
proliferation, survival and migration of tumour cells (Pollak 2008, Sachdev, 
Zhang et al. 2009, Davison, de Blacquiere et al. 2011, Pollak 2012). The 
importance of signal transduction through IGF-IR in malignant transformation, 
tumour cell survival and proliferation in many different cancers particularly 
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breast cancer has been demonstrated (Cohen, Baker et al. 2005, Davison, de 
Blacquiere et al. 2011, Pollak 2012). There is a strong correlation between 
overexpression of IGF-IR and the early stage of breast cancer development. 
The risk for development of many cancers including breast cancer is higher in 
those with highest levels of circulating IGF-1 and low levels of IGFBP3 
(Hankinson, Willett et al. 1998, Schernhammer, Holly et al. 2005, Renehan, 
Harvie et al. 2006). The strong correlation between plasma levels of IGF-1 and 
high mammographic density is reported and that IGF-1 might be one of the risk 
factor in breast cancer development by having effect on enhancement of breast 
density (Diorio, Pollak et al. 2005). Mitogenic effects of both insulin-like growth 
factors (IGF-1 and IGF-2) has been reported in stimulation of breast cancer cell 
proliferation (Laban, Bustin et al. 2003).  
Numerous studies have demonstrated the relationship between oestrogen and 
IGF activity in hormone-responsive breast cancer and regulatory role of 
oestrogens in the expression of key components of the IGF signal transduction 
pathway such as IGF-2, IGF-IR, IRS-1 and IRS-2 (Stewart, Johnson et al. 1990, 
Schiff, Massarweh et al. 2004, Bernard, Legay et al. 2006). Moreover, co-
expression of IGF-IR and oestrogen receptor is also reported in breast tumours 
(Surmacz, E et al 2000). Oestrogen may be responsible towards enhancing the 
responsiveness of oestrogen receptor-positive breast cancer cells to IGFs. It is 
also speculated that one of the possibilities in induction of breast cancer cell 
migration by IGFs in oestrogen responsive breast cancer cells might be due to 
participation of oestrogen in tumour progression. (Stewart, Johnson et al. 1990, 
Bernard, Legay et al. 2006, de Blaquière, May et al. 2009).  
There is a large body of literatures showing IGF signal transduction pathway as 
promising therapeutic tool in various oestrogen-responsive subtypes of breast 
cancer. However, the importance of IGF signal transduction pathway in 
oestrogen non-responsive breast cancer subgroups, particularly triple-negative 
breast cancer cells is not well established (Gluz, Liedtke et al. 2009). Several 
studies failed to demonstrate a response of oestrogen non-responsive breast 
cancer cells, mainly triple-negative breast cancer cells to IGFs. For instance; in 
2001, Bartucci et al were not able to demonstrate a mitogenic response of 
triple-negative breast cancer cell line MDA-MB-231 to IGFs, but have shown a 
mitogenic effect of IGFs in the oestrogen-responsive breast cancer cell line 
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MCF-7. Furthermore, in 1999, Jackson et al could not illustrate the effect of 
IGFs on proliferation of MDA-MB468 IRS-1 transfected triple-negative breast 
cancer cell (Jackson and Yee 1999).  
In contrast, some other studies demonstrated the presence of IGF-IR in basal-
like breast cancer. In one study, the IGF gene signature was illustrated in most 
of the oestrogen receptor-negative breast tumours (Creighton, Casa et al. 
2008). Law et al (2008) showed the presence IGF-IR and phosphorylated IGF-
IR in different subtypes of breast tumours including triple-negative breast 
tumours. In in vitro part of the same study, growth of triple-negative breast 
cancer cell line SUM149 was shown to be inhibited with the inhibitor of IGF-IR 
and the insulin receptor BMS-536924 (Law, Habibi et al. 2008). In a recent 
study, Davison et al (2011) illustrated the potential effect of IGF signaling 
pathway on proliferation and survival of oestrogen non-responsive breast 
cancer cells (Davison, de Blacquiere et al. 2011). The findings provided 
promising evidence for further investigation of IGF signal transduction pathway 
as a therapeutic target in treatment of triple-negative breast cancer patients. 
1.9.4 Targeting strategies 
IGF-IR targeting strategies have progressed over the past few decades and 
reached to the clinical trials for treating various malignancies. Targeted 
strategies consist of decrease in the bioactivity or concentration level of ligands 
or inhibition in receptor activity with receptor-specific antibodies or small-
molecule tyrosine kinase inhibitors (Figure 1.14). 
 
Figure 1.14: Targeting strategies for inhibition of IGF signal transduction pathway. 
Induction of downstream signalling activation through binding of insulin and insulin-like growth 
factors to their receptors (a). This event can be inhibited either with specific antibodies against 
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ligands (b), which prevent ligands bind to their receptors, using receptor-specific antibodies (c) 
which is followed by blocking the IGF-1 receptor or IGF-IR/IR hybrids activity, but not effective 
against IR alone. Small molecule inhibitor that block the tyrosine kinase activity and is more 
effective against all IR-IGF-1R family members (d). Taken from (Pollak 2008). 
 
There are many monoclonal therapeutic antibodies against IGF-IR which have 
been studied preclinically and evaluated in clinical trials. Although these 
receptor-specific antibodies share several similarities, they can be differentiated 
by characteristic of the immunoglobulin (IgG) subclass and serum half-life. 
Some of the antibodies which are currently in clinical trials have shown the 
promising results particularly in combination with other chemotherapeutic drugs 
(Kurzrock, Patnaik et al. 2010, McCaffery, Tudor et al. 2011, Pollak 2012). 
Figitumumab, Pfizer (CP-751, 871), a fully humanized IgG2 monoclonal 
antibody against the type I IGF receptor was developed and has been 
evaluated in several clinical trials. In phase II clinical trials, figitumumab in 
combination with chemotherapeutic drugs exhibited very promising outcome.  
The response rate and progression-free survival of patients with advanced non-
small cell lung cancer increased (Karp, Pollak et al. 2009). However, there were 
some disappointing phase III trials on figitumumab, which showed lack of 
efficacy of the antibody. Identification of predictive biomarkers is essential to 
define a subset of patients that may benefit from figitumumab therapy (Jassem, 
Langer et al. 2010, Reidy, Vakiani et al. 2010, Pollak 2012).  
Administration of IGF-IR monoclonal antibodies, despite sparing insulin 
receptor, results in serious metabolic toxicity such as hyper-glycemia or hyper-
insulinemia. This event is due to elevation in the level of growth hormone and 
IGF-1 as a result of blockade in IGF-1 receptor. Nonetheless, increase in IGF-1 
level due to receptor blockade has no detrimental effect, but it is the high level 
of growth hormone which causes peripheral insulin resistance which leads to 
the metabolic cytotoxicity. However, these metabolic adverse events can be 
treated by adding metformin in the regime of the patients.  
Another widely investigated strategy in preclinical trial experiments is use of 
tyrosine kinase inhibitors. Inhibition of IGF-IR activity alone reveals some 
moderate effects on preventing the growth of tumours but it is important to bring 
the involvement of insulin receptor into the consideration (Rodon, DeSantos et 
al. 2008, Pollak 2012). Targeting both IGF-IR and insulin receptor has been 
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more potential antineoplastic, when the insulin receptor expresses in tumour 
cells (Pollak 2008, Rodon, DeSantos et al. 2008).  
BMS-754807, a potent and reversible small molecule tyrosine kinase inhibitor of 
the type I IGF receptor and the insulin receptor is currently being studied in 
several clinical trials. BMS-754807 inhibits effectively the growth of a wide 
variety of human tumour types in vitro, including breast, lung, colon and gastric. 
In a triple-negative tumour xenograft model, BMS-754807 inhibited the growth 
of tumour grafts as monotherapy, and resulted in complete tumour regression 
when combined with cytotoxic agents (Litzenburger, Creighton et al. 2011). In 
another in vitro study, BMS-754807 in combination with letrozole or tamoxifen 
showed anti-proliferative effects on oestrogen receptor-positive breast cancer 
cells by enhancing the activity of the hormonal agents (Mezi, Todi et al. 2012). 
Based on several clinical trials, combination therapies are of importance in 
cancer treatment (Pollak 2008, Pollak 2012). For instance, there is evidence for 
the role of IGF-IR and the insulin receptors tyrosine kinase inhibitors in 
resistance of cancerous cells to rapamycin and its analogues; hence combining 
these drugs with inhibitors is of interest. Likewise, there are several substantial 
evidneces which have reported the resistance of cells to EGF receptor family 
targeted therapies due to cross activity of IGF-IR-mediated signalling, hence 
there is a interest in co-targeting both receptor families by simultanous inhibition 
of both receptor families (Lu, Zi et al. 2001, Buck, Eyzaguirre et al. 2008, Guix, 
Faber et al. 2008).  
1.10 Epidermal growth factor family 
1.10.1 EGF ligands and EGF receptors 
The human epidermal growth factor receptor tyrosine kinases (ErbBs) and their 
ligands play important roles in mediating cellular proliferation, differentiation, 
survival and migration. Moreover, their crucial role in regulation of cancer cell 
growth, angiogenesis and metastasis has been reported (Kataoka 2009, 
Sasaki, Hiroki et al. 2013, Tebbutt, Pedersen et al. 2013). 
The human epidermal growth factor receptors family are expressed in different 
tissues of epithelial, mesenchymal and neuronal lineage. They belong to 
subclass I of the receptor tyrosine kinase super-family and comprises four 
receptors; EGFR (HER-1 or ErbB-1), HER-2 (neu or ErbB-2), HER-3 (ErbB-3) 
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and HER-4 (ErbB-4). All members of the ErbB family receptor have analogous 
structure and consist of extra-cellular ligand-binding domain, a single 
hydrophobic transmembrane site and an intracellular cytoplasmic tyrosine 
kinase domain. On the basis of binding to ErbB receptors, EGF ligands can be 
divided into three groups: the first group consists of epidermal growth factor 
(EGF), transforming growth factor-α (TGF-α), amphiregulin (AR) and epigen 
(EPG), which bind specifically to EGFR; the second group is composed of 
betacellulin (BTC), heparin binding EGF (HB-EGF) and epiregulin (EPR) which 
bind to both EGFR and ErbB-4. Neuregulins belong to the third group which 
forms two subgroups depending on their ability to bind to ErbB-3 and ErbB-4 
(NRG-1 and NRG-2) or bind only to ErbB-4 (NRG-3 and NRG-4) (Figure 1.15) 
(Yarden and Pines 2012). ErbB-2 is not capable of binding to any of the known 
EGF ligands; however, it is activated through hetero-dimerization with other 
ligand-bound receptors, and known as a preferred co-receptor for hetero-
dimerization with other receptors (Foley, Nickerson et al. 2010). In addition, 
ErbB-3 lacks tyrosine activity and is only capable of transducing signals by 
hetero-dimerization with the other receptors. Although, it has been recently 
reported that HER-3 can bind to ATP and demonstrate low level of tyrosine 
activity (Shi, Telesco et al. 2010).  Hence, the activity of both the HER-2 and 
HER-3 is based on their hetero-dimerization with other family members. 
The EGF family of growth factors are derived from transmembrane precursors. 
Their availability and receptor activation is being regulated through ectodomain 
shedding (Hynes and Lane 2005, Kataoka 2009). This process is catalysed by 
cell surface proteases which belong to the metalloproteinase family, particularly 
a disintigrin and metalloprotease ADAM family and matrix metalloproteinases 
(MMPs). EGF ligands are cleaved by these proteases in the process of 
ectodomain shedding which leads to release of soluble form of EGF ligands in 
order to facilitate their binding to HER family members. Among these proteases 
involved in ectodomain shedding process, ADAM9, ADAM10, ADAM15 and 
ADAM17 have been linked with shedding between EGF ligands in many tumour 
cells. An association of EGFR activation and high level of ADAM17 has been 
reported in primary breast tumours (Hynes and Lane 2005, Kataoka 2009, 
Eccles SA 2011).   
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Ligand binding to ErbB receptors induces both homo-dimerization and hetero-
dimerization of receptors which leads to phosphorylation of tyrosine kinase 
residues within cytoplasmic tail and subsequently triggers activation of 
downstream signalling pathways, including the two main RAS-ERK and PI3K-
Akt pathways (Hynes and McDonald 2009, Tebbutt, Pedersen et al. 2013). 
Abnormal activity of tyrosine kinase receptor family member leads to 
unregulated growth and tumourigenesis in various tumour cells including breast, 
lung, head and neck, brain and colon tumours as well as melanoma (Yarden 
and Pines 2012).   
 
Figure1.15: Structure and function of ErbB family receptors. The four receptors and crystal 
structure of their three major domains are illustrated. The structures of four receptors are similar 
and comprise extracellular ligand-binding domain, transmembrane domain and intracellular 
tyrosine kinase domain. Dashed circles indicate the dimerization loops; black arrows represent 
the ligand-binding clefts. Of note, ErbB2 does not have ligand binding clefts and white arrows 
indicate the ATP binding clefts. The coloured rectangles below the receptor structures indicate 
specificities of the docking site, the specific ligands for each receptors and the abnormalities 
which that have important roles in cancer development and progression. Taken from (Yarden 
and Pines 2012). 
1.10.2 Activation of EGFR family signal transduction pathways 
Phosphorylated EGFR acts as a docking site for direct binding of adaptor 
proteins Grb2 and Sos or through adaptor molecule Src homology 2 (Shc).  As 
mention also in previous section (1.9.2), this interaction makes conformational 
rearrangement in Sos, which leads to activation of Ras, Raf which induces 
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subsequently phosphorylation of mitogen-activated protein kinase (MAPK) 
extracellular signal-regulated kinases 1 and 2 (Scaltriti and Baselga 2006). 
Activated MAPK enters the nucleus for further activation of specific transcription 
factors important in cellular proliferation process (Figure 1.16).  
Additional targets of HER-2 and HER-3 signalling are Phospholipase C- 
gamma, protein kinase C activation (PLCγ-PKC) and Janus Kinase-Signal 
Transducer and Activators of Transcription Factor (JAK-STAT) pathways. PLCγ 
binds directly to the activated EGFR and in turn activate PKC, which 
subsequently activate c-Jun and MAPK, which are important for cell proliferation 
(Patterson RL 2005).     
                    
Figure 1.16: ErbB signalling pathway. Ligand binding to ErbB receptors induces the activation 
of the receptor which is followed by receptor homo-dimerization or hetero-dimerization and 
subsequent phosphorylation and activation of the tyrosine kinase residue and recruitment of 
numerous adaptor proteins to specific docking sites of the receptor. Activation of the both PI3K-
AKT and MAPK pathways results in activation of genes responsible for cell survival and 
proliferation. 
1.10.3 Role of EGF receptor in breast cancer 
Inappropriate regulation in ErbB signal transduction pathway activity may result 
in uncontrolled growth stimulation and tumourigenesis in many cancers, 
including breast cancer. A diversity of molecular mechanisms such as 
overexpression of the ErbB receptors due to gene amplification, mutation 
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activation of the receptors or activation of receptors through autocrine and 
paracrine ligand binding may explain their contributions (Eccles 2011) 
Overexpression of all four ErbB receptors is observed in breast cancer. Their 
expression level can be ranked in the order ErbB2>EGFR>ErbB3>ErbB4. 
Overexpression of the ligands such as NRGs in breast cancer has also been 
reported. Combined measurement of EPG and NRG4 reported to be strong 
predictors for relapse-free interval and overall survival in breast cancer 
(McIntyre, Blackburn et al. 2010). Recent gene expression analyses and 
functional studies have elucidated the significant role of EGFR in progression of 
particular subtypes of breast cancer (Foley, Nickerson et al. 2010). High 
expression of amplified or non-amplified EGFR has been observed in basal-like 
breast cancer which is a subgroup of triple-negative breast cancer (Sutton, Han 
et al. 2010). Expression of TGFα, NRG2β and expression of ADAM and MMP 
proteases is significantly higher in oestrogen receptor-negative tumours than 
oestrogen receptor-positive tumours (Foley, Nickerson et al. 2010). Similarly, in 
basal-like tumours, there is a correlation between expression of EGFR and 
expression of TGFα and ADAM17 (Kenny 2007). A Recent study reported the 
ability of an inhibitor of ADAM17 to block the invasion and migration in several 
triple-negative breast cancer cell lines (Giricz, Calvo et al. 2013).  
Overexpression of EGFR has been reported in 67% of triple-negative breast 
cancer patients who carry a BRCA1 mutated gene (Burga, Hu et al. 2011). 
These findings suggest that EGFR inhibitors could be partially effective in 
preventing the progression of these tumours in triple-negative breast cancer 
patients with BRCA1 mutation. However, to date, clinical trials failed to show 
responses in unselected groups of triple-negative breast cancer patients 
(Burga, Hu et al. 2011). 
1.10.4 EGFR targeting strategies  
Over the past 20 years, various efforts have been made to develop therapeutic 
agents that target EGFR and HER-2 and these novel therapeutic options have 
shown results toward treatment of several human malignancies (Tebbutt, 
Pedersen et al. 2013, Yewale, Baradia et al. 2013).    
The most promising tools in clinical trials for targeting EGFR are monoclonal 
antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs). 
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Monoclonal antibodies interact with extracellular domain of EGFR and obscure 
the ligand-binding site, therefore inhibit the ligand-binding to EGFR and prevent 
further EGFR tyrosine kinase activity. The potential mechanisms for action of 
mAbs are not understood clearly. In general, Monoclonal antibodies can 
stimulate the immunologically mediated mechanism such as anti-tumour-
dependent cellular toxicity (ADCC) and complement-mediated cytotoxicity 
(Mellstedt 2003). They can induce receptor internalization and in this way inhibit 
ligand-induced autophosphorylation of EGFR (Kataoka 2009). Small-molecule 
tyrosine kinase inhibitors (TKIs) reversibly block the adenosine 5’ triphosphate 
(ATP) interaction with the intracellular catalytic domain of EGFR tyrosine 
kinase; hence they prevent the autophosphorylation of EGFR and further 
downstream signalling (Yewale, Baradia et al. 2013). 
Anti-EGFR monoclonal antibodies exclusively identify EGF receptors due to 
their high selectivity for the receptor. Monoclonal antibodies to EGFR are 
cetuximab, panitumumab (Figure 1.16). Cetuximab is the most frequent anti-
EGFR antibody in use in clinical trials. It is a chimeric IgG1 antibody which 
causes the EGFR internalisation and stimulates the activation of ADCC and 
complement-mediated cytotoxicity. Currently, cetuximab and panitumumab are 
used as anti-EGFR mAbs for treatment of metastatic head and neck and 
colorectal cancers (Yewale, Baradia et al. 2013). 
A recent study on triple-negative breast cancer cells showed that the 
combination of cetuximab and panitumumab had no cooperative effect on triple-
negative tumour cells and did not improve receptor degradation due to 
overlapping of their antigenic epitopes. Combination of non-competitive 
antibodies to EGFR has shown to be effective in inhibition in growth of both in 
vitro and in vivo triple-negative tumour cells by degradation of EGFR (Ferraro, 
Gaborit et al. 2013). Consequently, in current clinical trials, combination of two 
non-competitive anti-EGFR mAbs has been used on both squamous cell 
carcinoma of head and neck and metastatic colorectal cancer. The combination 
of two non-competitive antibodies showed better inhibitory effect on tumour 
growth than antibodies with the overlapping epitopes (Koefoed, Steinaa et al. 
2011).  
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HER-2 has no specific tyrosine kinase inhibitor. Afatinib and lapatinib are dual 
tyrosine kinase inhibitors that target both EGFR and HER-2. Trastuzumab and 
pertuzumab are two antibodies that target HER-2. Since HER-2 has no ligand, 
antibodies that targeted this receptor can block the tyrosine kinase activity 
through inhibition of receptor dimerization, although the exact mechanism 
underlying the HER-2 targeted antibodies are not known (Tebbutt, Pedersen et 
al. 2013). Trastuzumab has shown clinical advantage, particularly in 
combination with other antibodies such as pertuzumab and cytotoxic drugs for 
treatment of HER-2 positive metastatic breast cancer (Baselga, Cortés et al. 
2012). It is a humanized anti-HER-2 monoclonal antibody that can inhibit the 
function of HER-2 through inducing the receptor internalization and degradation. 
Trastuzumab induces ADCC regulated by natural killer (NK) cells. Based on 
recent studies, combination of anti-HER-2 antibodies with the ability to identify 
different epitopes has more potential in inhibition of ligand-mediated invasion 
compared to single agent (Borriello, Laccetti et al. 2011).  
Various tyrosine kinase inhibitors with different level of selectivity have been 
developed. The first generation of EGFR tyrosine kinase inhibitors, are erlotinib 
and gefitinib which inhibit EGFR tyrosine kinase activity (Figure 1.17) (Tebbutt, 
Pedersen et al. 2013). Both of these inhibitors have been reported to shown 
little efficacy when they are used as single agent in breast cancer, even in triple-
negative breast cancer patients with high levels of EGFR (Eccles 2011). 
Therefore, currently in clinical trials these EGFR tyrosine kinase inhibitors are 
used in combination with other cytotoxic or molecularly-targeted agents. As 
mentioned above, lapatinib that inhibits both tyrosine kinase activity of EGFR 
and HER-2, induces the down regulation of both MAPK and PI3K-AKT 
signalling pathways. Lapatinib has been also used in combination with other 
cytotoxic and molecularly-targeted agents such as trastuzumab (Eccles 2011). 
In phase III clinical trials, combination of lapatinib with trastuzumab has shown 
to be effective towards improvement of progression-free survival in breast 
cancer patients and also decrease the risk of disease progression in patients 
who have failed to trastuzumab alone (Eccles 2011).   
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Figure 1.17: Therapeutic targeting strategies in EGFR and HER-2. Therapeutic monoclonal 
antibodies of both EGFR and HER-2 target the extracellular domain of the receptors. Tyrosine 
kinase inhibitors block tyrosine kinase domain. The clinically approved drugs are illustrated in 
bold. Afatinib is a recent clinically approved drug by the US Food and Drug Administration in 
2013 (Tebbutt, Pedersen et al. 2013).  
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1.11 Trefoil factor family of proteins  
1.11.1 The trefoil protein structure 
The mammalian trefoil factor family (TFF) are the secreted proteins that have a 
unique domain called a trefoil domain which contains a three loop structure. 
There are three mammalian trefoil proteins: TFF1 (pS2, PNR-2), TFF2 (hsp, 
spasmolytic poly-peptide, SP) and TFF3 (hITF, intestinal trefoil factor). The 
trefoil domain is 42-43 amino acids long.it has an absolutely conserved 
sequence of six cysteine residues. That helps to stabilise the unique compact 
three-loop structures through formation of three intra-molecular disulphide 
bonds. The nucleotide sequences that encode TFF1, TFF2, and TFF3 have 
been identified in different species of human, porcine, rat, chimpanzee, murine 
and canine. The alignment of these three proteins orthologous are shown in 
Figure 1.18 (Thim and May 2005). 
 
 
Figure 1.18: Amino acid sequence alignments of mammalian trefoil proteins in different 
species. The green coloured residues are conserved between the orthologous, and the purple 
coloured residues are with substitution. Adapted from (Thim and May 2005). 
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The main site of trefoil factor expression is in the epithelial cells of 
gastrointestinal mucosa. TFF1 is synthesised mainly in the stomach, TFF2 in 
the stomach and duodenum, while TFF3 is expressed in the goblet cells of 
small and large intestines (May, Semple et al. 2004, Westley, Griffin et al. 
2005). 
TFF1 is 60 amino acids long and has a single trefoil domain, TFF2 has 106 
amino acids residues and contains two trefoil domains and TFF3 is 59 amino 
acids long and has a single trefoil domain (Thim and May 2005). Both TFF1 and 
TFF3 have an extra cysteine residue near the carboxy-terminus that facilitates 
the formation of homodimers or heterodimers with other proteins (Figure 1.19). 
Recombinant hTFF1 and hTFF3 can be produced as monomers and as 
disulphide-linked dimers (Figure 1.20). It has been reported that monomeric 
TFF2 can stimulate cell migration, whereas, monomeric TFF1 compared to 
dimeric TFF1, has noticeably lower bioactivity (Prest, May et al. 2002). Further 
study demonstrated that, dimerization might be necessary for TFF1 to induce 
cell migration, whereas, TFF3 has shown to be able to stimulate the cell 
migration without dimerization in case of mutation (Taupin and Podolsky 2003). 
Overall dimeric forms of both TFF1 and TFF3 compares to the monomeric 
forms have more efficacies in protection of gastrointestinal tissues (Marchbank, 
Westley et al. 1998).  
.  
Figure 1.19: Structure of TFF1. (A) Amino acid sequence for TFF1 shows the trefoil domain. 
(B) Location and orientation of conserved cysteine residues which form intra-molecular 
disulphide bonds. Taken from citation Westley, Griffin et al. 2005). 
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Based on the high resolution nuclear magnetic resonance studies of monomeric 
and dimeric forms of trefoil proteins, the compact structure of trefoil proteins can 
show the secondary structure. The secondary structure might have role in TFFs 
resistance to the protease degradation and keep them functional in the 
gastrointestinal luminal surface (Taupin and Podolsky 2003). Comparison 
between isoelectric points of human TFF1 and TFF3 monomers demonstrates 
that both of the monomers are acidic. TFF1 with the isoelectric point value of 
3.94 is more acidic than the TFF3 with isoelectric point value of 4.75. Both TFF1 
and TFF3 contain acidic charged residues in their N- and C-termini. TFF1 has 
greater number of acidic residues in termini, outside of the trefoil domain, while 
TFF3 has more charged residues inside the trefoil domain of which most of 
them are basic residues (May, Church et al. 2003).  
 
Figure 1.20: Trefoil proteins dimerization.  Ribbon illustration of (A) TFF1 homodimer, (B) 
TFF2 homodimer and (c) TFF3 homodimer. Adapted from (Muskett, May et al. 2003)  
 
1.11.2 The function of trefoil proteins 
The exact role of trefoil proteins in tumourigenesis is controversial. Different 
biological roles have been assigned to trefoil proteins including tumour 
suppressive and tumour promoting role. Trefoil proteins have an important role 
in protection of the gastrointestinal mucosa layer against the damage and also 
subsequent repair through motogenic and anti-apoptotic activity; hence they 
help in formation of a protective barrier during the process of restitution. In 
response to injury, trefoil proteins production and secretion are increased and 
they act in an autocrine fashion to stimulate the migration of epithelial cells over 
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the basement membrane to the site of the injury (Figure 1.21). The precise 
signalling pathways which mediate the effects of trefoil proteins and determine 
the function of putative trefoil protein receptors have not been clarified. If 
malignant transformation occurs in epithelial cells, then the motogenic and anti-
apoptotic properties of trefoil proteins may lead to migration, invasion and 
metastases of the malignant cells (Taupin and Podolsky 2003).  
 
Figure 1.21: A schematic illustration of restitution. Local injury occurs to the mucosal 
epithelial cells on the basement membrane (a) that leads to cell detachment and death (b) 
which is followed by exposure of matrix elements and rapid expression of (motogens; M) from 
the matrix and adjacent cells (c) that helps to speed the repair, and subsequently leads to 
migration of epithelial cells and inhibition of cell death (d). Restoration between cells and their 
matrix (e). Taken from citation (Taupin and Podolsky 2003). 
 
It has been reported that trefoil proteins act as a tumour suppressor by inhibition 
of the cell proliferation in gastric cancer which was confirmed through loss of 
approximately 50% of TFF1 expression in gastric carcinomas (Lefebvre, 
Chenard et al. 1996). Similarly, a recent study in gastric cancer reported the 
decrease in the TFF1 expression followed by increase in expression of TFF3 in 
gastric tumours, which indicate TFF3 as a marker of poor prognosis in this 
cancer (Im, Yoo et al. 2013). TFF1-null mice demonstrated hyperplasia and 
dysplasia in the stomach, which was followed by intra-epithelial and intra-
mucosal carcinoma. This evidence can support the hypothesis that TFF1 act as 
46 
 
gastric tumour suppressor genes (Buache, Etique et al. 2011). Trefoil proteins 
overexpression has a tumour progressive effect through stimulation of the 
migration and invasion of tumour cells. Hence it has been proposed that they 
are involved in tumour dissemination (Prest, May et al. 2002). The 
inconsistencies about the function of trefoil proteins can provide an explanation 
why trefoil protein expression, in particular TFF1, exerts a beneficial effect to 
normal cells by having an influence on mucosal protection and wound repair 
during local damage and subsequently undesirable effects to cancerous cells by 
exhibiting their role as motogenic, pro invasive and pro angiogenic factors. 
Inappropriate expression of TFF1 may contribute to tumourigenesis due to its 
anti-apoptotic and angiogenic characteristics (Emami, Rodrigues et al. 2004). 
Over expression of trefoil proteins is reported in several important human solid 
tumours such as: breast, lung, colon, and prostate cancer. An investigation into 
TFF1 function in gastrointestinal cells demonstrated that, TFF1 has anti-
proliferative and anti-apoptotic roles (Bossenmeyer-Pourié, Kannan et al. 2002). 
TFF1 activates two cellular responses: firstly, it reduces the gastrointestinal 
cellular proliferation through delaying the G1-S phase cell phase transition by 
keeping the cells inside G1 phase of the cell cycle and subsequently postpones 
their entry into S phase, secondly, it protects cells from apoptosis that can occur 
by chemical, anchorage free or Bad-induced apoptosis which was 
demonstrated by reduction in the activities of caspase-3, -6, -8 and -9 
(Bossenmeyer-Pourié, Kannan et al. 2002). Collectively, these results elucidate 
evidence in support of both an anti-proliferative and an anti-apoptotic role for 
TFF1 in cancerous cells (Bossenmeyer-Pourié, Kannan et al. 2002). Over 
expression of TFF3 has been shown to enhance the cell survival and migration, 
also it showed to increase the anchorage-independent growth of the oestrogen 
receptor-positive breast carcinoma (Kannan, Kang et al. 2010). 
1.11.3 Trefoil proteins in breast cancer 
It is known that breast cancer cells are influenced by the hormonal levels in 
human body. Significant numbers of human breast cancers depend on 
oestrogen level. Research has been directed towards identification of the genes 
which are affected by the level of oestrogen in tumour cells as potential markers 
of response to hormonal therapy and novel therapeutic targets. Studies show 
that amongst the three trefoil proteins, TFF1 and TFF3 are expressed at high 
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levels in breast tumour cells while TFF2 is not generally expressed (Poulsom, 
Hanby et al. 1997). Both TFF1 and TFF3, particularly TFF1 are oestrogen-
responsive genes that have been identified most frequently in breast tumour 
cells (Masiakowski, Breathnach et al. 1982, May and Westley 1997, May and 
Westley 1997). In contrast to the reduction in expression of TFF1 in gastric 
tumours, TFF1 expression is not reduced in breast tumours and its expression 
in breast cancer cells is under the control of oestrogen. In the very first line of 
evidence, It has been demonstrated that oestrogen increases the concentration 
of TFF1 mRNA up to 100-fold (May and Westley 1988). 
The TFF1 promoter has been reported to be regulated also by other molecules 
apart from oestrogen such as human growth factor (hGH), insulin-like growth 
factor 1 (IGF-1), transforming growth factor beta (TGF-β), epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) (Baus-Loncar and Giraud 2005). 
In contrast to screen-detected tumours in which TFF1 expression is associated 
positively with oestrogen receptor expression, in interval breast cancers there is 
discrepancy between oestrogen receptor and TFF1 expression. In this particular 
type of breast cancer levels of TFF1 expression are noticeably higher, whereas 
levels of expression of oestrogen receptor is lower (Crosier, Scott et al. 2001). 
This observation suggests that, in interval breast cancer TFF1 is likely to be 
expressed independently from oestrogen receptor and TFF1 expression might 
be more related to the Ki67 proliferation marker of proliferation as interval 
cancers are characterized by high level of Ki-67, hence this might lead to the 
possibility that cell division and migration might be responsible in rapid 
development of tumours.  
An association between HER-2 and TFF3 expression has been reported in 
breast cancer cell lines. In a microarray analysis of pooled mRNA from three 
HER-2 negative and three HER-2 positive breast cancer cell lines, abundant 
TFF3 mRNA has been identified in the HER-2 positive breast cancer cell line 
samples. This observation was validated by northern transfer analysis which 
showed that there is an expression of TFF3 in two out of the three cell lines 
which are positive for HER-2 (Wilson, Roberts et al. 2002). However, further 
analysis did not demonstrate an association between HER-2 and TFF3 
expression in primary breast tumour cells. The study did not consider the 
oestrogen receptor status in the cell lines. In 2013, Yue et al reported the high 
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expression of TFF3 in HER-2 positive breast cancer patients and demonstrated 
that silencing HER-2 in HER-2 positive SK-BR-3 breast cancer cells, induced 
downregulation of TFF3 in this cell line (Yue, Xiang et al. 2013).  
One group has suggested that TFF1 has oncogenic functions in breast cancer 
cells. They reported that overexpression of TFF1 increases the anchorage-
independent growth in MCF-7 cells which is followed by an increase in cell 
migration and invasion. The same group reported that overexpression of TFF1 
results in increasing the MCF-7 cell number; this was achieved by increased 
cell proliferation and decreased cell survival. Inhibition of TFF1 functions with a 
polyclonal antibody, caused inhibition of viability of mammary carcinoma cells 
both in vitro and in xenograft models. These findings have to be reconciled with 
very high endogenous expression of TFF1 in MCF-7 cells. On the basis of their 
results, this group proposed that antagonism of the function of TFF1 has 
potential therapeutic value for TFF1-positive mammary carcinoma (Amiry, Kong 
et al. 2009).  
In contrast, in a more recent study, the oncogenic property of TFF1 in human 
breast cancer cells was tested and a negative effect of TFF1 on the 
development of mammary tumours has demonstrated clearly (Buache, Etique et 
al. 2011). The data support the conclusion that expression of TFF1 leads to 
migration and invasion in the mammary epithelial cell lines but that the 
overexpression of TFF1 has no effect on tumourigenicity or anchorage 
dependent or independent proliferation of breast cancer cells. Endogenous 
knockdown of TFF1 in oestrogen-responsive breast malignant cells decreased 
the cellular invasion and motility. Interestingly knockdown of endogenous TFF1 
decreases the formation or progression of tumours in the in vivo mice model. 
Whereas, deficiency in the expression level of TFF1 had result in the 
development of mammary tumour in nude mice. Collectively, these 
observations can show the positive effect of TFF1 against tumourigenicity in 
breast tumours (Buache, Etique et al. 2011). 
The non-steroidal anti-oestrogen tamoxifen is used as a treatment in 
premenopausal patients with advanced breast cancer. In breast cancer cell 
lines, expression of TFF1 is induced weakly by tamoxifen, and anti-oestrogens 
prevent the large increase in TFF1 concentrations that is induced by oestrogen 
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(May and Westley 1986, Prest, May et al. 2002). Prest et al (2002) suggested 
that the motility of breast cancer cells can be stimulated by oestrogen through 
induction of TFF1, and that the efficacy of hormonal therapies may result in part 
from their ability to reduce TFF1 expression and as a result breast cancer cell 
migration. Both TFF1 monomer and dimer stimulate the migration of breast 
cancer cells, but the dimer has more capability in stimulating the migration of 
breast cancer cells. There are variety of hormones and growth factors which 
activate and bind to their receptors through cross-linking with monomer 
receptors. Thus it might be possible that TFF1 dimer is more potential in 
migration of breast cancer cells through a bivalent dimeric receptor (Prest, May 
et al. 2002). Additionally, another study showed the role of TFF3 in regulating 
the anti-oestrogen resistance breast carcinoma and that overexpression of 
TFF3 induce the oestrogen independent growth in breast cancer cells and 
subsequently promotes the resistance of cells to anti-oestrogen therapies such 
as tamoxifen or fulvestrant (Kannan, Kang et al. 2010).  
The presence of metastatic cancer in axillary lymph nodes is one of the 
significant prognostic factors for predicting the recurrence of the disease. 
According to gene microarray-based study, TFF1 is one of the genes which are 
identified as a useful molecular marker for detection of metastatic breast 
cancer. In addition, measurement of the level of TFF1 over expression in 
axillary lymph nodes which contain metastatic breast cancer led to the 
speculation that TFF1 is also a potentially informative prognostic marker for 
detection of micro metastatic breast cancer (Mikhitarian, Gillanders et al. 2005). 
In a recent immunohistochemical study on role of TFF3 in oestrogen receptor-
positive breast tumours, TFF3 expression was observed in both normal breast 
epithelia and malignant tumours and there was a strong correlation between 
expression of TFF3 and the presence of axillary lymph nodes, which can 
suggest the possible involvement of TFF3 in invasion and metastasis of breast 
cancer (Ahmed, Griffiths et al. 2012).  
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Hypothesis: 
Ligands of insulin-like growth factor and epidermal growth factor receptors 
family promote metastasis in oestrogen receptor-negative breast cancers. 
Aim: 
The specific aims for the research planned to address the hypothesis are: 
To elucidate the effect of growth factors on cell survival and migration of 
oestrogen receptor-negative breast cancer. 
1. To analyse the biological roles of IGFs and EGFs on oestrogen receptor-
negative breast cancer cells by: 
i) Protection of cells from anoikis 
ii) Stimulation of cell migration 
2. To investigate the expression of IGF-IR, EGFR, HER-2 and TFF1 and 
TFF3 in oestrogen receptor-negative breast cancer by 
immunohistochemistry and analyse their association with biomarkers of 
cell survival and growth. 
3. To test the effectiveness of drugs that inhibit the IGF and EGF signal 
transduction pathways in: 
i) Inhibition of cell survival protective effect 
ii) Inhibition of the migratory effects  
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Chapter 2.  Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines 
The human breast cancer cell lines and their characteristics investigated in this 
study are listed in (Table 2.1). There are three oestrogen responsive breast 
cancer cell lines; MCF-7, BT-474, EFM-19 and five oestrogen non-responsive 
breast cancer cells lines; SK-BR-3, HCC1419, HCC2218 which are HER-2 
positive and Hs578T, MDA-MB 231 which are triple-negative breast cancer cell 
lines. 
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 Table 2.1: Human breast cancer cell lines characteristics. Cell line origins, receptor status, 
morphology, growth medium, sources and references. 
 
2.1.2 Routine cell culture 
The cell lines MCF-7, BT-474, EFM-19, SK-BR-3, HCC-1419, MDA-MB-231 
and Hs578T cells were cultured routinely as adherent monolayer and HCC-
2218 were cultured as suspension in tissue culture flasks (Corning) in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4-(2-hydroxylethyl)-1-
piperazineethaneusulfonic acid (HEPES) modification (sigma) and 10%  foetal 
bovine serum (FBS), supplemented with 1 μg/ml insulin (Sigma). Cells were 
maintained at 37oC in a humidified 5% CO2-saturated atmosphere. 
 
Cell line 
 
Origin 
 
ERα 
 
PgR 
 
HER-
2 
 
Morphology 
 
Growth 
medium 
 
References 
 
MCF-7 
 
 
Human breast 
adenocarcino
ma pleural 
effusion 
 
+ 
 
+ 
 
_ 
 
Epithelial 
cells 
 
DMEM, 10% 
FBS, 1 µgml-
1 insulin 
 
Engel, et al., 
1978 
Soule, et al., 
1973 and 
 
BT-474 
 
 
Primary 
human breast 
adenocarcino
ma 
 
 
+ 
 
+ 
 
+ 
 
Epithelial 
cells 
 
DMEM, 10% 
FBS, 1 µgml-
1 insulin 
 
Simon, et al., 
1984 and 
Clayton, et 
al., 1997 
 
EFM-19 
 
 
Human breast 
adenocarcino
ma pleural 
effusion 
 
+ 
 
+ 
 
+ 
 
Epithelial 
cells 
 
DMEM, 10% 
FBS, 1 µgml-
1 insulin 
 
Simon, et al., 
1984 and 
Clayton, et 
al., 1997 
 
SK-BR-3 
 
 
Human breast 
adenocarcino
ma pleural 
effusion 
 
_ 
 
_ 
 
+ 
 
Epithelial 
cells 
 
DMEM, 10% 
FBS, 1 µgml-
1 insulin 
 
Engel, et al., 
1978 
 
HCC-1419 
 
 
Human breast 
invasive ductal 
carcinoma 
 
_ 
 
_ 
 
+ 
 
Epithelial 
cells 
 
RPMI 1640, 
10% FBS, 1 
µgml-1 insulin 
 
Gazdar AF, 
et al, 1994 
 
HCC-2218 
 
 
Primary 
human breast 
ductal 
carcinoma 
 
_ 
 
_ 
 
+ 
 
Epithelial 
cells 
 
RPMI 1640, 
10% FBS, 1 
µgml-1 insulin 
 
Gazdar AF, 
et al, 1998 
 
Hs578T 
 
 
Primary 
human breast 
carcinoma 
 
_ 
 
_ 
 
_ 
 
Epithelial 
cells 
 
DMEM, 5% 
FBS, 1 µgml-
1 insulin 
 
Engel, et al., 
1978 and 
Hackett, et 
al., 1977 
 
MDA-MB-
231 
 
Human breast 
adenocarcino
ma pleural 
effusion 
 
_ 
 
_ 
 
_ 
 
Epithelial 
cells 
 
DMEM, 5% 
FBS, 1 µgml-
1 insulin 
 
Engel, et al., 
1978; 
Cailleau, et 
al., 1978 
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Cells were grown in culture medium to approximately 70-80% confluence or as 
necessary, medium was removed and cells were washed with warm phosphate 
buffer saline (PBS) before being detached by incubation in a trypsin-EDTA 
solution (0.17% trypsin and 0.07% Na4EDTA in PBS w/v) (Sigma). All cell lines 
apart from EFM-19 cells were detached using a 1:3 x trypsin-EDTA solution 
diluted in PBS. EFM-19 cells were detached using a 1 x trypsin-EDTA solution. 
HCC2218 cells were grown in suspension. Cells were collected by 
centrifugation at 1,200 rpm for 5 minutes (Beckman Allegra X-12 R, rotor SX 
4750) and resuspended in fresh medium prior to reseeding into fresh flask. 
MCF-7 and BT-474 cells were typically reseeded at 1:6 to 1:9  dilution, SK-BR-
3, HCC-1419 and HCC-2218 cells at 1:3 to 1:6 dilution and MDA-MB-231 and 
Hs578T cells at 1:10 to 1:20 dilution. Medium was changed 24 hours after 
seeding and subsequently every 72 hours at minimum. 
Long term storage of the cells was in 70% DMEM, 20% FBS and 10% of 
dimethyl sulphoxide (DMSO) in 0.5 ml aliquots in liquid nitrogen.  
Cell lines were checked regularly by E. C. Matheson using a MycoAlert kit 
(Lonza Biologics, Slough, UK) to confirm the absence of Mycoplasma 
contamination. 
2.1.3 Preparation of dextran-coated charcoal stripped serum (DCCS) 
Dextran-coated charcoal treated serum was prepared by addition of 20 g of acid 
washed and neutralized charcoal (Sigma) and 0.2 g of dextran T70 (Pharmacia) 
in a 250 ml of centrifuge bottle (Beckman) and mixed thoroughly with 250 ml of 
deionised water. The suspension was allowed to stand at room temperature for 
10 minutes then centrifuged at 7,000 rpm (Beckman Avanti J-26 XP centrifuge, 
JA 16.250 rotor) at 4oC for 15 minutes. The supernatant was discarded and 
pellet was resuspended in 250 ml of deionized water and allowed to stand for 
10 minutes. The suspension was centrifuged again at 7,000 rpm for 15 minutes 
at 4oC. The supernatant was discarded and the pellet was resuspended in 200 
ml of newborn calf serum (Invitrogen). The suspension was transferred to a 500 
ml glass conical flask and agitated in a shaking water bath at 55oC for 40 
minutes. Treated serum was transferred to a fresh 250 ml centrifuge bottles and 
centrifuged at 10,000 rpm (JA 16.250 rotor) for 30 minutes at 4oC. The 
supernatant were collected and transferred to the new centrifuge bottles and 
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again centrifuged at 10,000 rpm for 30 minutes at 4oC. The supernatant were 
collected and filtered by 0.45 μm filters under tissue culture hood and stored at -
20oC.    
2.1.4 Withdrawal of cells from the effect of steroid hormones and growth 
factors  
Cells were withdrawn from the effects of growth factors and steroid hormones in 
maintenance medium by incubation in phenol red-free DMEM (Sigma) and 10% 
of DCCS. Normal growth medium was removed from the cells, cells were 
washed with PBS and the medium was replaced with DCCS medium. Medium 
was changed daily during withdrawal period, which was at least two days for 
experiments requiring withdrawal from IGFs and EGFs, one day to two days, 
depending on the types of the experiments.   
2.1.5 Stimulation assay  
Cells were grown to 70% confluence, detached from tissue culture flasks by 
incubation of trypsin-EDTA solution and pelleted as described in section 2.1.2. 
Pellets were resuspended in the maintenance medium and were counted using 
haemocytometer. Cells were seeded in 12 well plates at a density of 10 x 104 
cells/well for MDA-MB231 and Hs578T cells, and 20 x 104 cells/well for SKBR-3 
cells and left to grow for 24-48 hours to allow attachment. Medium were 
aspirated with pulled glass Pasteur pipette and wells were washed with 1 ml of 
PBS. The medium were replaced with 1 ml of DCCS medium daily and cells 
were cultured for 48 hours. After 48 hours of withdrawal, cells were washed 
once with PBS and incubated in in phenol red-free DMEM and 10% DCC-CS 
alone or supplemented with various concentration of IGF-1 or EGF. Cells were 
incubated for 15 minutes prior to protein extraction by radioimmunoprecipitation 
assay (RIPA) buffer plus inhibitors. Aliquots of protein were measured for the 
levels of total and phosphorylated proteins in IGF and EGF signal transduction 
pathways by Western transfer as described in section 2.3.2. 
2.1.6 Preparation of poly (2-hydroxylethylmethylacrylate) coated plates 
Poly (2-hydroxylethylmethylacrylate) (Sigma) was dissolved in 97% ethanol at a 
concentration of 10 mg/ml and to avoid precipitation, the solution stored at 
37oC. Tissue culture plates were coated with poly-HEMA solution under the 
aseptic condition in a tissue culture hood. Twelve well plates were coated with 
0.5 ml per well poly-HEMA solution. After coating plates were incubated at 37oC 
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with gentle agitation until dry. The same procedure was repeated using the 
same volumes of poly-HEMA solution. Wells were then washed with 1 ml of 
sterile PBS and stored at 4oC.  
2.1.7 Anoikis assay 
Cells were grown to 70% confluence, detached from tissue culture flask by 
incubation with a trypsin-EDTA and recovered as described in section 2.1.2. 
Cells were counted with haemocytometer and diluted to the required density in 
the experimental medium. For experiments to test the protective effect of IGF-1 
and EGF, cells were resuspended in phenol red-free DMEM medium without 
serum (SFM) supplemented with IGF-1 concentration of 0.5 to 50 ng/ml and 
EGF at concentration of 0.1 to 50 ng/ml in 0.01% bovine serum albumin (BSA) 
or with 0.01% BSA alone. For 12 well plates, the cell suspension was diluted to 
a density of 15 x 104 to 20 x 104 cells/ml and 2 ml of cell suspension were added 
to each well. MDA-MB-231 cells incubated for 24 hours prior to protein 
extraction with RIPA buffer plus inhibitors as described in Section 2.2.1, or 
processed for analysis with the flow cytometer (ImageStream X Mack II-Amnis) 
as described in Section 2.6. Hs578T and SK-BR-3 cells were incubated for 6 
hours prior to protein extraction. 
For experiments designed to investigate the effects of monoclonal antibody 
against the type I IGF receptor CP-751, 871 or dual tyrosine kinase inhibitor 
BMS-754807, on anti-anoikis effect of IGF-1 in SFM, cells were grown to 
approximately 70% confluence, following detachment and recovery as 
described in section 2.1.2, cells were re-suspended in SFM and counted using 
a haemocytometer. The cell suspension was diluted to a density of a 70 X 104 
cells/ml in SFM supplemented with experimental inhibitors or the solvent, and 
cells were incubated for 30 minutes. The cell suspension then diluted to a 
density of 10 x 104 cells/ml in the SFM in the absence or presence of CP751, 
871 at concentration ranging from 1-10 µg/ml or BMS-754807 at concentration 
ranging from 1 to 10 µM, and in the absence or presence of IGF-1 at 
concentration of 50 ng/ml. Cells were seeded into a fresh 12 well Poly-HEMA 
coated plate at density of 20 x 104 cells/well in 2 ml of experimental medium 
and incubated for different periods of time, depending on the cell lines under 
investigation as described above, prior to protein extraction with RIPA buffer 
plus inhibitors as described in section 2.2.1.  
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For experiment designed to investigate the effect of antibody against type I IGF 
receptor CP-751871, on anti-anoikis effect of IGF-1 in MDA-MB-231 cells, cells 
were cultured into two T 25 cm2 tissue culture flasks and incubated in the DCCS 
medium supplemented with CP-751, 871 or IgG2 antibody (Sigma 15404) at 
concentration of 10 µg/ml for 24 hours. Cells were detached and recovered as 
described in section 2.1.2 and were re-suspended in DCCS medium and 
counted in a haemocytometer. Cells were added into poly-HEMA coated plate 
at a density of 20 x 104 cells/well and incubated for 24 hours, prior to protein 
extraction. 
For experiments designed to investigate the effect of EGFR inhibitor gefitinib or 
dual tyrosine kinase inhibitor lapatinib on anti-anoikis effect of EGF, following 
cell detachment and recovery, cells were re-suspended in SFM and counted in 
a haemocytometer. The cell suspension was diluted to a density of a 70 X 104 
cells/ml in SFM supplemented with experimental inhibitors or the solvent, and 
cells were incubated for 30 minutes. The cell suspension then diluted to a 
density of 10 x 104 cells/ml in the SFM in the absence or presence of 
experimental inhibitors at concentration ranging from 1- 10 µM and in the 
absence or presence of EGF at concentration of 50 ng/ml. Cells were seeded 
into a fresh 12 well poly-HEMA coated plate at density of 20 x 104 cells/well in 2 
ml of experimental medium and incubated for different periods of time, 
depending on the cell lines under investigation as described above, prior to 
protein extraction with RIPA buffer plus inhibitors as described in section 2.2.1. 
2.2 Protein extraction and quantification 
2.2.1 Cell lysates and protein extraction in RIPA buffer 
For protein extraction from attached cells, wells were washed with cold PBS 
and then lysed with radioimmunoprecipitation (RIPA) buffer which contains 50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 (v/v) and 0.25% 
sodium deoxycholate (w/v). Protease and phosphatase inhibitors were added to 
give final concentrations of 1 µg/ml Aprotinin, 1 µg/ml Pepstatin, 1 µg/ml 
leupeptin, 2mM Orthovanadate, 2mM sodium Fluoride, 2 mM phenyl methyl 
sulphonyl fluoride (PMSF). For 12 well plate 80 to 120 μl per well of RIPA buffer 
plus inhibitors was used per well. For 6 well plates 200 to 250 μl of RIPA buffer 
plus inhibitors per well was used. For tissue culture T75cm2 flask 1 ml of RIPA 
buffer plus inhibitors were used per flask. After addition of lysis buffer, cells 
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were kept on the ice with gentle agitation for 30 minutes. The cell lysates were 
collected to Eppendorf tubes and clarified from debris by centrifugation at 1400 
rpm (Hettich Mikro 22R) for 10 minutes. The supernatants were transferred to 
the freshly labelled tubes and stored in -20oc. 
For protein extraction from non-attached cells cultured in poly-HEMA coated 
plates, the cells and medium were collected into the 15 ml falcon tubes 
(Greiner). Each well was washed with 1 ml of cold PBS by pipetting gently over 
the surface of the well to maximise the cell collection and added to the cell 
suspension. Cell suspension was centrifuged at 2, 500 rpm (Beckman Allegra 
X-12R SX 4750 rotor) for 5 minutes at room temperature. The supernatant was 
removed and cells were lysed with 50 to 70 µl of RIPA buffer plus inhibitors. 
2.2.2 Measurement of protein concentration by bicinochoninic acid (BCA) 
protein assay 
Protein concentration of cell lysates were measured with a bicinchoninic acid 
assay (BCA: Pierce), which is a colorimetric assay for quantification and 
identification of total proteins. This method is the Biuret reaction in which Cu+2 
ions in the BCA reagent are reduced to Cu+.  The purple colour produced as a 
result of the chelating of two molecules of BCA with one molecule of Cu+ ion, 
which show the strong absorbance at 562 nm. Aliquots of 0.5 µl of lysates were 
diluted in 4.5 µl of deionized water. Protein standards are ranging from 
concentration of 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2 mg/ml were prepared form 
bovine serum albumin (Sigma) in RIPA buffer that had been diluted in 1 in 10 
dilution of sterile deionised water. BCA working reagent contained 50 parts of 
reagent A and 1 part of reagent B. five µl of each known standard solutions and 
each known samples were mixed with 95 µl of the BCA working solution and 
incubated at 37oC for 30 minutes and kept in ice to stop the reactions and avoid 
further development of the colour. The optical density of the samples was 
measured with spectrophotometer (Beckman DU 640) at the 562 nm wave 
length, the protein concentration of unknown samples were calculated on the 
basis of BSA standard curve. 
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2.3 Western transfer analysis 
2.3.1 Protein gel electrophoresis 
Protein samples were separated by sodium dodecylsulfate (SDS)-
polyacryamide gel electrophoresis. The acrylamide to bisacrylamide ratios were 
200:1 for the separating gel and 20:1 for the stacking gel. The separating gels 
contained 12% acrylamide, 0.37 M Tris-HCl pH 8.8 and 0.1% sodium dodecyl 
sulphates (SDS), 0.05% ammonium persulphate (w/v) and 0.1% N, N, N’, N’-
tetramethylethylenediamine (TEMED) (v/v). The stacking gel contained 3% 
acrylmide, 125 mM Tris-HCl pH 6.8 and 0.1% SDS (w/v), 0.1% of ammonium 
persulphate (w/v) and 0.5% TEMED. Gels were cast in vertical slab minigel 
apparatus (Hoeffer) and allowed to polymerise, 45 minutes for the separating 
gels and for the stacking gel 15 to 20 minutes. Separating gels of 20% 
acrylamide and stacking gel containing 5% of acrylamide were used for trefoil 
protein analysis because of their small molecular mass.  
Samples aliquots containing equal amount of protein were mixed with 10 µl 
aliquots of 0.125 M Tris-HCl, 25 mM Na2 EDTA, 4%  SDS (w/v), 20%  glycerol, 
0.01% bromophenol blue and 10%  β-mercaptoethanol, pH 6.8 (2xSDS mix) 
and kept for boiling for at least 10 minutes in 95oC heat block. Full range 
molecular weight marker (Amersham Rainbow markers) was loaded in a 
separate lane alongside with the protein samples in order to estimate the 
molecular mass of the analysed proteins. The gels were electrophoresed in 
0.38 M glycine, 0.05 M Tris-HCl pH 8.5, and 0.1% SDS running buffer at a 
constant current of 10 mA per gel.   
2.3.2 Western transfer 
Proteins were transferred from the gel to Westran 0.45 µM nitrocellulose 
membrane (VWR) or Westran 0.2 µM polyvinylidene difluoride (PVDF) 
membrane using semi-dry transfer apparatus (S&S CarboGlas, Peqlab 
PerfectBlue). The transfer sandwich comprised of two pieces of 3MM filter 
papers were soaked in 0.3 M Tris-HCl pH 10.4, 20% methanol (anode 1) and 
placed on the glass plate of the apparatus. Another piece of filter paper soaked 
in 25 mM Tris-HCl pH 10.4, 20% methanol (anode 2) was placed on top of the 
two sheets. A sheet of PDVF membrane that had been pre-wet in methanol and 
equilibrated in anode buffer 2or a sheet of nitrocellulose membrane that pre-wet 
in sterile distilled water and equilibrated in anode 2 buffer was placed on top of 
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this assembly. The gel was placed on top of the membrane and covered with 
the other remaining three sheets of 3MM filter paper soaked in 25 mM Tris-HCl, 
40 mM 6-amino-n-hexanoic acid pH 9.4, 20% methanol (cathode solution). 
Proteins were transferred from the gel into the membrane with current of 100 
mA for 10 to 45 minutes dependent upon the molecular mass of the protein. 
The membranes were dried overnight. 
PVDF membranes were pre-wet in methanol and fix in 0.2% gluteraldehyde for 
45 minutes at room temperature on an orbital shaker. The nitrocellulose or 
PVDF membranes were washed thrice with 20mM Tris-HCl pH 7.6 and 137 mM 
NaCl containing 1% Tween 20 (TBS-Tween) each time for 5 minutes and 
blocked in 5% skimmed milk in TBST for 60 minutes at room temperature. The 
membranes were washed thrice each time in 5 minutes in TBST solution and 
were incubated with primary antibodies in 5% milk- TBST overnight at 4oC. 
Membranes were rinse with TBS-Tween and washed a further three times for 5 
minutes in TBS-Tween. Membranes were then incubated in 50 ml tubes with 
horse-radish peroxide (HRP) conjugated secondary antibodies diluted in 5% 
milk-TBS-Tween for 60 minutes at room temperature. Membranes were washed 
thrice for 5 minutes with TBS-Tween and then in a final wash with 1 x TBS 
before development. 
For filter development and visualise the proteins the membranes were 
incubated with Supersignal West Dura extended duration substrate 
chemiluminescent solutions Luminol/Emhancer and Peroxide buffer in 1:1 ratio 
for 5 min and exposed to X-ray film (Fuji SuperRX). The films were developed 
using the development machine. Exposure times ranged from 1 second to 
overnight. 
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The antibodies used for Western transfer analysis are listed in Table 2.2. 
Antibody Source Company  Catalogue 
number 
AKT 
 
Rabbit Cell Signalling 9227 
phospho-AKT (Ser 473) 
 
Rabbit Cell Signalling 4060 
EGFR 
 
Rabbit Cell Signalling 4267F 
phospho-EGFR 
 
Rabbit Cell Signalling 3777S 
ERK 1 and 2 
 
Rabbit Cell Signalling 2933 
phospho-ERK 1 and 2 
(MAPK)*(Thr 202/Tyr 204) 
 
Rabbit Cell Signalling 9102 
GAPDH (HRP-conjugated) 
 
Rabbit Santa Cruz Sc-25778 HRP 
HER-2 Rabbit 
 
Cell Signalling 4290P 
 
phospho-HER-2 Rabbit Cell Signalling 
 
2243S 
 
HER-3 Rabbit Santa Cruz Sc-285 
phospho-HER-3     Rabbit 
 
Cell signalling 4784p 
IGF-IR Rabbit Cell Signalling 9323 
phospho-IGF-IR/IR (Tyr 1135/1136) Rabbit Cell Signalling 3027 
Cleaved PARP (Asp 214) Rabbit Cell Signalling 9541 
Table 2.2: List of antibodies. Source, manufacturers of the primary antibodies used in 
Western transfer analysis. *All the figure references to “MAPK” in the results chapters refer 
specifically to ERK 1 and 2. 
 
2.4 In vitro wounding assay 
Cells were plated at 2-5 x 105 cells/well in 24-well plates, and incubated for 24 
hours to allow them to attach. The 24-well plates in this assay had been scored 
by two parallel lines on the underside of the plate across the middle of the each 
well. After 24 hours of incubation cells were withdrawn and incubated for 
another 24 hours. The cell monolayer in each well was wounded with a p20-200 
Gilson pipette tip through centre of the well perpendicular to the scored lines. 
Cells were washed once with phenol red-free DMEM, incubated with phenol 
red-free DMEM and 0.01% BSA for 2 hours. After 2 hours of incubation, cells 
were washed once with phenol red-free DMEM and medium replaced with the 
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phenol red-free DMEM and 0.01% of BSA in the presence and absence of 
growth factors in triplicate. Images were captured at x100 magnification with 
digital camera from each wound after 0, 2, 4, 6 hours of time points. Image J 
software was used to make a 20 measurements of the width of each wound at 
the site of each score line and the mean width was calculated. The migration of 
the cells at each edge was calculated by subtraction of wound width at a time 
point from the wound width at the start of the experiment and then division of 
the width by 2. The mean movement of the cells is then calculated from the 2 
points in 3 wells for each condition. 
2.5 Immunofluorescence 
Glass coverslips (22 x 22mm) were immersed into a petridish containing 100% 
ethanol to sterilise. The sterilized coverslips were placed in 6-well plate by using 
the needle and forceps. Cells were plated at a density of 4-6 x 105 in per well in 
2 ml in 6 well plates. Cells were incubated for 24 to 48 hours to allow the cells to 
attach. Cells were washed with PBS and fixed in methanol precooled to -20c or 
paraformaldehyde at room temperature for 20 minutes. After fixation, cells were 
washed twice with PBS each time for 20 minutes. Cells were blocked in 5% 
goat serum, 1 x PBS and 0.3% Titron X-100 for 1 hour at room temperature. 
Cells were incubated with primary antibodies at overnight at 4oC (Table 2.3). 
The next day, coverslip were washed thrice with PBS, each time for 15 minutes 
and incubated with secondary antibody (Alexa fluor 488 conjugated anti-mouse 
1gG, A-11001, Invitrogen) at a dilution of 1:1000 for 1 to 2 hours at room 
temperature. The plates were covered with foil due to light sensitivity of the 
fluorophores. After incubation, cells were washed with PBS thrice each for 15 
minutes whilst covered with foil. Phalloidin (Alexa flour 555) which stains the 
cytoskeleton by interaction with F-actin was added 15 minutes prior to addition 
of the mounting medium DAPI. Mounting medium DAPI (H-1200, Vector 
laboratories UK) which stain the DNA in the cell nuclei was added to the glass 
slides before the coverslips were inverted into the glass slides. The cells were 
examined under the confocal microscope (Zeiss LSM).  
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Antibody Source Manufacturer Dilution 
TFF1 Mouse Raised in  our laboratory 1 : 10 
TFF3 Mouse Raised in  our laboratory 1 : 20 
Table 2.3: List of antibodies. Source, manufacturer and dilution of the primary antibodies used 
for immunofluorescence.  
 
2.6 Imagestream Flow cytometry  
To evaluate cell death in non-attached condition, cells that had undergone 
anoikis as described in section 2.1.7 were collected by centrifugation at 2500 
rpm for 5 minutes. The cells were incubated in 1% formaldehyde for 20 minutes 
at room temperature, permeabilized in 0.3% saponin for 1 hour at room 
temperature and blocked with 5% goat serum and 0.3% saponin for another 1 
hour at room temperature. Cells were washed with 500 µl of PBS and stained 
with anti-caspase-3 antibody and Draq5TM (Biostatus, UK) dye, which stains the 
double- stranded DNA in the nuclei overnight at 4oC (Table 2.4). After overnight 
incubation cells were washed with PBS and centrifuged at 400 g for 10 minutes 
and re-suspended in 60 µl of PBS. Images from a total of 1,000 cells from each 
sample were collected with the ImageStreamX (Amnis Crop.) and analysed with 
IDEAS 4.0 Software. The intensity of caspase-3 staining for all cells which is 
sum of the pixel values for each individual cell was displayed in a histogram. 
The threshold for positivity was determined using visual inspection of the 
corresponding images. All cells above this threshold were gated as being 
caspase-3 positive. 
Antibody Source Manufacturer Dilution 
 
Cleaved Caspase-3 (Asp 175) 
Alexa ®488 
 
Rabbit 
 
Cell signalling 
 
1 : 100 
    
 
Table 2.4: List of antibodies. Source, manufacturer and dilution of antibodies used for flow 
cytometry. 
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2.7 Expression of IGF-IR, EGFR, HER-2 and trefoil proteins in breast 
cancer tissue 
2.7.1 Patients and samples 
Ethical permission for the work described in this thesis was obtained from the 
Joint Newcastle Health Hospitals and University of Newcastle upon Tyne 
Ethical Committee. Formalin-fixed, paraffin-embedded tissue blocks from 93 
breast cancer patients were included in this study. All patients were diagnosed 
with breast cancer at the Pathology Department of the Royal Victoria Infirmary 
of the Newcastle Hospitals NHS Trust between 2000 to 2005. Ninety-two of the 
samples were surgical resection specimens and one was core biopsy 
specimen. The lesions investigated included 37 in situ breast carcinomas, 79 
invasive tumours. In addition 7 samples of normal breast tissues distant from 
tumours and lymph nodes tumour deposits from 26 patients were studied.  
2.7.2 Construction of tissue microarray (TMA) 
The original haematoxylin and eosin (H&E) stained sections of breast tissue 
were reviewed with the related formalin-fixed, paraffin-embedded tissue blocks 
that represent normal breast tissue, in situ carcinoma and invasive breast 
tumours. Duplicate cores of 1 millimetre in diameter size were punched from the 
donor block and inserted into the recipient block with Galileo TMA CK 3500 
machine. Each TMA block contained 84 cores of breast lesions, a core of 
mouse liver was included to allow the orientation of each block, a core of normal 
human liver served as reference for IGF-IR immuno-reaction, a core of normal 
human kidney for EGFR immuno-reactivity, a core of breast tumour known to be 
HER-2 positive for HER-2 immuno-reactivity, a core of normal human stomach 
served as reference for TFF1 immuno-reaction and a core of normal human 
ileum serve as reference for TFF3 immuno-reaction (Figure 2.1). The TMA 
blocks were incubated for three cycles of heating in a 37oC incubator for one 
hour and cooling down to room temperature for 30 minutes to congeal the 
tissue cores inserted into the paraffin blocks. Duplicate blocks were prepared 
from each group of cases. Section of 4 µm thick were prepared from each TMA 
block, loaded on superfrost glass slides and incubated at 37oC for at least two 
hours.   
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 Figure 2.1: Construction of tissue microarray block. One millimetre cores from 84 
oestrogens receptor-negative breast tumours were selected and inserted into the recipient TMA 
block. A core from mouse liver (top left) included to allow the correct orientation of the TMA 
block,  core from HER-2 positive breast tumour ( yellow arrow), core from normal human liver 
(black arrow), normal human kidney (blue arrow), normal stomach (red arrow) and normal ileum 
(green arrow) provided references for the HER-2, IGF-IR, EGFR, TFF1 and TFF3 immuno-
reactivity. A 4 µm sections stained with haematoxylin and eosin is shown. Magnification is x20. 
 
2.7.3 Haematoxylin and eosin staining 
TMA sections was de waxed in xylene for 5 minutes and rehydrated through 
graded alcohols of absolute, 95% and 70% ethanol and rinsed in tap water. The 
sections were stained with Harris haematoxylin for 5 minutes, rinsed in running 
tap water and the colour of the stain was cleared by dipping the slide twice in 
acid alcohol followed by a rinse in tap water. The sections were then stained 
with eosin for 30 seconds, washed in running water, dehydrated by dipping in 
graded alcohol, clear in xylene and mounted with DPX. 
2.7.4 Immunohistochemistry 
The expression of IGF-IR, EGFR, HER-2, TFF1 and TFF3 proteins in different 
breast lesions and the association between expression of these proteins and 
expression of other key markers of proliferation and apoptosis was analysed in 
the breast samples included in the constructed tissue microarray. The 
antibodies, their source and the concentrations optimised of 
immunohistochemistry are shown in Table 2.5. 
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Antibody  Source Manufacturer Dilution Incubation time Catalogue 
number 
 
IGF-IR 
 
Rabbit 
 
Cell signalling 
 
1:2400 
 
Overnight at 4 oC 
 
3027S 
 
EGFR 
 
Rabbit 
 
Cell signalling 
 
1:50 
 
Overnight at 4 oC 
 
    4267S 
 
TFF1 
 
Mouse 
 
Raised in our 
laboratory 
 
1:10 
 
60 min at room 
temperature 
 
 
- 
TFF3 Mouse Raised in our 
laboratory 
1:20 60 min at room 
temperature 
- 
HER-2 Rabbit Cell signalling 1:400 Overnight at 4 oC 2165S 
Ki-67 
 
Mouse Dako 1:400 60 min at room 
temperature 
 
M7240 
 
 
9661S 
 Cleaved-caspase-3 
Rabbit Cell signalling 1:300 Overnight at 4 oC 
 
Table 2.5: List of antibodies. Source, manufacturer, dilution and targets of the antibodies used 
for immunohistochemistry.  
 
After deparafinization and rehydration as described in section 2.8.3, TMA 
sections were incubated in 3% hydrogen peroxide for 10 minutes to block the 
endogenous peroxidase activity and then washed in running tap water for 5 
minutes. Antigen retrieval was in 10mM citrate buffer, pH 6.0 with either using a 
pressure cooker (Decloaking chamber, Biocare medical) at 125°C for 45 
minutes. Following antigen retrieval the tissues were left to cool down for 10 
minutes and washed 2 x 5 minutes in Tris buffered saline pH 7.6 contain 1% 
Tween 20 (TBS/Tween) solution. The tissues were incubated with appropriate 
mouse or rabbit primary antibodies diluted in TBS appropriated duration (Table 
1.2). The sections were rinsed in TBS/Tween for 2 x 5 minutes while shaking at 
room temperature. The sections reacted with rabbit antibody were probed with 
horse radish peroxidise (HRP-Polymer) for 30 minutes and rinsed in 
TBS/Tween for 2 x 5 minutes. Whereas, sections reacted with mouse 
antibodies were incubated with the Universal Probes (X-Cell Plus Polymer HRP 
detection kit) for 30 minutes, and washed two times in TBST/Tween for 5 
minutes. All sections were rinsed in running tap water. For development of the 
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colour, 3, 3’ Diaminobenzidine (DAB) solution was added to the tissues for 5 
minutes. The sections were rinsed in running water and counterstained in Gill II 
haematoxylin for 10 seconds. Sections were washed with water, dipped in Scott 
tap water to clear the colour and dehydrated through graded alcohols, cleared 
in xylene and mounted in distrene phthalein xylol (DPX). 
2.7.5 Evaluation of immunohistochemistry 
2.7.5.1 Evaluation of IGF-IR, EGFR and HER-2 immuno-reactivity 
Thousand cells were assessed in each case. The intensity of immuno-reaction 
in each cell was scored as 0, 1, 3 and 10 corresponding to negative, weak, 
intermediate and strong membranous IGF-IR, EGFR and HER-2 expression 
respectively. For each case, the number of negative, weak, moderately-positive 
and strongly-positive immuno-reactive cells was counted. The final score is 
obtained with the following equation: 1 x percentage of weakly stained cells + 3 
x percentage of moderately stained cells + 10 x percentage of strongly stained 
cells. A total score between 0 and 1000 was obtained where 0 occurs when all 
cells are negative and 1000 occurs when all cells are strongly-positive (Figure 
2.2). The final score for each tumour was the mean values of duplicate cores 
(Ahmed, Griffiths et al. 2012). 
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 Figure 2.2: Intensity of immuno-reaction to IGF-IR, EGFR and HER-2 in breast cancer 
cells. Sections of breast cancer were tested for expression of IGF-IR (A) EGFR (B) and HER-2 
(C) by immunohistochemistry. Tumour cells were negative (blue arrows), weakly (yellow 
arrows), moderately (green arrows) or strongly (red arrows) immuno-reactive. Magnification is 
x200.   
 
2.7.5.2 Evaluation of TFF1, TFF3, Ki-67 and cleaved caspase-3 immuno-
reactivity 
The immunohistochemical expression of TFF1, TFF3, proliferation marker Ki-67 
and apoptotic marker cleaved caspase-3 in breast cancer tissue was assessed 
without knowledge of IGF-IR, EGFR or HER-2 expression. Duplicate cores with 
an average of 1000 tumour cells were analysed for each tumour. The immuno-
reactivity of the proteins was evaluated on the basis of the histoscore that was 
described in previous section (Section 2.7.5.1). For TFF1, TFF3 and cleaved 
caspase-3 cytoplasmic immuno-reactivity was evaluated. For Ki-67 nuclear 
immuno-reactivity was evaluated. The final score for each tumour was the mean 
values of duplicate cores. 
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2.7.6 Statistical analysis 
All statistical analyses used the SPSS 21 software package (SPSS, Inc, Illinois, 
Chicago, USA). Duplicate samples were tested for each case and the mean 
histoscores were used for the statistical analyses. The data were analysed by 
non-parametric tests in which the cases are ranked according to the expression 
level of the tested protein and the mean ranks were used for the statistical 
analyses. The association between expression of the biomarkers and various 
clinical and pathological variables was analysed. Correlations between two 
continuous variables was tested with Pearson Rank Correlation test while 
correlation between a continuous variable and a categorical variable was tested 
with Spearman`s rho Correlation test. The distribution of expression of each 
biomarker amongst two independent groups was compared with the Mann-
Whitney test and amongst more than two groups with the Kruskall-Wallis test. 
Wilcoxon signed rank test was used for paired variables to compare the 
expression of the biomarkers in invasive tumours. The frequency of 
occurrences between two variables was evaluated by Crosstabs in descriptive 
statistics.   
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Chapter 3. The effect of insulin-like growth factor-1 on anoikis 
and migration of oestrogen receptor-negative breast cancer 
cells 
 
3.1  Introduction  
Survival of mammary epithelial cells is affected by their attachment to the 
neighbouring epithelial and myoepithelial cells which secret basement 
membrane proteins. Attachment of cells to the extracellular matrix is mediated 
by transmembrane cell surface receptors called integrins and activates 
important components of downstream cell survival signals namely, Ras mitogen 
activated protein kinase (MAPK) pathway and phosphatidylinositol 3-kinase 
(PI3K) AKT pathway (Kim, Koo et al. 2012, Taddei, Giannoni et al. 2012). 
Inappropriate attachment or loss of adhesion of the cells to extracellular matrix 
leads to cell death. This particular type of cell death is called anoikis (Frisch and 
Francis 1994). Anoikis is caspase-dependant cell death, as cell detachment 
triggers activation of caspase-8, which in turn activates caspase-7 and 
subsequently caspase-3 that result in cleavage of its substrates and cell death 
(Taddei, Giannoni et al. 2012, Simpson, Anyiwe et al. 2008).  
An in vitro assay to measure anoikis was first introduced by Folkman and 
Moscana (1978). In 1994, Frisch et al described the induction of anoikis by 
culturing the epithelial cells in plates coated with the inert hydrogel substance 
called poly-HEMA, which prevents cells attachment (Frisch and Francis 1994). 
Nuclear fragmentations and blebbing of the membrane are features that occur 
during anoikis. In normal conditions, detached epithelial cells are eliminated 
through anoikis to inhibit their reattachment to the new incorrect matrix, hence 
preventing dysplastic growth and proliferation of the cells (Kim, Koo et al. 2012, 
Taddei, Giannoni et al. 2012). Anoikis has a significant role in the physiological 
induction of cell death to mediate tissue haemostasis and developmental 
processes (Frisch and Screaton 2001, Grossmann 2002, Kim, Koo et al. 2012). 
The protective role of IGF-1 against stuarosporine-induced cell death in triple-
negative breast cancer cells has been reported (Davison, de Blacquiere et al. 
2011), but the role of IGF-1 on anoikis in oestrogen receptor-negative breast 
cancer cells has not been reported before.  
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Breakdown of anoikis contributes to neoplasia and eventually tumour 
metastasis. Resistance of tumour cells to anoikis is one of the main 
characteristics of malignancy development in which cells tend to survive in 
anchorage independent conditions and gain the ability to migrate to distant sites 
throughout the body (Valentinis, Reiss et al. 1998, Kim, Koo et al. 2012). 
Metastasis which is dissemination of cancer cells from the primary site to distant 
organs is the initial step in migration and invasion of cancerous cells into 
surrounding tissues (Yamaguchi, Wyckoff et al. 2005). Cancerous cells move as 
a group or single cells, in the form of an elongated or an amoeboid shape 
(Brooks, Lomax-Browne et al. 2010). Tumour cells use different mechanisms of 
migration which are similar to the migration mechanism that occur in normal, 
non-neoplastic cells and spread within the tissues (Karp, Pollak et al. 2009). 
Invasive carcinoma cells gain a migratory phenotype that is associated with 
involvement of various genes products associated with cell motility. The 
malignant cells respond to signals from the microenvironment that cause 
tumour invasion (Wang, Goswami et al. 2004). Identification of molecules 
involved in migration of cancerous cells could be important in anti-metastasis 
targeted therapy. IGF-1 has been reported to play an important role in 
metastasis of oestrogen receptor-negative MDA-MB-435 breast cancer cells 
(Tang, Su et al. 2008).  
The aims in this chapter are to investigate the effect of IGF-1 on anoikis in 
oestrogen non-responsive MDA-MB-231, Hs578T, and SK-BR-3 breast cancer 
cells. The responsiveness of components of the IGF signal transduction 
pathway to IGF-1 was tested in a panel of oestrogen non-responsive breast 
cancer cell lines (Table 3.1). The role of the type I IGF receptor in IGF-1 
mediated protection from anoikis was investigated with specific inhibitor of the 
type I IGF receptor. In addition, the effect of IGF-1 on migration of oestrogen 
receptor-negative breast cancer cells was studied and the inhibitory role of an 
antibody against IGF-IR and a dual IGF-IR and insulin receptor tyrosine kinase 
inhibitor on migration of the cells were evaluated. 
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Cell lines ER status PgR status HER-2 status IGF-IR status 
MCF-7 + + - + 
BT-474 + + + + 
EFM-19 + + + + 
SK-BR-3 - - + + 
Hs578T - - - + 
MDA-MB-231 - - - + 
HCC-2218 - - + + 
HCC-1419 - - + + 
 
Table 3.1: Characteristics of different breast cancer cell lines. 
 
3.2  Results 
3.2.1 Expression of the type I IGF receptor in different breast cancer cell 
subtypes 
The response of cells to stimulation by IGF-1 is required expression of the type I 
IGF receptor family member and downstream signal transduction proteins in the 
cells. IGF ligands transduce their signals through type I IGF receptor. 
Interaction of IGF-1 with the type I IGF receptor is considered as the main 
mechanism in activation of IGF downstream signal transduction pathway. This 
event leads to activation of two main downstream signalling cascades: Ras 
mitogen activated protein kinase (MAPK) pathway and phosphatidylinositol 3-
kinase (PI3K) and AKT pathway which play important roles in mediating the cell 
survival and proliferation.   
To evaluate whether IGF signal transduction pathways might be important in 
oestrogen receptor-negative breast cancer cells, the expression of the type I 
IGF receptor was compared in oestrogen-responsive breast cancer cells. 
The relative expression of the type I IGF receptor was evaluated in oestrogen-
responsive MCF-7, BT-474, EFM-19 and oestrogen non-responsive SK-BR-3, 
Hs578T, MDA-MB-231, HCC-2218 and HCC-1419 breast cancer cell lines by 
western transfer analysis. Breast cancer cell lines were cultured in maintenance 
medium, their proteins extracted and analysed for the relative expression of the 
type I IGF receptor by western transfer analysis (Figure 3.1). 
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 Figure 3.1: Expression of type I IGF receptor in different types of breast cancer cell line. 
MCF-7, BT-474, EFM-19, SK-BR-3, Hs578T, MDA-MB-231 (MDA-231), HCC-2218 and HCC-
1419 cells were cultured to approximately 80% confluence and their proteins extracted with 1 ml 
of RIPA buffer per 75 cm2 tissue culture flask as described in Material and Methods Section. 
Aliquots containing 20 μg of extracted proteins were electrophoresed on a 12% denaturing 
polyacrylamide gel and transferred to a nitrocellulose membrane at 100 mA for 45 minutes. 
Membrane was incubated with IGF-IR antibody (1:1000 dilution) and GAPDH (1:20,000 dilution) 
(A). Densitometric scanning of X-ray films determined the amount of each protein by analysis 
with LabWork 4.0 software. The mean + SEM after normalisation to GAPDH expression are 
shown (B). 
 
The type I IGF receptor was expressed at relatively high levels in oestrogen 
receptor-positive breast cancer cells. Amongst oestrogen-responsive breast 
cancer cells, MCF-7 cells expressed the highest level of type I IGF receptor and 
BT-474 cells expressed the lowest level of type I IGF receptor. EFM-19 cells 
expressed relatively high levels of type I IGF receptor, at a lower level than 
MCF-7 cells and at a higher level than BT-474 cells. Amongst oestrogen non-
responsive cells, triple-negative MDA-MB-231 cells expressed high levels of 
type I IGF receptor. Hs578T cells expressed the type I IGF receptor at much 
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lower levels than MDA-MB-231 cells. Amongst HER-2 positive breast cancer 
cells, SK-BR-3 and HCC-1419 cells expressed relatively low levels of type I IGF 
receptor which suggests the possibility that these cells might be less responsive 
to IGF-1 compared to other cell lines. HCC-2218 expressed relatively high 
levels of the type I IGF receptor. The results demonstrate the considerable 
variation in expression of the type I IGF receptor in oestrogen receptor-negative 
breast cancer cell lines. 
3.2.2 Induction of anoikis in oestrogen non-responsive breast cancer 
cells 
A robust method was required to create the conditions under which cells would 
be induced to undergo anoikis, in order to investigate the effect of IGF-1 on 
anoikis. Anoikis was induced by coating the tissue culture plates with poly (2-
hydroxyethyl methacrylate) (poly-HEMA), which is an inert hydrogel that inhibit 
the cell attachment. Cells undergo morphological changes during the anoikis 
process. Non-attached cells are morphologically round with the appearance of 
membrane blebbing, whereas attached cells are morphologically flattened 
polygonal shapes and proliferate as a monolayer sheets (Figure 3.2).   
3.2.2.1 Induction of anoikis in triple-negative breast cancer cells 
MDA-MB-231 and Hs578T cells were seeded in poly-HEMA coated plates and 
cultured in serum-free medium for different lengths of time up to 24 hours. 
Proteins were extracted after each particular time and the extent of cell death 
measured by analysing caspase substrate and marker cleaved PARP (Figure 
3.2).  
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 Figure 3.2: Induction of anoikis in triple-negative breast cancer cell lines. MDA-MB-231 
(A, C, E) and Hs578T (B, D, F) cells were cultured in phenol red free Dulbecco’s Modified 
Eagle’s medium (DMEM) without serum (serum-free medium) in non-attached condition. 
Photographs of cells in both attached and non-attached condition are shown. Cells (A, B) were 
seeded in 12-well poly-HEMA coated plates at the density of 20 X 104 cells/well in 2 ml of 
serum-free medium and cultured for various length of time up to 24 hours. Cells were lysed with 
50 μl of RIPA buffer after each specific time point and proteins were extracted. Aliquots of 10 μl 
protein were electrophoresed on 12% denaturing polyacrylamide gels and transferred to 
nitrocellulsoe membrane at 100 mA for 45 minutes. This followed by incubating the membrane 
was with cleaved PARP antibody (1:2000 dilution) and GAPDH (1:20,000 dilution). The 
illustrated figures are representative of bands from one experiment in triplicate that have been 
replicated at least twice (C, D). Densitometric scanning of X-ray films determined the amount of 
each protein by analysis with LabWork 4.0 software. The mean + SEM after normalisation to 
GAPDH expression are shown (E, F). Asterisks indicates the amount of cleaved PARP was 
statistically higher than in the original cells (One way ANOVA, *p<0.05, **p<0.001, ***p=0.0001, 
****p<0.0001).  
 
In MDA-MB-231 cells, cleaved PARP was detected after 2 hours of incubation 
in non-attached conditions in serum-free medium. Greater amounts of cleaved 
PARP were gradually detected as the incubation time increased. In Hs578T 
cells, cleaved PARP was detected first after incubation for 4 hours and greater 
amounts of cleaved PARP were observed after 24 hours. Based on the results, 
both MDA-MB-231 and Hs578T cells appear to undergo detectable levels of 
anoikis following culture in non-attached conditions in serum-free medium for 24 
hours.  
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3.2.2.2 Induction of anoikis in HER-2 receptor positive breast cancer 
cells 
To induce anoikis, SK-BR-3 cells were cultured in non-attached conditions in 
serum-free medium. Cells were lysed after 0, 2, 4, 6 and 24 hours incubation. 
The results shown in Figure 3.3 demonstrate that cleaved PARP was detected 
after 4 hours of incubation and maximum amounts of cleaved PARP were 
detected at 6 hours of incubation and remained the same up to 24 hours of 
incubation.  
 
Figure 3.3: Induction of anoikis in HER-2 positive SK-BR-3 breast cancer cell line. SK-BR-
3 cells (A) were cultured in phenol red free Dulbecco’s Modified Eagle’s medium (DMEM) 
without serum (serum-free medium) in non-attached condition. Photographs of cells in both 
attached and non-attached condition is shown (A). Cells were seeded in 12-well poly-HEMA 
coated plates at the density of 20 X 104 cells/well in 2 ml of serum-free medium and cultured for 
various length of time up to 24 hours. Cells were lysed with 50 μl of RIPA buffer after each 
specific time point and proteins were extracted. Aliquots of 10 μl protein were electrophoresed 
on 12% denaturing polyacrylamide gels and transferred to nitrocellulose membrane at 100 mA 
for 45 minutes. This followed by incubating the membrane with cleaved PARP antibody (1:2000 
dilutions) and GAPDH (1:20,000 dilutions). The illustrated figures are representative of bands 
from one experiment in triplicate that have been replicated at least twice (B). Densitometric 
scanning of X-ray films determined the amount of each protein by analysis with LabWork 4.0 
software. The mean + SEM after normalisation to GAPDH expression are shown (C). Asterisks 
indicates the amount of cleaved PARP was statistically higher than in the original cells (One 
way ANOVA, ***p=0.0001, ****p<0.0001).  
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3.2.3 The mechanism of IGF-1 signal transduction pathway 
3.2.3.1 Activation of proteins involved in the IGF signal transduction 
pathway by different concentrations of IGF-1 in triple-negative 
breast cancer cells 
To establish whether IGF downstream signal transduction pathways were 
activated in triple-negative MDA-MB-231 and Hs578T cells, the effect of 
stimulation with IGF-1 on the IGF signal transduction pathway was investigated. 
Cells were withdrawn from the effect of IGFs for two days by culture in medium 
containing dextran-coated charcoal treated serum (DCCS). The activation by 
phosphorylation of IGF signal transduction pathway components was 
determined by stimulation with various concentrations of IGF-1 up to 200 ng/ml 
(Figure 3.4).   
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 Figure 3.4 Activation of proteins involved in the IGF-1 downstream signal transduction in 
MDA-MB-231 and Hs578T cells. MDA-MB-231 (A) and Hs578T (B) were seeded at 10 X 104 
cells/well in 1 ml of maintenance medium. Cells allowed to attach by incubation for 24 hours. 
Cells were removed from the maintenance medium, washed with 0.5 ml of PBS and medium 
were replaced with 1 ml of DCCS medium every day for two days. Medium was replaced with 1 
ml of DCCS which was supplemented with IGF-1 at different concentration of 0, 0.05, 0.5, 5, 50, 
100, 200 ng/ml for 15 minutes. After 15 minutes of incubation, cells were lysed with 50 µl per 
well of RIPA buffer. Aliquots of 10 µg protein were electrophoresed on 12% denaturing 
polyacrylamide gels, followed by transformation to nitrocellulose membrane for 45 minutes at 
100 mA. Membrane were incubated with IGF-IR (1:1000 dilution), phosphorylated IGF-IR 
(1:1000 dilution for MDA-MB-231 cells and 1:500 dilution for Hs578T cells), AKT (1:5000 
dilution), phosphorylated AKT (1:5000 dilution), MAPK (1:10,000 dilution for MDA-MB-231 and 
1:20,000 dilution for Hs578T), phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 
dilution). Illustrated results represent one experiment in triplicate. Densitometric scanning of X-
ray films determined the amount of each protein by analysis with LabWork 4.0 software. The 
mean + SEM after normalisation to GAPDH expression are shown. Asterisks denotes 
statistically significant increase in the phosphorylation of IGF-IR, AKT and MAPK with increasing 
IGF-1 concentration (One way ANOVA, *p<0.05).      
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Stimulation with IGF-1 induced a concentration dependent increase in 
phosphorylation of the IGF-IR which was detected at 0.5 ng/ml in MDA-MB-231 
and Hs578T cells (long exposures, not shown). IGF-1 did not affect the 
expression level of total IGF-IR after 15 minutes of stimulation. In MDA-MB-231 
cells, no phosphorylated AKT was observed in the absence of IGF-1. In 
response to IGF-1 stimulation, Akt phosphorylation was detected at IGF-1 
concentration of 0.5 ng/ml and increased in a concentration dependent manner 
with increasing the concentrations of IGF-1. In Hs578T cells, no phosphorylated 
AKT was detected in the absence of IGF-1, AKT phosphorylation was observed 
at 0.05 ng/ml IGF-1 concentration and higher. Stimulation with IGF-1 did not 
alter the expression level of total AKT in either of the cell lines. Phosphorylation 
of MAPK was not detected in the absence of IGF-1 in either of MDA-MB-231 or 
Hs578T cells. In MDA-MB-231 cells, MAPK phosphorylation was detected at 
IGF-1 concentrations of 0.05 ng/ml and higher, and increased with increasing 
IGF-1 concentration. In Hs578T cells, phosphorylation of MAPK at only 42 kDa 
was detected at 0.05 ng/ml IGF-1 concentration and higher. The amount of total 
MAPK did not change following IGF-1 stimulation.  
The response of triple-negative MDA-MB-231 and Hs578T cells to stimulation 
with IGF-1 resulted in activation of IGF signal transduction pathway, which 
confirms that IGF-mediated signalling is functional in these cells. This was 
demonstrated by phosphorylation of downstream signalling components AKT 
and MAPK after treatment with certain concentration of IGF-1. 
3.2.3.2 Activation of downstream effector proteins by IGF-1 in IGF-1 
signal transduction pathway in HER-2 positive SK-BR-3 breast 
cancer cells     
To evaluate whether IGF downstream signal transduction pathway is functional despite 
the very low level of IGF-IR in HER-2 positive breast cancer cell line, SK-BR-3 cells 
were cultured in dextran-coated charcoal treated serum (DCCS) medium to 
withdrawn from the effect of IGFs. The phosphorylation of IGF signal 
transduction components was determined by stimulation with various 
concentrations of IGF-1 up to 200 ng/ml (Figure 3.5). Aliquots of proteins were 
analysed by western transfer for phosphorylation of IGF-IR, AKT, MAPK (Figure 
3.5). 
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 Figure 3.5: Response of SK-BR-3 to stimulation by IGF-1. SK-BR-3 cells were seeded at 
density of 20 X 104 cell/well in 1 ml of maintenance medium and incubated for 48 hours for 
proper attachment. Cells were removed from medium and were replaced with 1 ml of DCCS 
medium daily for two days. Cells were washed with 0.5 ml of PBS and treated with 1 ml DCCS 
supplemented with IGF-1 at different concentration of 0, 0.05, 5, 50, 100, 200 ng/ml for 15 
minutes. After 15 minutes of incubation, cells were lysed with 50 µl per well of RIPA buffer. 
Aliquots of 10 µg of protein were analysed by electrophoresis in 12% denaturing polyacrylamide 
gel and transferred to nitrocellulose membrane for 45 minutes at 100 mA. Membranes were 
incubated with IGF-IR antibody (1:1000 dilution), phosphorylated IGF-IR (1:2000 dilution), AKT 
(1:10,000 dilution), phosphorylated AKT (1:15000 dilution), MAPK (1:20,000 dilution), 
phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution).  Representative 
results are shown from an experiment in triplicate. Densitometric scanning of X-ray films 
determined the amount of each protein by analysis with LabWork 4.0 software. The mean + 
SEM after normalisation to GAPDH expression are shown. Asterisks denotes statistically 
significant increase in the phosphorylation of IGF-IR, AKT and MAPK with increasing IGF-1 
concentration (One way ANOVA, *p<0.05). 
 
In SK-BR-3 cells, stimulation with IGF-1 induced an increase in phosphorylation 
of IGF-IR in a concentration dependent manner which detected at 0.05 ng/ml. 
There was no AKT phosphorylation in the absence of IGF-1. AKT 
phosphorylation in response to IGF-1 in a concentration dependent manner was 
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detected at IGF-1 concentration of 0.5 ng/ml and higher. The amount of total 
AKT did not change following IGF-1 stimulation. Phosphorylated MAPK was 
detected in the absence of IGF-1 at a low level and increases by stimulation 
with the different concentrations of IGF-1. Data showed that increased in the 
concentration of IGF-1, did not alter total IGF-IR, total AKT and total MAPK 
expression level.   
Stimulation with IGF-1 in SK-BR-3 cells, suggests that IGF-1 activates the IGF 
signal transduction pathways. Phosphorylation of downstream protein MAPK 
was observed after treatment with lower concentrations of IGF-1 than 
phosphorylation of IGF-IR. This difference might be due to amplification of the 
signals transduced downstream, which may participate in different thresholds 
for detection of the activated proteins. 
3.2.4 Protective effect of IGF-1 against anoikis in oestrogen receptor-
negative breast cancer cells 
The effect of IGF-1 on the survival of oestrogen receptor-negative MDA-MB-
231, Hs578T and SK-BR-3 breast cancer cells in non-attached condition was 
evaluated by measurement of cleavage of PARP and activation of caspase-3 as 
measures of anoikis. 
3.2.4.1 Effect of IGF-1 on anoikis in non-attached condition in triple-
negative MDA-MB-231 and Hs578T breast cancer cells 
The effects of IGF-1 on survival of triple-negative breast cancer cells, MDA-MB-
231 and Hs578T in non-attached conditions in serum-free medium were 
assessed. Cells were incubated in the presence and absence of 50 ng/ml of 
IGF-1 in serum-free medium in non-attached condition for up to 24 hours. 
Proteins were extracted after incubation for 0, 6, 8 and 24 hours and level of 
PARP cleavage was measured by western transfer analysis (Figure 3.6). 
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Figure 3.6: Effect of IGF-1 on survival of triple-negative breast cancer cell lines. MDA-MB-
231 (A) and Hs578T (C) cells were seeded in 12 well poly-HEMA coated plates at density of 20 
X 104 cells/well in 2 ml of serum-free medium and incubated in the presence and absence of 50 
ng/ml of IGF-1. Proteins were extracted by 50 μl per well of RIPA buffer after incubation for 0, 6, 
8 and 24 hours. Aliquots of 10 µg protein were analysed by electrophoresis on denaturing 12% 
polyacrylamide gel and transferred for 45 minutes at 100 mA. Membranes were incubated with 
antibody against cleaved PARP (1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated 
images are representative of cleaved PARP from a triplicate experiment that have been 
repeated at least three times. Labwork 4.0 software used for densitometric analysis of the X-ray 
films and measurement were normalised with GAPDH (B, D). Column shows mean + SEM, 
Asterisks denotes statistically significant less cleaved PARP in the presence of IGF-1 compared 
with in the absence of IGF-1 (One way ANOVA, ** p<0.001,  ***p=0.0001, ****p<0.0001).  
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Cleaved PARP was significantly reduced in MDA-MB-231 cells after incubation 
with 50 ng/ml of IGF-1 in non-attached condition for 24 hours. In Hs578T cells, 
PARP cleavage was inhibited completely after incubation for 6 hours and the 
inhibition was apparent after 8 and 24 hours of incubation. The reduction in 
cleaved PARP detected in the presence of IGF-1 compared with in the absence 
of IGF-1 supports the hypothesis that IGF-1 inhibits anoikis in triple-negative 
MDA-MB-231 and Hs578T cells.               
3.2.4.2 Effect of IGF-1 on anoikis in HER-2 positive SK-BR-3 breast 
cancer cells   
 
The protective effect of IGF-1 against cell death in non-attached condition was 
investigated on HER-2 positive SK-BR-3 cells. Cells were incubated with 50 
ng/ml of IGF-1 in serum-free medium at different time points up to 24 hours. 
Proteins were extracted after 0, 6, 8 and 24 hours and the level of cell death 
were assessed by western transfer analysis (Figure 3.7).  
 
Figure 3.7: Effect of IGF-1 against cell death on HER-2 positive SK-BR-3 breast cancer 
cells. SK-BR-3 cells were seeded in 12 well poly-HEMA coated plates at density of 20 X 104 
cells/well in 2 ml of serum-free medium and incubated in the presence and absence of 50 ng/ml 
of IGF-1. Proteins were extracted by 50 μl per well of RIPA buffer after incubation for 0, 6, 8 and 
24 hours. Aliquots of 10 µg protein were analysed by electrophoresis on denaturing 12% 
polyacrylamide gel and transferred for 45 minutes at 100 mA. Membranes were incubated with 
antibody against cleaved PARP (1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated 
images are representative of cleaved PARP from a triplicate experiment that have been 
repeated at least three times. Labwork 4.0 software used for densitometric analysis of the X-ray 
films and measurement were normalised with GAPDH. Asterisks denotes statistically significant 
reduction in cleaved PARP in the presence of IGF-1 (One way ANOVA, * p<0.05). 
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Incubation of SK-BR-3 cells with 50 ng/ml IGF-1 induced statistically significant 
reduction in the level of PARP cleavage after 6 hours of incubation, but there 
was no reduction in the level of cleaved PARP after incubation for 8 or 24 
hours. Based on the result, low level of inhibition of anoikis by IGF-1 suggest 
that IGF-1 has minor protective effect against anoikis in SK-BR-3 cells. 
3.2.4.3 Effect of IGF-1 on activation of caspase-3 in MDA-MB-231 
cells in non-attached conditions  
Protective effect of IGF-1 against anoikis in non-attached cells was determined 
by measurement of PARP cleavage. To investigate whether IGF-1 also has 
effect on reduction of caspase-3 activity in order to confirm the survival effect of 
IGF-1 in anoikis, MDA-MB-231 cells cultured in non-attached condition in 
serum-free medium for 24 hours in the presence and absence of IGF-1. Cells 
were collected and incubated with FITC-labelled cleaved caspase-3 antibody 
and Draq 5 nuclei stain overnight and the amount of cleaved caspase-3 was 
analysed by flow cytometry (Figure 3.8).  
 
 
Figure 3.8: The effect of IGF-1 on activation of caspase-3 in non-attached condition. MDA-
MB-231 cells were seeded into 12 well poly-HEMA coated plates in 2 ml of serum-free emdium 
at density of 20 X 104 cells/well and cultured in the presence and absence of 50 ng/ml IGF-1. 
After 24 hours of incubation, cells were collected, washed with PBS, fixed, permeabilised and 
blocked. Cells were incubated with FITC-labelled antiobodies against cleaved caspase-3 and 
Draq 5 (nuclei stain) overnight at 4oC. The fluorescence of the cells was measured by 
Imagestream X (Amnis Crop.) (A, C) and analysed with IDEAS 4.0 Software (B, D). The 
excitation was at 488 nm and 642 nm and cells were gated for the positivity of cleaved caspase-
3 intensity as described in Materials and Method Section. The percentage of the activated 
cleaved caspase-3 positive cells for an experiment was in triplicate.  
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Incubation of MDA-MB-231 cells for 24 hours in non-attached condition in 
serum-free medium, induced caspase-3 activation. The percentage of activated 
caspase-3 in the presence of IGF-1 was reduced by more than three fold 
(Figure 3.8), which supports the conclusion of the previous experiment that IGF-
1 is protective against anoikis in MDA-MB-231 cells. 
3.2.4.4 Effect of various concentrations of IGF-1 on anoikis in MDA-
MB-231 and Hs578T cells 
MDA-MB-231 and Hs578T cells were cultured in non-attached condition in 
serum-free medium and incubated with different concentration of IGF-1 up to 50 
ng/ml. Proteins were extracted from MDA-MB-231 cells after 24 hours and from 
Hs578T after 6 hours of incubation. To evaluate the relative amount of cleaved 
PARP, aliquots of extracted proteins were analysed by western transfer 
analysis (Figure 3.9). 
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Figure 3.9 The effect of various concentrations of IGF-1 on survival of triple-negative 
breast cancer cells. MDA-MB-231 (A) and Hs578T (B) cells were seeded in 12 well poly-
HEMA coated plates at density of 20 X 104 cells/well in 2 ml of serum-free medium, and 
incubated with different concentrations of IGF-1 up to 50 ng/ml. Proteins were extracted after 
incubation of 24 hours from MDA-MB-231 and incubation of 6 hours from Hs578T cells with 50 
μl per well of RIPA buffer. Aliquots of 10 µl protein were analysed by electrophoresis in 12% 
denatured gel and transferred for 45 minutes at 100 mA. Membranes were incubated with 
antibody against cleaved PARP (1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated 
images are representative of cleaved PARP from a triplicate experiment that have been 
repeated at least twice. Labwork 4.0 software used for densitometric analysis of the X-ray films 
and measurement were normalised with GAPDH. Lines shows mean + SEM. Asterisks denote 
the statistically significant less cleaved PARP in the presence of IGF-1 compared with in the 
absence of IGF-1 (One way ANOVA, *p<0.05, **p<0.001).  
 
 
In both MDA-MB-231 and Hs578T cells, PARP cleavage was induced by 
culturing the cells in non-attached conditions in serum-free medium. In the 
presence of IGF-1, the amount of cleaved PARP was reduced in a 
concentration dependent fashion in both MDA-MB-231 and Hs578T cells. In 
MDA-MB-231 cells, there appeared to be a reduction in the amount of cleaved 
PARP in the presence of IGF-1 at a concentration of 0.5 ng/ml compared to its 
absence, but the difference was not statistically significant (p=0.255). A 
statistically significant reduction was observed at IGF-1 concentration of 5 ng/ml 
or higher (p=0.019). There was a positive correlation between the reduction of 
cleaved PARP and increasing the concentration of IGF-1. In Hs578T cells, there 
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was a statistically significant reduction in the amount of cleaved PARP at IGF-1 
concentration of 10 ng/ml (p=0.012), followed by complete inhibition of cleaved 
PARP at IGF-1 concentration of 50 ng/ml.  
IGF-1 demonstrated a powerful survival effect on both triple-negative breast 
cancer cells. In Hs578T cells, the maximal reduction of cleaved PARP was 
greater than in MDA-MB-231 cells at the tested IGF-1 concentrations. Anoikis 
was completely inhibited in Hs578T cells at IGF-1 concentration of 50 ng/ml. 
These results demonstrated that MDA-MB-231 cells are more sensitive to 
anoikis than Hs578T cells and Hs578T cells are more responsive to IGF-1 
compared to MDA-MB-231 cells. The concentration dependent reduction in 
PARP cleavage in the presence of IGF-1 in MDA-MB-231 and Hs578T cells can 
suggest that the survival effect of IGF-1 is transmitted through the type I IGF 
receptor. 
3.2.5 The effect of dual tyrosine kinase inhibitor of IGF-IR and the insulin 
receptor (BMS-754807) on activation of IGF-IR and the insulin 
receptor in triple-negative breast cancer cell lines 
BMS-754807 is a small molecule tyrosine kinase inhibitor of both IGF-IR and 
the insulin receptor (IR). It binds to both IGF-IR and the insulin receptor and 
blocks their phosphorylation and activation. The effectiveness of dual tyrosine 
kinase inhibitor, BMS-754807 was evaluated on survival effect of IGF-1. 
To investigate the effectiveness of BMS-754807 and establish the concentration 
at which the maximum inhibition occurs in the cells in which IGF-1 had a 
protective effect, MDA-MB-231 and Hs578T cells were cultured in attached 
condition in full maintenance medium and incubated with different 
concentrations of BMS-754807 up to 20 µM for 30 minutes. This incubation was 
followed by 15 minutes stimulation of the cells with 50 ng/ml of IGF-1. Proteins 
were extracted and aliquots containing 10 μg of protein were analysed by 
western transfer for phosphorylated IGF-IR/IR, AKT and MAPK (Figure 3.10). 
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Figure 3.10: The effect of BMS-754807 on inhibition of IGF-IR and the insulin receptor 
activity in MDA-MB-231 and Hs578T cells. MDA-MB-231 and Hs578T cells were seeded into 
12 well tissue culture plates at density of 10 x 104 cells/well in 1 ml of maintenance medium. 
Cells were incubated for 24 hours to allow proper attachment. Medium was aspirated and cells 
were washed with 0.5 ml of PBS. Medium was replaced daily with 1 ml/well of DCCS medium 
for two days. After two days of incubation, medium was replaced with DCCS supplemented with 
BMS-754807 at final concentrations of 0, 0.1, 1, 10, 20 μM and cells were incubated with the 
antibody for 30 minutes. After 30 minutes of treatment, medium was replaced with the DCCS 
supplemented with 50 ng/ml of IGF-1 and cells were stimulated for 15 minutes. Proteins were 
extracted with 50 μl of RIPA buffer. Aliquots of 10 μg proteins were electrophoresed on 
denaturing 12 % polyacrylamide gels and transferred into nitrocellulose membrane for 45 
minutes at 100 mA. Membranes were incubated with phosphorylated IGF-IR (1:1000 dilution for 
MDA-MB-231 cells and 1:500 dilution for Hs578T cells), phosphorylated AKT (1:5000 dilution), 
phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). Representative 
bands are from duplicate experiment that has been repeated at least twice. Lines shows mean 
+ SEM, Asterisks represent the statistically significant reduction in phosphorylation of IGF-IR/IR, 
AKT and MAPK in the presence of BMS-754807 compared with in the absence of BMS-754807 
(One way ANOVA, * p<0.05).   
  
In MDA-MB-231 cells, complete inhibition of IGF-IR phosphorylation stimulated 
by 50 ng/ml of IGF-1 was detected at concentrations of 1 μM of BMS-754807 
and above. Whereas, in Hs578T cells treatment with BMS-754807 following 
stimulation with 50 ng/ml of IGF-1, induced reduction in phosphorylation of IGF-
IR from 0.1 μM concentration and followed by complete inhibition of 
phosphorylation at 1 μM concentrations and higher. In MDA-MB-231 cells, 
reduction in phosphorylation of AKT was detected at 0.1 μM concentrations of 
BMS-754807 and followed by complete inhibition of AKT phosphorylation at 
higher concentrations. In Hs578T cells, phosphorylation of AKT reduced 1 μM 
and fully inhibited at higher concentrations of 10 μM and higher. In MDA-MB-
231 cells, decrease in phosphorylation of MAPK was detected at concentration 
of 0.1 μM and higher. In Hs578T cells, BMS-754807 reduced the 
phosphorylation of MAPK at concentration of 10 μM and higher. Complete 
inhibition of MAPK phosphorylation at highest concentration was not achieved 
in either MDA-MB-231 or Hs578T cells. 
Treatment of MDA-MB-231 and Hs578T cells stimulated by IGF-1 with dual 
tyrosine kinase inhibitor against IGF-IR and the insulin receptor resulted in full 
inhibition of phosphorylation of IGF-IR and the insulin receptor and AKT at 
BMS-754807 concentration of 1 μM.  There was a potential inhibition of IGF-1 
stimulated phosphorylation of MAPK in both triple-negative cell lines.  
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3.2.6 Dual tyrosine kinase inhibitor of IGF-IR and the insulin receptor 
abrogates the anti-anoikis effect of IGF-1 
The effect of dual tyrosine kinase inhibitor of IGF-IR and insulin receptor in 
preventing the survival effect of IGF-1 was investigated.  
MDA-MB-231 and Hs578T cells were cultured in non-attached conditions in 
serum-free medium in the presence and absence of BMS-754807, and in the 
presence and absence of IGF-1. Proteins were extracted after 24 hours in 
MDA-MB-231 cells and after 6 hours in Hs 578T cells. Aliquots containing 10 μg 
of protein were analysed by western transfer for phosphorylation of IGF-IR, 
cleaved PARP and phosphorylation of downstream key proteins AKT and 
MAPK (Figure 3.11).  
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Figure 3.11: The effect of dual tyrosine kinase inhibitor of IGF-IR and the insulin receptor 
against anti-anoikis effect of IGF-1 on triple-negative breast cancer cell lines.  MDA-MB-
231 and Hs578T cells were seeded into 12 well poly-HEMA coated plates at 20 X 104 cells/well 
in 2 ml of serum-free medium, in the presence of 1 µM of BMS-754807 or vehicle (DMSO) for 
MDA-MB-231 cells or Hs578T cells in the presence and absence of 50 ng/ml of IGF-1. Proteins 
were extracted after incubation of 24 hours in MDA-MB-231 cells and incubation of 6 hours in 
Hs578T cells with 50 μl per well of RIPA buffer. Aliquots of 10 µg proteins were analysed by 
electrophoresis in denaturing 12% polyacrylamide gels and transferred for 45 minutes at 100 
mA. Membranes were incubated with antibody against phosphorylated IGF-IR (1:1000 dilution 
for MDA-MB-231 cells and 1:500 for HS578T cells), cleaved PARP (1:2000 dilution), 
phosphorylated AKT (1:5000 dilution for MDA-MB-231 cells and 1:10,000 dilution for Hs578T 
cells), phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). Illustrated 
images are representative of cleaved PARP from a triplicate experiment that have been 
repeated at least three times. Labwork 4.0 software used for densitometric analysis of the X-ray 
films and measurement were normalised with GAPDH. Error bars are + SEM, Asterisks denotes 
statistically significant increase in the amount of cleaved PARP in the presence of BMS-754807 
compared in the absence of BMS-754807 in MDA-MB231 and Hs578T cells (One way ANOVA, 
***p=0.0001, ****p<0.0001).   
 
In MDA-MB-231, stimulation with IGF-1 in the absence of BMS-754807 induced 
the strong IGF-IR phosphorylation. In the presence of 1 µM BMS-754807, no 
phosphorylation of IGF-IR was detected in response to stimulation with IGF-1, 
compared with in the absence of BMS-754807. In the presence of 50 ng/ml 
IGF-1 anoikis was significantly inhibited. The degree of anoikis in serum-free 
medium was markedly different in the presence of BMS-754807 compared with 
the absence of BMS-754807. The protective effect of IGF-1 against anoikis was 
reduced significantly in the presence of BMS-754807 which was demonstrated 
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by significant increase in the amount of cleaved PARP in the presence of BMS-
54807 compared with in the absence of BMS-754807 (p=0.0001).  
The increase in the phosphorylation of AKT in response to stimulation with IGF-
1 was completely inhibited in the presence of BMS-754807. Although IGF-1 
induced phosphorylation of MAPK was not inhibited completely in the presence 
of BMS-754807, there was a significant reduction in the phosphorylation of 
MAPK. 
In Hs578T cells, stimulation with IGF-1 in the absence of BMS-754807 induced 
phosphorylation of IGF-IR, whereas in the presence of 1 µM BMS-754807, IGF-
1 stimulated IGF-IR phosphorylation was not observed. The level of anoikis in 
serum-free medium was slightly higher in the presence of BMS-754807 
compared with in the absence of BMS-754807. In the presence of 50 ng/ml 
IGF-1 anoikis was inhibited. The anti-anoikis effect of IGF-1 was reduced 
significantly in the presence of BMS-754807 (p=<0.0001). This was 
demonstrated by significant increase in the amount of cleaved PARP.   
The increase in the phosphorylation of AKT in response to IGF-1 was inhibited 
completely in the presence of BMS-754807, whereas increased in the amount 
of MAPK in the presence of IGF-1 was significantly reduced in the presence of 
BMS-754807.    
Based on the showed results, the complete inhibition of activated AKT and 
significant reduction in the activated MAPK suggest that dual tyrosine kinase 
inhibitor might be effective in inhibition of survival effect of IGF-1. 
3.2.7 Effect of CP-751, 871 on inhibition of type-1 IGF-IR by IGF-1 on triple 
negative breast cancer cells 
CP-751, 871 (Pfizer) is a fully humanised IgG2 monoclonal antibody against the 
type I IGF receptor. CP-751, 871 binds to the type I IGF receptor but not to the 
insulin receptor and inhibits the activity of the receptor through internalization of 
the type I IGF receptor and reduction in level of the receptor. 
To determine the appropriate concentration for inhibition of type I IGF receptor, 
different concentrations of antibody were incubated in triple-negative MDA-MB-
231 and Hs578T breast cancer cells. 
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MDA-MB-231 and Hs578T cells were cultured in attached condition in full 
maintenance medium and incubated with various concentrations of monoclonal 
antibody CP-751, 871 up to 20 μg/ml for 24 hours in MDA-MB-231 and for 6 
hours in Hs578T cells. After incubation with the antibody, both cell lines were 
stimulated with the 50 ng/ml of IGF-1 for 15 minutes. Proteins were extracted 
after 15 minutes of stimulation and analysed for phosphorylation of IGF-IR by 
western transfer (Figure 3.12).  
 
Figure 3.12: Effect of CP-751, 871 on activation of type I IGF receptors in MDA-MB-231 
and Hs578T cells. MDA-MB-231 and Hs578T cells were seeded into 12 well tissue culture 
plates at density of 10 x 104 cells/well in 1 ml of maintenance medium. Cells were incubated for 
24 hours to allow attachment. Medium was aspirated and cells were washed with 0.5 ml of PBS. 
Medium was replaced daily with 1 ml/well of DCCS medium for two days. After two days of 
incubation, medium was replaced with DCCS supplemented with CP-751, 871 antibody at final 
concentrations of 0, 0.1, 1, 10, 20 μg/ml and cells were incubated with the antibody for 24 hours 
(MDA-MB-231 cells) and 6 hours (Hs578T cells). After treatment of cells with various 
concentrations of antibody, medium was replaced with the DCCS supplemented with 50 ng/ml 
of IGF-1 and cells were stimulated for 15 minutes. Proteins were extracted with 50 μl of RIPA 
buffer. Aliquots of 10 μg proteins were electrophoresed on a denaturing 12 % polyacrylamide 
gel and transferred into nitrocellulose membrane for 45 minutes at 100 mA. Membranes were 
incubated with phosphorylated IGF-IR (1:1000 dilution for MDA-MB-231 cells and 1:500 dilution 
for Hs578T cells) and GAPDH (1:20,000 dilution). Representative images are from duplicate 
experiments are shown. Labwork 4.0 software used for densitometric analysis of the X-ray films 
and measurement were normalised with GAPDH. Lines shows mean + SEM, Asterisks 
represent the statistically significant reduction in phosphorylation of IGF-IR in the presence of 
CP-751, 871 compared with in the absence of CP-751, 871 (One way ANOVA, * p<0.05).   
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In MDA-MB-231 cells phosphorylation of IGF-IR was reduced at a concentration 
of 0.1 μg/ml of CP-751, 871 and complete inhibition of phosphorylation 
stimulated with 50 ng/ml of IGF-1 was detected at concentrations of 20 μg/ml. In 
Hs578T cells treatment with the antibody following stimulation with 50 ng/ml of 
IGF-1 induced a concentration dependent decrease in the phosphorylation of 
IGF-IR, detected from 0.1 μg concentration and complete inhibition was 
detected at concentrations of 10 μg and higher.  
3.2.8 Inhibition of type I IGF receptor abrogate the protective effect of 
IGF-1 against cell death by CP-751, 871 inhibitor in anoikis 
To determine whether the survival effect of IGF-1 is through type I IGF receptor 
in anoikis condition, the effect of IGF-1 in anoikis was tested in the presence 
and absence of 20 μg/ml and 10 μg/ml concentration of CP 751, 871 from the 
previously optimised concentrations in MDA-MB-231 and Hs578T cells 
respectively.  
MDA-MB-231 and Hs578T cells were seeded into poly-HEMA coated plates in 
serum-free medium and treated with the presence and absence of CP-751, 871 
and in the presence and absence of the IGF-1. Proteins were extracted after 24 
hours from MDA-MB-231 cells and after 6 hours from Hs578T cells. Aliquots of 
proteins were analysed for phosphorylated IGF-IR and cleaved PARP by 
western transfer (Figure 3.13).  
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Figure 3.13: The effect of CP-751, 871 on the anti-anoikis effect of IGF-1 in triple-negative 
breast cancer cell lines. MDA-MB-231 cells first were cultured in two 25 cm2 tissue culture 
flasks and incubated for 24 hours in the presence of 20 μg/ml CP-751, 871 antibody or vehicle 
IgG2. After 24 hours of treatment, cells were seeded into poly-HEMA coated plates at 20 X 104 
cells/well in 2 ml of serum-free medium, in the presence and absence of CP-751, 871 or IgG2, 
and  in the presence and absence of 50 ng/ml of IGF-1 and incubated for 24 hours. Hs578T 
cells were seeded into 12 well poly-HEMA coated plates at density of 20 X 104 cells/well in 2 ml 
of serum-free medium and incubated in the presence and absence of 10 μg/ml of CP-751, 871 
or IgG2 and in the presence and absence of 50 ng/ml IGF-1. Proteins were extracted after 
incubation of 24 hours in MDA-MB-231 and after incubation of 6 hours in Hs578T cells with 50 
μl per well of RIPA buffer plus inhibitors. Aliquots of 10 µl protein were analysed by 
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electrophoresis in 12% denatured gel and transferred for 45 minutes at 100 mA. Membranes 
were incubated with antibody against total IGF-IR (1:1000 dilution), phosphorylated IGF-IR 
(1:1000 dilution for MDA-MB-231 cells and 1:500 dilution for Hs578T cells), cleaved PARP 
(1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated images are representative of 
cleaved PARP from a triplicate experiment that have been repeated at least three times. 
Labwork 4.0 software used for densitometric analysis of the X-ray films and measurement were 
normalised with GAPDH. Error bars are + SEM, Asterisks denotes that cleaved PARP 
significantly increased in the presence of CP-751, 871 compared with in the absence of CP-
751, 871 in both cell lines (One way ANOVA, **p<0.001, ***p=0.0001, ****p<0.0001).  
  
In presence of 20 μg/ml CP-751, 871 the amount of total IGF-IR was reduced in 
both MDA-MB-231 and Hs578T cells. The amount of cleaved PARP that was 
induced in each cell lines after incubation in non-attached condition in serum-
free medium was reduced by more than 60-70% in the presence of 50 ng/ml 
IGF-1. In each cell line, in the present of IGF-1, there was an increase in the 
amount of cleaved PARP which was statistically significant in the presence of 
CP-751, 871 compared to the absence of CP-751, 871. In MDA-MB-231 cells 
the amount of cleaved PARP in the presence of IGF-1 was increased by almost 
two fold in the presence of CP-751, 871 compared to the absence of CP-751, 
871. In Hs578T cells the increase in cleaved PARP was almost more than two 
fold in the presence of CP-751,871 compared to the absence of CP-751, 871.  
In conclusion, CP-751,871 inhibited completely the protective effect of IGF-1 
against anoikis in both cells lines, which supports the hypothesis that blocking 
the type I IGF receptor can inhibit the survival effect of IGF-1 and that IGF-1 
extents its effects through the type I IGF receptor.  
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3.2.9 Effect of dual tyrosine kinase inhibitor on anoikis in full 
maintenance medium 
In this chapter the preceding results demonstrate that firstly, anoikis can be 
induced in triple-negative breast cancer cells when cultured in non-attached 
conditions in serum-free medium and secondly, IGF-1 has a powerful survival 
effect under these conditions. In patients, tumor cells are not present in serum-
free medium, but they are exposed to growth factors as well as to other serum 
components. Therefore, to evaluate whether BMS-754807 potentiates the cell 
death in full maintenance medium in non-attached cells, MDA-MB-231 cells 
were cultured in non-attached conditions in full maintenance medium. Effects of 
IGF-1 were inhibited with the dual tyrosine kinase inhibitor of both IGF-IR and 
the insulin receptor BMS-754807. Proteins were extracted after 24 hours of 
incubation and analysed for phosphorylation of IGF-IR and cleaved PARP by 
western transfer (Figure 3.14).            
Figure 3.14: The effect of dual tyrosine kinase inhibitor BMS-754807 on anoikis in MDA-
MB-231 cells cultured in full maintenance medium. MDA-MB-231 cells were cultured into 12 
well poly-HMEA coated plates at density of 20 X1 04 cells/well in 2 ml of full maintenance 
medium in the presence of 1 µM BMS-754807 or vehicle (DMSO). Proteins were extracted after 
24 hours with 50 µl of RIPA buffer. Aliquots of 10 µg proteins were analysed by electrophoresis 
in denaturing 12% polyacrylamide gel and transferred for 45 minutes at 100 mA. Membranes 
were incubated with antibody against total IGF-IR (1:1000 dilution), phosphorylated IGF-IR 
(1:1000 dilution), cleaved PARP (1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated 
images are representative of cleaved PARP from a triplicate experiment that have been 
repeated at least twice. Labwork 4.0 software used for densitometric analysis of the X-ray films 
and measurement were normalised with GAPDH. Error bars are + SEM, Asterisks denotes 
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there was a statistically significant decrease in total level of IGF-IR in the presence of BMS-
754807. Asterisks denotes that there was a significant inhibition in IGF-IR phosphorylation, 
significant decrease in AKT phosphorylation and significant increase in the amount of cleaved 
PARP in the presence of BMS-754807 compared with in the absence of BMS-754807 in MDA-
MB-231 cells in full maintenance medium (One way ANOVA, ***p=0.0001, ****p<0.0001).  
  
There was a reduction in the amount of total IGF-IR following incubation with 
BMS-754807 for 24 hours. Phosphorylation of IGF-IR was completely inhibited 
in the presence of BMS-754807 compared with in the absence of BMS-754807. 
Relatively small amounts of cleaved PARP were detected after 24 hours 
incubation of cells in full maintenance medium in non-attached conditions. The 
amount of the cleaved PARP increased significantly by almost 10 fold in the 
presence of 1 μM BMS-754807 compared with in the absence of BMS-754807. 
AKT phosphorylation was decreased significantly in the presence of BMS-
754807.   
The increase in the level of cleaved PARP and decrease in the level of AKT in 
the presence of BMS-754807 despite the presence of 10% foetal calf serum in 
the medium, supports the hypothesis that IGFs play a more important role 
against anoikis than any other serum components in MDA-MB-231 cells. The 
results suggest that IGF signalling pathway is important in these triple-negative 
breast cancer cells.  
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3.2.10 Effect of IGF-1 on migration of oestrogen receptor-negative breast 
cancer cells 
Increase in cell motility is one of the factors associated with development of 
malignancy and metastasis. The effect of IGF-1 on migration of oestrogen 
receptor-negative breast cancer cells was evaluated using a wound healing 
assay. 
3.2.10.1 Effect of IGF-1 on migration of triple-negative MDA-MB-231 
and Hs578T breast cancer cells  
Both triple-negative MDA-MB-231 and Hs578T cells were plated at high density 
in 24 well plates which had been scored on their under surface with two parallel 
lines. Cells were incubated for 24 hours to allow confluent monolayer formation. 
Cells were washed and withdrawn from the effects of hormones in phenol red-
free DMEM medium supplemented with dextran-coated charcoal-treated new 
born calf serum (DCC-CS) for 16 hours. Cells monolayers were wounded with a 
sterile pipette tip through the monolayer, washed with phenol free-red DMEM to 
remove any cell debris or detached cells and incubated in 0.01% BSA and 
phenol free-red DMEM for 2 hours. After 2 hours of incubation, the first images 
were taken (time 0). Cells were incubated in the presence or absence of IGF-1 
for up to 6 hours and images were captured every two hours. Each condition 
was in triplicate. The cell migration was evaluated by measuring the distance of 
the edge of the wound towards the centre of the wound by using Image J 
software (Figure 3.15). The width of each wound was measured 20 times and 
the mean of the measurement was calculated.  
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Figure 3.15: Effect of IGF-1 on migration of triple-negative breast cancer cells. MDA-MB-
231 (A) and Hs578T (B) cells were seeded at density of 40 X 104 cells/well into 24 well plates 
that had scored on the under surface with two parallel lines across the middle of each well. 
Cells were withdrawn in phenol free DMEM medium supplemented with 10% charcoal-treated 
new born calf serum as described in Materials and Methods Section. The monolayers were 
wounded with a sterile 20-200 µl Gilson pipette tip through the centre of the well, perpendicular 
to the scored lines. Wounded cells were washed twice with 0.5 ml of phenol red-free DMEM and 
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incubated in phenol red-free DMEM supplemented with 0.01% of BSA for two hours. After two 
hours of incubation, cells were washed again and incubated with phenol red-free DMEM 
medium and 0.01% BSA alone ( ) or supplemented with 50 ng/ml of IGF-1 ( ) for various 
times up to 6 hours. Images were captured at the beginning of the experiment (time 0) and after 
each two hours of treatment up to 6 hours. Three separate measurements in three different 
wells were made for each treatment condition. The distance between the wounds was 
measured with Image J Software programme. The mean + SEM are shown. Statistically 
significant increases in the cell migration in the presence of IGF-1 compared to the absence of 
IGF-1 in both MDA-MB-231 and Hs578T cells are shown (one-way ANOVA, Asterisks 
**p<0.001, ****p<0.0001). 
  
As illustrated in the Figure 3.15, in both MDA-MB-231 and Hs578T cells, there 
was a statistically significant increase in the migration of the cells at 4 and 6 
hours of incubation in the presence of IGF-1 as compare with in the absence of 
the IGF-1. IGF-1 enhanced the migration of MDA-MB-231 and Hs578T cells two 
fold and three fold respectively. On the basis of the demonstrated results, IGF-1 
showed a potent migratory effect on both triple-negative breast cancer cells. 
 
3.2.10.2 Effect of IGF-1 on migration of HER-2 positive SK-BR-3 breast 
cancer cells 
The effect of IGF-1 on migration of HER-2 positive SK-BR-3 breast cancer cells 
was evaluated with the in vitro wounding assay as described in detail in section 
3.3.1. Wounded monolayers of SK-BR-3 cells incubated in the presence and 
absence of 50 ng/ml IGF-1 for 0, 2, 4 and 6 hours and at each incubation time 
images of the cells were captured. Each condition was in triplicate. The width of 
the each wound was measured 20 times and the average of them was 
calculated. The cell migration was evaluated by measuring the distance of the 
edge of the wound towards the centre of the wound by using Image J software 
(Figure 3.16).   
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 Figure 3.16: Effect of IGF-1 on migration of SK-BR-3 cells. SK-BR-3 cells were seeded at 
density of 40 X 104 cells/well into 24 well plates that had scored on the under surface with two 
parallel lines across the middle of each wells. Cells were withdrawn in phenol free DMEM 
medium supplemented with 10% charcoal-treated new born calf serum as described in 
Materials and Methods section. Monolayer cells were wounded with a sterile 20-200 µl Gilson 
pipette tip through the centre of the well, perpendicular to the scored lines. Wounded cells were 
washed twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free DMEM 
supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells were 
washed again and incubated with phenol red-free DMEM medium and 0.01% BSA alone ( ) 
or supplemented with 50 ng/ ml of IGF-1 ( ) for various time points up to 6 hours. Image were 
captured at the beginning of the experiment (time 0) and after each two hours of treatment up to 
6 hours. Three separate measurements in three different wells were made for each treatment 
condition. The distance between the wounds was measured using Image J software 
programme. The mean + SEM are shown. Asterisks denotes a statistically significant increase 
in the cell migration in the presence of IGF-1 compared to the absence of IGF-1 in SK-BR-3 
cells (One way ANOVA, *p<0.05). 
 
The effect of IGF-1 on migration of SK-BR-3 cells are illustarted in Figure 3.16. 
IGF-1 stimulated the migration of the cells. There were no statistically significant 
movement after 2 and 4 hours of incubation but statistically significant 
movement was observed in the presence of IGF-1 after 6 hours of incubation. 
The increase in the motility of SK-BR-3 cells in the presence of IGF-1 suggest 
that IGF-1 plays a role in inducing the migration of this cell line.  
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3.2.11 Effect of antibody against IGF-IR and a dual tyrosine kinase 
inhibitor of IGF-IR and the insulin receptor on migration of 
oestrogen-receptor negative breast cancer cells 
In the previous sections the powerful effect of IGF-1 on migration of oestrogen 
receptor-negative breast cancer cells was evaluated. The ability of the type I 
IGF receptor antibody CP-751, 871 or the dual tyrosine kinase inhibitor BMS-
754807 to inhibit the migratory effect of IGF-1 was investigated with wound 
healing assay used in oestrogen receptor-negative cell lines, as described in 
Section 3.3.1.  
3.2.11.1 Effect of an antibody against IGF-IR and dual tyrosine kinase 
inhibitor of IGF-IR and the insulin receptor on migration of triple-
negative MDA-MB-231 and Hs578T breast cancer cells 
Wounded MDA-MB-231 and Hs578T cells were incubated in the presence and 
absence of 50 ng/ml IGF-1 and in the presence and absence of 10 μg CP-751, 
871 or 1 μM BMS-754807 at 0, 2, 4 and 6 hours (Figure 3.17). 
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 Figure 3.17: Effect of antibody against IGF-IR and dual tyrosine kinase inhibitor of IGF-IR 
and the insulin receptor against migration of triple-negative breast cancer. MDA-MB-231 
(A) and Hs 578T (B) cells were seeded at density of 40 X 104 cells/well into 24 well plates that 
had scored on the under surface with two parallel lines across the middle of each wells. Cells 
were withdrawn in phenol free DMEM medium supplemented with 10% charcoal-treated new 
born calf serum as described in Materials and Methods Section. Monolayer cells were wounded 
with a sterile 20-200 µl Gilson pipette tip through the centre of the well, perpendicular to the 
scored lines. Wounded cells were washed twice with 0.5 ml of phenol red-free DMEM and 
incubated in phenol red-free DMEM supplemented with 0.01% of BSA for two hours. After two 
hours of incubation, cells were washed again and incubated with phenol red-free DMEM 
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medium and 0.01% BSA alone ( ) or supplemented with 50 ng/ml of IGF-1 ( ), or in the 
presence of 1 µM BMS-754807 and 50 ng/ ml IGF-1 ( ), or in the presence of 10 µg/ml CP-
751807 and 50 ng/ml IGF-1( ) for various time up to 6 hours. Images were captured at the 
beginning of the experiment (time 0) and after each two hours of treatment up to 6 hours. Three 
separate measurements in three different wells were made for each treatment condition. The 
distance between the wounds was measured using Image J software programme. The mean + 
SEM are shown. Asterisks denotes that there was statistically significant reduction in the 
migration of cells in the presence of CP-751,871 compared to its absence and in the presence 
of BMS-754807 compared with in the absence of BMS-754807 in both MDA-MB-231 and 
Hs578T cells (One way ANOVA, *p<0.05, ** P<0.001, *** p=0.0001, ****P<0.0001).  
 
As illustrated in the Figure 3.17, there was a statistically significant increase at 4 
and 6 hours of incubation in migration of both MDA-MB-231 and Hs578T cells in 
the presence of IGF-1 as previously observed. In the presence of CP-751, 871 
cell movements significantly decreased in both cell lines. In MDA-MD-231 cells, 
in the presence of CP-751,871 cell movement that was stimulated with IGF-1 
significantly decreased two fold after 2 and 4 hours of incubation and almost 
three fold after 6 hours. In Hs578T cells, CP-751,871 reduced the migratory 
effect of IGF-1 almost two fold after 2 and 4 hours of incubation and two and 
half fold after 6 hours. In the presence of BMS-754807, the motility of the MDA-
MB-231 cells in the presence of IGF-1 was significantly reduced two fold after 
incubation for 2 hours and gradually decreased five fold after 6 hours of 
incubation. The migration of Hs578T cell in response to IGF-1 was significantly 
decreased two fold after 2 hours of incubation with BMS-754807 and almost 
three and half fold after 6 hours incubation.  
The results demonstrated the effectiveness of both inhibitors on inhibition the 
migratory effect of IGF-1 in both triple-negative breast cancer cell lines, and that 
dual tyrosine kinase inhibitor has more inhibitory effect on migratory effect of 
IGF-1 compared to the type I IGF receptor antibody in both triple-negative 
breast cancer cells. 
3.2.11.2 Effect of antibody against IGF-IR and dual tyrosine kinase 
inhibitor of IGF-IR and the insulin receptor on migration of HER-2 
positive SK-BR-3 breast cancer cells  
The ability of antibody against type I IGF receptor CP-751, 871 and a dual 
tyrosine kinase inhibitor BMS-754807 to inhibit the migration of SK-BR-3 
stimulated with IGF-1 was tested in the in vitro wounding assay. Wounded SK-
BR-3 cells were incubated with the presence and absence of the IGF-1 and the 
two inhibitors for different times up to 6 hours (Figure 3.18).  
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 Figure 3.18: Effect of antibody against IGF-IR and dual tyrosine kinase inhibitor on SK-
BR-3 cells. SK-BR-3 cells were seeded at density of 40 X 104 cells/well into 24 well plates that 
had scored on the under surface with two parallel lines across the middle of each wells. Cells 
were withdrawn in phenol red-free DMEM medium supplemented with 10% charcoal-treated 
new born calf serum as described in Materials and Methods section. Monolayer cells were 
wounded with a sterile 20-200 µl Gilson pipette tip through the centre of the well, perpendicular 
to the scored lines. Wounded cells were washed twice with 0.5 ml of phenol red-free DMEM and 
incubated in phenol red-free DMEM supplemented with 0.01 % of BSA for two hours. After two 
hours of incubation, cells were washed again and incubated with phenol red-free DMEM 
medium and 0.01% BSA alone ( ) or supplemented with 50 ng/ml of IGF-1 ( ), or in the 
presence of 1 µM BMS-754807 and 50 ng/ml IGF-1 ( ), or in the presence of 10 µg/ml CP-
751807 and 50 ng/ml IGF-1( ) for various time points up to 6 hours. Image were captured at 
the beginning of the experiment (time 0) and after each two hours of treatment up to 6 hours. 
Three separate measurements in three different wells were made for each treatment condition. 
The distance between the wounds was measured using Image J software programme. The 
mean + SEM are shown. Asterisks denotes that there was statistically significant reduction in 
the migration of cells in the presence of CP-751,871 compared to its absence and in the 
presence of BMS-754807 compared with in the absence of BMS-754807 in SK-BR-3 cells. (One 
way ANOVA, ** p<0.001, *** p=0.0001, ****P<0.0001).  
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 In response to the IGF-1, SK-BR-3 cells migrated more than in the absence of 
IGF-1 after 6 hours incubation (p=0.035). Cell motility stimulated with IGF-1 was 
significantly reduced in the presence of CP-751,871 two fold after each period 
of incubation. Treatment of the cells with BMS-754807 significantly reduced the 
migration of the cells stimulated with IGF-1 one and half fold after 4 hours and 
two and half after 6 hours of incubation.  
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3.3 Discussion 
The ability to evade anoikis and increase in cell motility is important in the 
progression of malignant epithelial tumours and contributes to tumour 
metastasis. Anoikis resistance or survival of cells without attachment to the 
extracellular matrix is essential in enhancement of metastatic potential. 
Understanding the molecular mechanisms involved in anoikis resistance and 
migration of cancerous cells would be a requirement in development of potential 
therapeutic approaches. 
In this chapter, the effect of IGF-1 on survival and migration of oestrogen 
receptor-negative breast cancer cells was investigated. Effect of IGF-1 on cell 
survival of oestrogen receptor-negative breast cancer cells cultured in non-
attached condition was evaluated. The key components of IGF signal 
transduction pathways were functional in all tested oestrogen receptor-negative 
MDA-MB-231, Hs578T and SK-BR-3 breast cancer cell lines, as they were 
activated in response to stimulation with IGF-1 in a concentration-dependant 
manner.  
Valentinis et al (1999) reported that in mouse embryonic fibroblasts, 
overexpression of the type I IGF receptor in the presence of IGF-1 induced 
anoikis resistance which was related to both the presnece of type I IGF receptor 
and the concentration of IGF-1 (Valentinis, Reiss et al. 1998). Another study 
reported suppression of anoikis in the presence of IGF-1 via IGF-IR in human 
epithelial prostate cancer cell line LNCaP by culturing the cells in matrix-
deprived condition (Kim, Koo et al. 2012). There are few studies on the effect of 
IGFs against anoikis in breast cancer cells. In 2005, Ravid et al reported loss of 
reduction in number of viable MCF-7 cells assessed by mitochondrial activity 
with an MTT assay, after culturing the cells in non-attached condition in serum-
free medium in the presence of IGF-1 (Ravid, Maor et al. 2005). Sachdev et al 
(2009) reported that blocking the type I IGF receptor signalling pathway can 
increase the cell death, as measured by trypan blue exclusion in a metastatic 
variant of MDA-MB-435 breast cancer cells in non-attached conditions 
(Sachdev, Zhang et al. 2009).  
In 2011, Davison et al illustrated the potential effect of IGF signalling pathway 
on survival of oestrogen non-responsive breast cancer cells by using 
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staurosporine-induced cell death (Davison, de Blacquiere et al. 2011). The 
effect of IGF-1 on anoikis of oestrogen-receptor negative breast cancer cells 
were not studied before.  
The present study has shown that MDA-MB-231, Hs578T and SK-BR-3 cells 
underwent anoikis after culture in poly-HEMA coated plates. Stimulation with 
IGF-1 powerfully prevented anoikis in non-attached MDA-MB-231 and Hs578T 
cells cultured in serum-free medium, as this was demonstrated by reduction in 
the amount of cleaved PARP and cleaved caspase-3 in MDA-MB-231 cells and 
inhibition of PARP cleavage in Hs578T. These results are in agreement with the 
previous finding that IGF-1 has an important role on survival of lung cancer cells 
in anchorage-dependent condition (Sachdev, Zhang et al. 2009) and support 
the supposition that IGF-1 has important role on survival of triple-negative 
breast cancer cells (Davison, de Blacquiere et al. 2011).  
IGF-1 had minor effects on suppression of anoikis in HER-2 positive SK-BR-3 
breast cancer cells. A concentration-dependent effect of IGF-1 was observed in 
both MDA-MB-231 and Hs578T cells. There was a variation in potential effect of 
IGF-1 in suppression of anoikis in between cell lines. The protective effect was 
greater in any tested concentration of IGF-1 in Hs578T cells than MDA-MB-231 
cells, with complete inhibition of anoikis in Hs578T cells. This variation might be 
due to the different level of sensitivity towards anoikis in the cell lines, as MDA-
MB-231 appeared to be more susceptible and Hs578T cells more resistant. 
Another explanation can be due to requirement of various concentrations of 
IGF-1 in order to activate survival pathways, such as PI3K and AKT pathway in 
different cell lines. For instance here, MDA-MB-231 cells required higher 
concentrations of IGF-1 in order to activate PI3K and AKT pathway compared to 
Hs578T cells.    
Dual tyrosine kinase inhibitor of type I IGF receptor and the insulin receptor 
BMS-754807 effectively inhibited the survival effect of IGF-1 in both MDA-MB-
231 and Hs578T cells, followed by complete inhibition of the activation of AKT 
in both cell lines, also BMS-754807 showed inhibitory effect on MAPK activation 
in both cell lines as significant reduction in the activation of MAPK was 
observed. This is in agreement with the previous study on effective inhibition of 
BMS-754807 on phosphorylation of IGF-IR, AKT and moderate inhibition of 
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MAPK phosphorylation in MCF-7 cells (Mezi, Todi et al. 2012). Disruption in 
type I IGF receptor has been reported to make lung cancer cells more 
susceptible to anoikis, as greater loss of cell viability was observed using trypan 
blue exclusion (Sachdev, Zhang et al. 2009). Disruption in the activity of the 
type I IGF receptor through inhibitory antibody reduced the survival effect of 
IGF-1 by increasing the cell death in both MDA-MB-231 and Hs578T cells. Both 
tested inhibitors demonstrated inhibition of the survival effect of IGF-1 in both 
triple-negative cell lines; however the ability of the tyrosine kinase inhibitor to 
induce cell death and inhibit the PI3K and AKT pathway is a desirable 
characteristic.   
The importance of the activity of type I IGF receptor and the insulin receptor in 
non-attached condition was shown in MDA-MB-231 cells by increase in the cell 
death detected in the presence of dual tyrosine kinase inhibitor of type I IGF 
receptor and insulin receptor, despite the presence of serum in the culture 
medium. Enhancement in the activation of IGF signal transduction pathway was 
not affected by other serum components. Inhibition of type I IGF receptor by 
CP-751, 871 antibody did not increase the anoikis in MDA-MB-231 cells 
cultured in maintenance medium (data not shown), indicating that inhibition of 
both type I IGF receptor and the insulin receptor might have greater importance 
in cell survival in non-attached condition. 
In the second part of this chapter, the role of IGF-1 on migration of oestrogen-
receptor negative breast cancer cell lines was investigated in a monolayer 
wound-healing migration assay. Several studies addressed the implication of 
IGF-1 in migration of different malignant cells. Some literature reports the 
interaction of tumor cells with IGF-1 which results in mediating the tumor cells 
motility behavior (Friedl and Wolf 2003, Bravo-Cordero, Hodgson et al. 2012). In 
2010, Metalli et al reported that IGF-1 induced migration of bladder cancer cells 
through activation of type I IGF receptor as measured the migration of cells by 
wound healing assay. Tang et al in 2008 reported the migratory effect of IGF-1 
on migration MDA-MB-435 breast cancer cells by using the migration track 
assay (Tang, Su et al. 2008). It has been reported that IGF-1 induce migration 
of oestrogen receptor-positive MCF-7 cells and oestrogen receptor-negative 
MDA-MB-231 cells by using modified Boyden chamber (Bartucci, Morelli et al. 
2001). Doerr et al in 1996 demonstrated that inhibition of IGF-IR using the 
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monoclonal IGF-IR inhibitory antibody αIR-3 can prevent the migration of MCF-
7 and MDA-MB-231 breast cancer cells (Doerr and Jones 1996).  
In the present study, IGF-1 has been shown to stimulate migration of all 
oestrogen receptor-negative MDA-MB-231, Hs578T and SK-BR-3 breast cancer 
cells; as evidenced by reduction in distance between the measured wounds. 
The increase in migration stimulated by IGF-1 in MDA-MB-231, Hs578T and 
SK-BR-3 cells is 6 µm, 30 µm and 3 µm respectively, which is comparable to 
the distances reported in other studies (Jackson, Zhang et al. 2001, Mezi, Todi 
et al. 2012). This is agreed with previous studies that IGF-1 induces migration in 
oestrogen receptor-negative MDA-MB-435 breast cancer cells (Tang, Su et al. 
2008). The migratory effect of IGF-1 was found to be higher in MDA-MB-231 
and Hs578T than in SK-BR-3 cells.  
Inhibition of type I IGF receptor reported to significantly reduce the metastasis 
of MDA-MB-435 breast cancer cells, also shown to decrease the number of 
circulating tumour cells (Sachdev, Zhang et al. 2009). In the same study, 
disruption of type I IGF receptor investigated on invasion of lung cancer cells 
using Boyden chamber assay, and showed that disruption of type I IGF receptor 
inhibits the invasion of cells. Here, the current study shown that migratory effect 
of IGF-1 was inhibited by treatment of cells with antibody against type I IGF 
receptor CP-751,871, which is consistent with the previous findings that 
abrogation of type I IGF receptor inhibits the migration of breast cancer cells 
(Doerr and Jones 1996, Sachdev, Zhang et al. 2009). The growth inhibitory 
effects of dual tyrosine kinase inhibitor BMS-754807 on growth of triple-negative 
breast cancer tumourgrafts were reported (Jackson, Zhang et al. 2001). In the 
present study, dual tyrosine kinase inhibitor BMS-754807 showed potent 
inhibition against migratory effect of IGF-1. The significance of the inhibitory 
effect of BMS-754807 was slightly greater than the significance of the inhibitory 
effect of the CP-751, 871 antibody in all three cell lines tested after 6 hours of 
migration (p<0.0001 and p=0.0001, respectively).   
In conclusion, the findings in this chapter demonstrate that IGF signal 
transduction pathway activation plays a significant role in survival of triple-
negative breast cancer cells in anchorage-independent condition and that, IGF-
1 is important in stimulate the increase in migration of oestrogen receptor-
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negative breast cancer cells. Thereby, IGF-1 might contribute to the metastatic 
potential of breast cancer cells by participation in promotion of migration and 
survival of oestrogen receptor-negative breast cancer cells and that, targeting 
the IGF signal transduction pathway could provide valuable information for the 
treatment of metastatic oestrogen receptor-negative breast cancer.  
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Chapter 4. Immunohistochemical expression of insulin-like 
growth factor receptor (IGF-IR) 
4.1 Introduction  
As breast tissue grows, it undergoes several physiological and morphological 
changes cyclically under hormonal regulation. Hormones are considered as the 
key determinants for the majority of benign and malignant lesions in the breast 
(Guinebretiere, Menet et al. 2005). Well-known breast carcinoma prognostic 
factors such as tumour size, histological grade, presence of involved axillary 
lymph nodes, and hormonal receptor status play important roles in the 
identification of high risk patients with poor prognosis who might benefit from 
more aggressive therapies. These recognized prognostic factors are not 
sufficient for final treatment decisions; hence identification of biomarkers can 
facilitate prediction of the response of tumours to different therapies and 
improve the individualized treatment decision.  
Various clinical and experimental studies addressed the important role of IGF-
IR in breast cancer development and progression (Cohen, Baker et al. 2005, 
Davison, de Blacquiere et al. 2011, Pollak 2012). Other studies reported 
deregulation of the IGF signal transduction pathway in different human cancers 
including breast cancer and increased resistance of breast cancer cells to 
chemotherapy and radiotherapy associated with overexpression and activation 
of the type I IGF receptor (Lu, Zi et al. 2001, Morgillo, Woo et al. 2006, Sachdev 
and Yee 2006). It has been reported that IGF-IR function is associated with the 
action of oestrogen receptor in hormone-responsive breast cancer cells 
(Stewart, Johnson et al. 1990, Surmacz 2000). In an immunohistochemical 
study, activation of IGF-IR has been reported as a prognostic factor for breast 
cancer and that its activation was shown to be correlated with poor survival 
outcome in different breast cancer subtypes (Law, Habibi et al. 2008). 
The results of the in vitro studies described in chapter 3 demonstrate an effect 
of IGF-1 on survival and migration of oestrogen receptor-negative breast cancer 
cells. The expression of the type I IGF receptor in different subtypes of breast 
carcinoma and its association with proliferation marker, apoptotic marker and 
various clinico-pathological criteria in oestrogen receptor-negative breast 
tumours has not been studied before. This chapter is focused on the analysis of 
type I IGF receptor expression, and the possible correlations between IGF-IR 
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expression and expression of a proliferation marker Ki-67, an apoptotic marker 
cleaved caspase-3 in oestrogen receptor-negative breast tumours and in 
involved lymph nodes by immunohistochemistry. 
4.2 Patients demographic characteristics 
Oestrogen receptor-negative breast samples were selected without further bias 
from patients diagnosed with breast cancer at the Newcastle NHS trust, Royal 
Victoria Infirmary breast clinic during 2000-2005. The samples consist of 92 
surgical resection specimens. From these, we studied 7 samples of normal 
breast tissue. In addition, the cases investigated included 37 in situ breast 
carcinomas, 79 invasive breast carcinomas and 26 axillary lymph nodes 
harbouring metastatic breast tumour cells. 
4.3 Results 
4.3.1 Optimisation of the anti-IGF-IR antibody concentration 
To select the optimal dilution for the anti-IGF-IR antibody suitable for 
immunohistochemistry, three different concentrations of the anti-IGF-IR β 
antibody (cell signalling #3027L) were tested. At a dilution of 1 in 1200, the anti-
IGF-IR antibody gave strong and specific membranous immuno-reaction with 
minimal background (Figure 4.1 C). The immuno-reaction was weaker at a 
dilution of 1 in 1800 (Figure 4.1 B) and much weaker at dilution of 1 in 2400 
(Figure 4.1 A). An appropriate IGF-IR immuno-reaction was obtained with 1 in 
1200 concentration. 
 
Figure 4.1: Optimisation of immunohistochemistry with the anti-IGF-IR antibody. A breast 
tumour that expresses IGF-IR was analysed by immunohistochemistry with anti-IGF-IR antibody 
at a dilution of 1 in 2400 (A), 1 in 1800 (B) and 1 in 1200 (C). Strong membranous 
immunoreaction was detected at 1 in 1200 dilution. Magnification is x200.   
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4.3.2 Expression of IGF-IR in normal breast tissue 
Expression of IGF-IR was investigated in 7 cases of normal breast tissue by 
immunohistochemistry. Expression of IGF-IR was detected in all 7 cases. The 
mean histoscore was 137 and median histoscore was 160. The immuno-
reaction was strongly membranous (Figure 4.2). 
 
Figure 4.2: Expression of IGF-IR in normal breast tissue. Sections of normal breast tissue 
that have a histoscore of 125 (A) and 330 (B) are shown. Membranous immuno-reaction of IGF-
IR was detected in epithelial cells that line the acini. Original magnification is x200. 
 
4.3.3 Expression of IGF-IR in in situ carcinoma of the breast        
Expression of IGF-IR was detected in 32 lesions out of 37 in situ ductal 
carcinoma cases (86%). IGF-IR expression was membranous (Figure 4.3). The 
majority of the positive tumour cells expressed IGF-IR at a weak level and the 
mean histoscore was 110.95 and median histoscore was 72. However, 4 
tumours were strongly positive for expression of IGF-IR with a maximum 
histoscore of 706. 
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 Figure 4.3: Expression of IGF-IR in in situ breast carcinomas. Section of (A) comedo and 
(B) solid type of ductal carcinoma in situ with histoscores of 706 and 368, respectively were 
analysed by immunohistochemistry for expression of IGF-IR. The inset shows in situ neoplastic 
cells. Magnification is x200 for inset and x20 for the images.  
4.3.4 Expression of IGF-IR in invasive carcinoma of the breast 
All invasive breast tumours included in the study were analysed for IGF-IR 
expression in duplicate cores. The consistency of expression between the 
duplicate cores was tested. There was a strong correlation between IGF-IR 
expression measured in the duplicate cores (Pearson correlation, p=0.001). 
There is no significant difference in the expression levels in the duplicate cores 
(Wilcoxon ranked test p=0.843, Figure 4.4). This finding supports the 
consistency of the results, thereby validity of evaluating biomarkers expression 
in one millimetre cores of tissue. The mean values were used for the further 
analyses. 
 
Figure 4.4: Expression of IGF-IR in the duplicate cores of invasive tumours. Two cores (A 
and B) of one millimetre in diameter were taken from each tumour for the construction of TMA 
blocks. IGF-IR immuno-reactive sections were analysed for IGF-IR independently. There was a 
strong correlation of IGF-IR expression between the two cores tested in each tumour (Pearson 
correlation p=0.001).  
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In the invasive lesions investigated, IGF-IR immuno-reaction was demonstrated 
in 73 tumours out of 79 invasive carcinomas (92%). The immuno-reaction for 
IGF-IR was membranous (Figure 4.5) and most of the IGF-IR positive tumours 
showed weak expression of IGF-IR with a mean histoscore of 94 and median 
histoscore of 42. However, 7 tumours strongly expressed IGF-IR with maximum 
histoscore of 630. IGF-IR immuno-reaction was not detected in 6 tumours.   
 
Figure 4.5: Expression of IGF-IR in invasive breast cancer. Sections of invasive breast 
carcinomas with histoscore of 630 were tested for IGF-IR expression by immunohistochemistry. 
Specific membranous immuno-reaction was demonstrated in the neoplastic cells (black arrow). 
Yellow arrow indicates the malignant epithelial cells with weakly positive, green arrow 
moderately positive and red arrow strongly positive for expression of IGF-IR. Specific 
membranous immuno-reaction was demonstrated. Magnification is x40 and x200 for inset. 
 
4.3.5 IGF-IR expression and axillary lymph node metastasis      
To analyse the role of IGF-IR in further progression of breast cancer, IGF-IR 
expression was analysed in both primary tumours and corresponding metastatic 
lymph nodes deposits from same patient. Accurate histological assessment of 
the axillary lymph node was available for 26 cases. Out of 26 cases, 3 cases 
were free of tumour cells, while metastatic deposits were detected in 23 cases. 
There was a significant correlation between the expression of IGF-IR in the 
primary tumour cells and tumour cells with metastatic lymph node deposits 
(Pearson correlation, p=0.001, Figure 4.6). The expression of IGF-IR was found 
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to be higher in primary tumours (mean histoscore=207) than their metastatic 
counterparts (mean histoscore=143). The association of IGF-IR expression with 
number of involved lymph nodes were tested. There was no significant 
correlation between expression of IGF-IR and the number of axillary lymph 
node metastasis (Spearman‘s rho correlation, p=0.130). 
 
 
 
Figure 4.6: IGF-IR expression in primary and metastatic breast tumour cells in lymph 
nodes. IGF-IR expression was analysed by immunohistochemistry in both primary (A) and 
metastatic (B) tumour cells of the same patients in 26 tumours. There was a strong significant 
association between IGF-IR expression in primary and metastatic tumour cells (p=0.001) (C). 
Magnification is x200. 
 
4.3.6 Expression of IGF-IR in different types of breast lesions 
IGF-IR expression was demonstrated in normal breast tissues and different 
types of breast lesions. IGF-IR expression was detected in the epithelial cells of 
majority of the lesions and in all normal tissues (Figure 4.7). Amongst different 
types of breast lesions, IGF-IR is mostly expressed in invasive breast tumours.  
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Figure 4.7: Level of expression of IGF-IR in different breast lesions. The expression of IGF-
IR in normal breast tissues, in situ carcinomas, invasive carcinomas and metastatic breast 
tumour cells (LN metastasis). The horizontal bars represent the median range of the data, the 
boxes represent the 50th percentiles, whiskers represent the range of data, the circles represent 
the outlier values and the asterisks refer to extreme values.   
  
4.3.7 IGF-IR expression and patient’s age 
The age of the women investigated ranged from 33 to 97 years. The mean age 
was 59.4 and the median was 58.5 years. There was no significant correlation 
between expression of IGF-IR and the age of patients (Pearson’s rho 
correlation, p=0.625, Figure 4.8).   
 
Figure 4.8: Association of IGF-IR expression with patient age.  IGF-IR expression is shown 
against patient’s age. 
 
4.3.8 IGF-IR expression and the tumour size and grade          
The association between IGF-IR expression and tumour grade and size was 
investigated. The tumour size ranged from 14 mm to 90 mm. the mean size was 
27 mm and the median was 23 mm. The expression level of IGF-IR showed no 
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association with size of the tumour (Pearson’s rho correlation, p=0.376). 
Histological grade of the invasive tumours were assessed by Elston and Ellis’s 
modification of Bloom and Richardson grading method. Twelve tumours of the 
investigated tumours were moderately differentiated (grade 2) and 67 tumours 
were poorly differentiated (grade 3). IGF-IR expression was not associated with 
the tumour grade (Spearman’s rho correlation, p=0.515). There was no 
significant differences in the expression level of IGF-IR in lower grade and high 
grade tumours (Mann-Whitney test, p=0.448, Figure 4.9). 
 
Figure 4.9: Association of IGF-IR expression with tumour grade. The expression of IGF-IR 
is shown against the histological grades of invasive breast cancer. The horizontal bars 
represent the median values, the boxes represent the 50th percentiles, the whiskers represent 
the range of data, the dots refer to outlier values and the star refers to extreme values. 
 
4.3.9 Association between expression of IGF-IR and expression of Ki-67 
in malignant breast tumours 
It has been reported that IGF-I stimulates the proliferation of oestrogen non-
responsive breast cancer cells and that positive stimulation is mediated by IGF-
IR in vitro (Davison, de Blacquiere et al. 2011). To investigate the possibility that 
IGF-IR expression is associated with proliferation of breast cancer cells, the 
expression of Ki-67 was measured in in situ and invasive breast carcinoma and 
in tumour cells with axillary lymph node metastatic deposits by 
immunohistochemistry. Correlation between IGF-IR expression and expression 
of proliferation marker Ki-67 was tested. The statistical analysis was tested on 
142 cases which include in situ carcinomas, invasive carcinomas and tumour 
cells with lymph node metastases and there was a significant correlation 
between the expression of IGF-IR and Ki-67 expression in all the breast lesions 
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analysed (Pearson’s rho correlation p= 0.028). Further analysis evaluated in 
which particular tumour type of breast lesions the association was apparent.  
4.3.9.1 Association between expression of IGF-IR and expression of Ki-
67 in in situ breast carcinoma 
Ki-67 expression was investigated in 37 in situ breast carcinomas, of which its 
expression was detected in 28 tumours with mean histoscore of 82.5 and 
median histoscore of 54. Overall, Ki-67 was expressed at weak to moderate 
levels in in situ breast carcinomas. Ki-67 immuno-reaction was nuclear (Figure 
4.10).  
 
Figure 4.10: IGF-IR expression and expression of Ki-67 in in situ breast carcinoma. 
Sections from comedo type (A, B) and solid type (C, D) of in situ breast carcinomas were tested 
for IGF-IR (A, C) and Ki-67 (B, D) expression by immunohistochemistry. Magnification is x200.  
 
The association between expression of IGF-IR and Ki-67 was investigated in 
the 37 in situ carcinomas.  There was no correlation between expression of 
IGF-IR and Ki-67 expression in in situ breast tumours (Pearson’s rho 
correlation, p=0.838, Figure 4.11).  
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 Figure 4.11: Association of IGF-IR expression and expression of Ki-67 in in situ breast 
carcinoma. IGF-IR expression and Ki-67 expression were compared in 37 in situ breast 
carcinomas. No significant association was detected between IGF-IR expression and 
expression of Ki-67 (p=0.838).  
 
4.3.9.2 Association between expression of IGF-IR and expression of Ki-
67 in invasive breast carcinoma 
Ki-67 expression was investigated in 79 invasive breast tumour, of which 77 
tumours were positive for expression of Ki-67 with mean histoscore of 140 and 
median histoscore of 88. The majority of the positive tumour cells were 
moderately immuno-reactive. Correlation between IGF-IR expression and 
expression of Ki-67 was investigated in these invasive tumours (Figure 4.12). 
 
Figure 4.12: IGF-IR expression and expression of Ki-67 in invasive breast cancer.  
Sections from invasive breast carcinomas were tested for IGF-IR (A) and Ki-67 (B) expression 
by immunohistochemistry. Specific nuclei immuno-reaction was demonstrated. Arrows indicates 
the malignant epithelial cells with negative for expression of Ki-67 (blue arrow), weakly positive 
(yellow arrow), moderately positive (green arrow) and strongly positive (red arrow) are indicated. 
Magnification is x20 and for inset is x200.  
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There was a significant correlation between expression of IGF-IR and Ki-67 
expression in 79 invasive breast tumours (Pearson’s rho correlation, p=0.005, 
Figure 4.13), which supports the contention that IGF-IR is important for the 
proliferation of oestrogen receptor-negative breast tumour cells.  
 
Figure 4.13: Association of IGF-IR expression and expression of Ki-67 in invasive breast 
cancer. IGF-IR histoscores are shown against Ki-67 histoscores of 79 invasive breast cancers. 
Expression of IGF-IR was significantly associated with expression of Ki-67 (Pearson correlation, 
p=0.005). The r2 value is 0.344. 
 
4.3.9.3 Association between expression of IGF-IR and expression of Ki-
67 in breast tumour cells with involved lymph nodes 
Expression of Ki-67 was evaluated in 26 breast tumour cells with involved 
lymph nodes. Out of 26 tumour cells 25 expressed Ki-67 with a mean histoscore 
of 111 and a median histoscore of 74 (Figure 4.14).  
 
Figure 4.14: IGF-IR expression and expression of Ki-67 in lymph node involved breast 
tumours. Expression of IGF-IR (A, C) and Ki-67 (B, D) was analysed in breast tumours with 
axillary lymph node deposits by immunohistochemistry. Magnification is x40.  
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The association between IGF-IR expression and expression of Ki-67 was 
evaluated in breast tumours cells in the involved axillary nodes. No significant 
association was found between expression of IGF-IR and Ki-67 in the primary 
tumours with involved tumour cells in lymph nodes (Pearson’s rho correlation, 
p=0.354, Figure 4.15).   
 
Figure 4.15: Association of IGF-IR expression and expression of Ki-67 in primary breast 
tumours with involved tumour cells in lymph nodes. IGF-IR expression was compared with 
expression of Ki-67 in 26 breast tumour cells with involved lymph nodes. There was no 
association between IGF-IR expression and expression of Ki-67 in breast tumour cells with 
involved lymph nodes (p=0.592).  
 
4.3.10 IGF-IR and expression of cleaved caspase-3     
It has been reported that survival effect of IGF-1 in oestrogen non-responsive 
breast cancer cells is mediated through IGF-IR in vitro (Davison, de Blacquiere 
et al. 2011). In addition, in the previous findings of the current study, the survival 
effect of IGF-1 on cell death induced by lack of cell-matrix interaction and its 
mediation through IGF-IR in oestrogen non-responsive breast cancer cells was 
evaluated. Caspase-3 is a main executer of apoptosis. The association between 
IGF-IR expression and expression of cleaved caspase-3 was tested. The 
expression of cleaved caspase-3 was measured in 79 invasive breast tumours. 
The immuno-reactivity of cleaved-caspase-3 was cytoplasmic (Figure 4.16).  
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 Figure 4.16: Cleaved caspase-3 expression in invasive breast tumours. Expression of 
cleaved caspase-3 was analysed by immunohistochemistry in invasive tumours. Examples for 
positive (A) and negative (B) cytoplasmic immuno-reaction were demonstrated. Magnification is 
x200. 
Amongst the 73 IGF-IR positive tumours, 66 were negative for cleaved 
caspase-3 and only 7 were positive for cleaved-caspase-3. All of the six IGF-IR 
negative tumours were negative for cleaved caspase-3 (cross tabulation). 
However, cleaved caspase-3 positive tumours expressed low level of IGF-IR. 
There was no significant differences between expression levels of IGF-IR and 
cleaved-caspase-3 (Mann-Whitney test, p=0.427, Figure 4.17). 
 
 
 
Figure 4.17: Association of IGF-IR and cleaved caspase-3 in invasive breast tumours. The 
tumours were dichotomised for negative and positive caspase-3 expression at a histoscore of 
10. Sixty six tumours out of 73 IGF-IR positive tumours were negative for cleaved caspae-3 and 
7 tumours were positive for cleaved caspase-3. The cut off for positive cleaved caspase-3 
histoscore was >10. The whiskers represent the range of data, the boxes represent the 50th 
percentiles, the horizontal bars represent the median values, the dots refer to outlier values and 
the stars refer to extreme values.                        
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4.4 Discussion 
In this study, immunohistochemical expression of IGF-IR in normal breast 
tissues and different types of breast carcinomas: in situ, invasive and breast 
tumour cells in involved lymph nodes were investigated. In addition, the 
association between IGF-IR expression with different prognostic factors was 
studied. Immunohistochemical expression of IGF-IR was detected in all 7 cases 
of normal breast tissues, 86% of in situ breast carcinoma with mean histoscore 
of 110.95 and 92% of invasive breast cancer with mean histoscore of 94. 
The role of IGF-IR in mediating the invasion and metastasis of breast cancer 
has been reported (Kucab and Dunn 2003). The possibility of a relationship 
between IGF-IR expression and number of lymph node metastasis was 
investigated in the present study. There was no significant association between 
expression of IGF-IR and the number of axillary lymph node metastasis 
(p=0.130). Significant correlation between expression of IGF-IR in primary 
tumours and in the metastatic cells in lymph nodes was detected (p=0.001). 
However, the expression of IGF-IR was found to be higher in primary tumours 
than their metastatic counterparts, which is in agreement with the previous 
reports that expression of IGF-IR was more frequent in primary breast tumours 
than lymph node metastasis (Koda, Sulkowski et al. 2003). 
There was no association between IGF-IR expression and age of patients 
(p=0.732). Expression of IGF-IR showed no correlation with tumour size or 
grade (p>0.05). This finding agrees with a previous study in a cohort of 
oestrogen receptor-positive and negative breast tumours, that expression of 
IGF-IR is not associated with tumour size or grade (Koda, Sulkowski et al. 
2003). 
In 2011, Davison et al reported the role of IGF-1 in stimulating the proliferation 
of triple-negative breast cancer cells which was mediated through IGF-IR in 
vitro (Davison, de Blacquiere et al. 2011). In the current study, association of 
IGF-IR expression with expression of the proliferation marker Ki-67 was 
investigated. Expression of IGF-IR showed an association with expression of Ki-
67 in invasive breast tumours (Pearson’ rho correlation, p=0.005), which 
supports the contention that IGF-IR plays a significant role in mediating the 
proliferation of oestrogen receptor-negative breast cancer cells. Similarly, 
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expression of IGF-IR was investigated in in situ and metastatic breast tumour 
cells, but no significant correlation was found. 
The role of IGF-1 in stimulating the survival of triple-negative breast cancer cells 
mediated through IGF-IR has been demonstrated (Davison, de Blacquiere et al. 
2011). In addition, the mediation of oestrogen receptor-negative breast cancer 
cells survival by IGF-IR was demonstrated previously in chapter 3. Therefore, 
the association between expression of IGF-IR and cleaved-caspase-3 
expression as an apoptotic marker in oestrogen receptor-negative breast 
tumours was investigated. The majority of IGF-IR positive tumours were 
negative for the expression of cleaved caspase-3. However, 7 tumours were 
positive for expression of both cleaved caspase-3 and IGF-IR. This can support 
the contention that IGF-IR is maintaining the survival of oestrogen receptor-
negative breast cancer.     
In conclusion, expression of IGF-IR was detected in the majority of oestrogen 
receptor-negative breast tumours. The significant association between 
expression of IGF-IR with Ki-67 and inversely with cleaved caspase-3 agrees 
with the contention that IGF-IR plays an important role in proliferation and 
survival of oestrogen receptor-negative breast tumour cells.  
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Chapter 5. The effect of epidermal growth factors on anoikis 
and migration of oestrogen receptor-negative breast cancer 
cells 
5.1  Introduction 
Members of the human epidermal growth factor receptor tyrosine kinase family, 
EGFR/HER-1, HER-2, HER-3 and HER-4 are activated by their respective 
ligands which induce receptor dimerization and leads to autophosphorylation of 
tyrosine residues on the receptor cytoplasmic domains. Subsequently multiple 
downstream signalling pathways are activated including the Ras-MAPK and 
PI3K-AKT pathways that are important in mediating cell survival and 
proliferation (Hynes and McDonald 2009, Tebbutt, Pedersen et al. 2013).  
HER-2 is not capable of binding to any of the known EGF ligands; however, it is 
activated through hetero-dimerization with other ligand-bound receptors and is 
involved in increases in the cell survival, motility and proliferation of tumour cells 
(Moasser 2007). HER-3 lacks tyrosine autophosphorylation activity, hence it is 
only capable of transducing signals through hetero-dimerization with other 
family member receptors, namely: EGFR, HER-2 and HER-4 (Moasser 2007). 
Hetero-dimerization of HER-2 and HER-3 is reported as a potent activator of 
PI3K-AKt signalling, which plays an oncogenic role in proliferation of breast 
tumour cells (Lee-Hoeflich, Crocker et al. 2008).  
In 2010, Chiu et al reported that in invasive breast carcinoma, decrease in 
survival of breast cancer patients is associated with HER-3 overexpression 
(Chiu, Masoudi et al. 2010). Several studies reported the frequent 
overexpression of EGFR and HER-2 in breast cancer and their significant roles 
in tumour growth, proliferation and migration (Garcia, Vizoso et al. 2003, Hirsch, 
Shen et al. 2006, Memon, Sorensen et al. 2006). Expression of heregulin in 
30% of breast tumours and its contribution to proliferation, motility and 
metastasis of breast cancer cells has been reported (Hijazi, Thompson et al. 
2000, Tsai, Shamon-Taylor et al. 2003).  
In breast cancer, heregulin contribution in tumour progression and induced 
growth in an anchorage-dependent and independent manner has been reported 
to be independent from oestrogen(Lupu, Cardillo et al. 1996). 
130 
 
To our knowledge, no study has reported on the effect of EGF and heregulin-1 
(HRG) on survival in anchorage-independent and monolayer migration of 
oestrogen receptor-negative breast cancer cells. Hence, in this chapter, the 
effect of EGF and heregulin on survival and migration of oestrogen receptor-
negative breast cancer cell lines: MDA-MB-231, Hs578T, and SK-BR-3 cells 
were investigated. The role of EGFR and HER-2 in EGF and heregulin-1 
mediated protection from anoikis and stimulated migration of cells has been 
investigated further with gefitinib an inhibitor against EGF receptor and lapatinib 
a dual tyrosine kinase inhibitor of EGFR and HER-2. 
  
5.2 Result 
5.2.1 Expression of EGFR, HER-2, HER-3 in different subtypes of breast 
cancer cells  
The relative expression of EGFR, HER-2 and HER-3 was investigated in 
oestrogen-responsive MCF-7, BT-474, EFM-19 and oestrogen non-responsive 
SK-BR-3, Hs578T, MDA-MB-231, HCC-1419 and HCC-2218 breast cancer cell 
lines. Cell lines were cultured in maintenance medium and extracted proteins 
were analysed for EGFR, HER-2 and HER-3 expression by western transfer 
analysis (Figure 5.1). 
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 Figure 5.1: ErbB receptor expression in different types of breast cancer cells. MCF-7, BT-
474, EFM-19, SK-BR-3, Hs578T, MDA-MB-231 (MDA-231), HCC-1419 and HCC-2218 cells 
were cultured to approximately 80% confluence and their proteins extracted with 1 ml of RIPA 
buffer per 75 cm2 tissue culture flask as described in the Materials and Methods Section. 
Aliquots of 20 μg of extracted proteins were electrophoresed on a denaturing 12% gel and 
transferred to nitrocellulose membrane at 100 mA for 45 minutes. Membranes were incubated 
with EGFR antibody (1:10,000 dilution), HER-2 (1:2000 dilution), HER-3 (1:2000 dilution), 
developed with SuperSignal and exposed to X-ray film. Densitometric scanning of X-ray films 
determined the amount of each protein by analysis with LabWork 4.0 software. The mean + 
SEM after normalisation to GAPDH expression are shown. 
                                                                         
Amongst oestrogen-responsive cells, MCF-7 cells express low levels of EGFR 
and HER-3, and no HER-2 expression was detected in this cell line. BT-474 
cells express relatively high levels of EGFR and HER-2 and low levels of HER-
3. In EFM-19 cells, HER-2 and HER-3 were detected but no EGFR expression 
was observed. Amongst oestrogen non-responsive cells, SK-BR-3 and 
HCC2218 cells expressed high levels of EGFR, HER-2 and HER-3. These 
results suggest that these two cell lines might be highly responsive to all EGF 
ligands. In contrast, HCC1419 cells do not express EGFR but do express HER-
2 and HER-3 which suggests that they might be responsive to heregulin but not 
EGF. Triple-negative breast cancer cells, MDA-MB-231 and Hs578T cells 
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express relatively high levels of EGFR but no HER-2, and HER-3 expression 
was only observed at a low level in MDA-MB-231 cells.  
Based on these results, the relatively high expression of EGFR in oestrogen 
non-responsive cells suggests that the EGF signal transduction pathway might 
be important in mediating the cell survival and migration of this subtype of 
breast cancer.  
5.2.2 Activation of downstream effector proteins by EGF and heregulin-1 
in EGF signal transduction pathways in SK-BR-3 cells. 
To investigate the ability of EGF ligands to activate EGF downstream signal 
transduction pathway in SK-BR-3 cells which express high level of EGFR, HER-
2 and HER-3, cells were withdrawn from the effects of EGF by culture in 
dextran-coated charcoal treated serum (DCCS) medium for two days. Cells 
treated with 50 ng/ml EGF or 50 ng/ml heregulin-1 for 15 minutes, proteins were 
extracted and lysed. Aliquots of proteins were analysed for phosphorylation of 
EGFR, HER-2, HER-3, AKT, and MAPK by western transfer (Figure 5.2).   
 
Figure 5.2: Activation of proteins involved in the EGF downstream signal transduction 
pathway in SK-BR-3 cells. SK-BR-3 cells were seeded both at 20 X 104 cells/well in 1 ml of 
maintenance medium. Cells were allowed to attach by incubation for 24 hours. Cells were 
removed from the maintenance medium, washed with 0.5 ml of PBS and medium were replaced 
with 1 ml of DCCS medium every day for two days. Medium was replaced with 1 ml of DCCS 
supplemented with 50 ng/ml EGF or 50 ng/ml heregulin-1(HRG) for 15 minutes. After 15 
minutes of incubation, cells were lysed with 50 µl per well of RIPA buffer. Aliquots of 10 µg 
protein were electrophoresed on 12% denaturing polyacrylamide gel and transferred to 
nitrocellulose membrane for 45 minutes at 100 mA. Membranes were incubated with antibodies 
against phosphorylated EGFR (1:20,000 dilution), phosphorylated HER-2 (1:2000 dilution), 
phosphorylated HER-3 (1:2000 dilution), phosphorylated AKT (1:10,000 dilution), 
phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). Representative 
results are shown are from one experiment in triplicate.                     
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Reasonable levels of EGFR and HER-2 phosphorylation was stimulated by 
EGF in SK-BR-3 cells as these cells express high level of EGFR and HER-2. 
Incubation of cells with EGF induced some phosphorylation of HER-3 which 
suggests that EGF-induced activation of EGFR has formed heterodimers with 
HER-3, because EGF is not a HER-3 ligand. There was a detectable activation 
of AKT and MAPK after EGF stimulation which agrees with the contention that 
activation of EGFR homodimers and EGFR and HER-2 heterodimers induce 
activation of downstream proteins and suggest that EGFR has preference to 
form heterodimers with HER-2 than HER-3. 
Incubation of SK-BR-3 cells with heregulin-1 did not stimulate phosphorylation 
of EGFR which is consistent with the inability of the ligand to bind to EGFR. 
Reasonable amount of HER-2 and HER-3 phosphorylation was stimulated by 
heregulin-1 which suggests that activated HER-3 formed heterodimers with 
HER-2 but not EGFR, as no EGFR was activated.  Heregulin-1 stimulated 
detectable AKT and MAPK activation which supports the supposition that 
activated HER-2-HER-3 heterodimer was sufficient to activate PI3K/AKT and 
MAPK pathways. 
Taken these data together, stimulation of SK-BR-3 cells with EGF resulted in 
detectable homo-dimerization of EGFR-EGFR and hetero-dimerization of 
EGFR-HER-2 and some EGFR-HER-3, subsequently activated downstream 
signalling molecules. Heregulin-1 induced activation of HER-2-HER-3 
heterodimers, followed by activation of AKT and MAPK at high level.  
 
5.2.3 Effect of EGF and heregulin-1 on anoikis in HER-2 positive SK-BR-3 
cells 
Based on the results of previous experiments, EGF and heregulin-1 showed 
noticeable effect on activation of downstream effector molecules in part through 
hetero-dimerization of receptors. To investigate if EGF and heregulin-1 have 
protective effects against cell death, SK-BR-3 cells were cultured in non-
attached conditions in serum-free medium in the presence of 50 ng/ml EGF or 
50 ng/ml heregulin-1 for different length of time up to 24 hours. Proteins were 
extracted after each incubation time and analysed by western transfer for 
presence of cleaved PARP (Figure 5.3). 
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Figure 5.3: Effect of EGF and heregulin-1 on survival of SK-BR-3 cells. SK-BR-3 cells were 
cultured in phenol red-free Dulbecco’s Modified Eagle’s medium (DMEM) without serum (serum-
free medium) in non-attached condition. Cells were seeded in 12-well poly-HEMA coated plates 
at the density of 20 X 104 cells/well in 2 ml of serum-free medium, in the presence and absence 
of 50 ng/ml EGF (A) or heregulin-1 (B) and cultured for various length of time up to 24 hours. 
Proteins were extracted and lysed with 50 μl of RIPA buffer after each specific time point. 
Aliquots of 10 μl protein were electrophoresed on 12% denatured gels and transferred to 
nitrocellulose membrane at 100 mA for 45 minutes. The membranes were incubated with 
cleaved PARP antibody (1:2000 dilution) and GAPDH (1:20,000 dilution). The illustrated figures 
are representative of bands from one experiment in triplicate that have been replicated at least 
two times. Densitometric scanning of X-ray films determined the amount of each protein by 
analysis with LabWork 4.0 software. The mean + SEM after normalisation to GAPDH 
expression are shown. Asterisks denotes statistically significantly less cleaved PARP in the 
present of EGF and heregulin-1 than in the absence of EGF and heregulin-1 (One way ANOVA, 
***p=0.0001, ****p<0.0001).  
135 
 
Based on the results, in the presence of 50 ng/ml EGF, PARP cleavage was 
inhibited completely after 6 hours in SK-BR-3 cells. Additionally, incubation of 
SK-BR-3 cells with 50 ng/ml heregulin-1 induced almost complete inhibition in 
cleaved PARP after 4, 6, 8 hours and a statistically significant reduction after 24 
hours.  
In SK-BR-3 cells both EGF and heregulin-1 showed powerful survival effects. 
The reduction in cleaved PARP observed in the present of EGF and hereguilin-
1 supports the contention that these two ligands protect the SK-BR-3 cells 
against anoikis. These findings agree with previous observation that stimulation 
of SK-BR-3 cells with EGF and heregulin-1 was induced noticeable activation of 
PI3K and AKT pathway through activation of EGFR-EGFR homodimer, EGFR-
HER-2 and HER-2-HER-3 heterodimers respectively. 
 
5.2.4 Activation of downstream effector proteins in EGF signal 
transduction pathway by different concentrations of EGF in HER-2 
positive SK-BR-3 breast cancer cells 
To evaluate other concentrations of EGF on EGF downstream signal 
transduction pathway in SK-BR-3 cells, cells were cultured in DCCS medium for 
48 hours. This was followed by stimulation of cells with various concentrations 
of EGF up to 100 ng/ml for 15 minutes. Aliquots of proteins were analysed by 
western transfer for phosphorylation of EGFR, AKT and MAPK (Figure 5.4). 
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 Figure 5.4: Response of SKBR-3 to stimulation by EGF. Cells were seeded at a density of 
20 X 104 cells/well in 1 ml of maintenance medium and incubated for 48 hours for proper 
attachment. After 48 hours of incubation maintenance medium were replaced with 1 ml of 
DCCS medium daily for two days. Cells were washed with 0.5 ml of PBs and treated with 1ml 
DCCS supplemented with EGF at different concentration of 0, 0.01, 0.1, 1, 10, 100 ng/ml for 15 
minutes. After 15 minutes of stimulation, cells were lysed with 50 µl per well of RIPA buffer. 
Aliquots of 10 µg of protein were analysed by electrophoresis in a 12% denaturing 
polyacrylamide gel and transferred to nitrocellulose membrane for 45 minutes at 100 mA. 
Membranes were incubated with EGFR antibody (1:10,000 dilution), phosphorylated EGFR 
(1:20,000 dilution), AKT (1:10,000 dilution), phosphorylated AKT (1:15,000 dilution), MAPK 
(1:20,000 dilution), phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). 
Representative results are shown from an experiment in triplicate. Densitometric scanning of X-
ray films determined the amount of each protein by analysis with LabWork 4.0 software. The 
mean + SEM after normalisation to GAPDH expression are shown. Asterisks denotes 
statistically significant increase in the phosphorylation of EGFR, AKT and MAPK with increasing 
EGF concentration (One way ANOVA, *p<0.05). 
 
EGF induced a concentration dependent increase in the phosphorylation of 
EGFR that was detected from 0.1 ng/ml in SK-BR-3 cells. No phosphorylation of 
AKT or MAPK was detected in the absence of EGF. AKT phosphorylation was 
detected at concentration of 0.01 ng/ml and higher, whereas MAPK 
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phosphorylation was detected after stimulation with EGF at a concentration of 
0.1 ng/ml and higher. The amount of total AKT or MAPK did not change. 
Stimulation of SK-BR-3 cells with various concentrations of EGF resulted in 
activation of EGFR mediated signal transduction pathways. Phosphorylation of 
downstream protein AKT was detected after stimulation with lower 
concentrations of EGF than phosphorylation of the EGFR. This difference in 
apparent sensitivity might be due to amplification of the signal downstream of 
the receptors. 
5.2.5 Effect of different EGF concentrations on anoikis in SK-BR-3 cells 
In previous experiment (section 5.2.3) protective effect of EGF at concentration 
of 50 ng/ml on anoikis of SK-BR-3 cells were shown. In this section the 
concentration dependence of protective effect of EGF against cell death in SK-
BR-3 cells was investigated. 
SK-BR-3 cells were cultured in non-attached conditions in serum-free medium 
in the presence of different concentrations of EGF up to 50 ng/ml. Proteins were 
extracted after incubation for 6 hours and analysed by western transfer to 
determine the amount of cleaved PARP (Figure 5.5).  
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 Figure 5.5: Effect of various concentrations of EGF on anoikis in SK-BR-3 cells. SK-BR-3 
cells were seeded in 12 well poly-HEMA coated plates at density of 20 X 104 cells/well in 2 ml of 
serum-free medium, and incubated with different concentrations of EGF up to 50 ng/ ml. 
Proteins were extracted after incubation of 6 hours from with 50 μl per well of RIPA buffer. 
Aliquots of 10 µl protein were analysed by electrophoresis in 12% denatured gel and transferred 
for 45 minutes at 100 mA. Membranes were incubated with antibody against cleaved PARP 
(1:2000 dilution) and GAPDH (1:20,000 dilution). Illustrated images are representative of 
cleaved PARP from a triplicate experiment that have been repeated at least twice. Labwork 4.0 
software used for densitometric analysis of the X-ray films and measurement were normalised 
with GAPDH. Error bars show mean + SEM, Asterisks represent the statistically significant less 
cleaved PARP in the presence of EGF compared with in the absence of EGF (One way 
ANOVA, p*<0.05). 
 
The amount of cleaved PARP detected was reduced in the presence of EGF in 
a concentration-dependent manner in SK-BR-3 cells. There was a reduction in 
the amount of cleaved PARP in the presence of EGF at 1 ng/ml compared to its 
absence, which was not statistically significant. A statistically significant 
reduction in cleaved PARP was observed at EGF concentration of 10 ng/ml and 
higher, followed by complete inhibition of cleaved PARP at 50 ng/ml (p= 0.034).  
EGF had a powerful survival effect in SK-BR-3 cells. The concentration 
dependence of the protective effect of EGF against anoikis in SK-BR-3 cells can 
support the contention that the survival effect of EGF is transmitted through the 
EGF receptor. The protective effect of EGF which was detected from 1 ng/ml is 
consistent with the previous observation that activation of the EGFR was 
stimulated at 1 ng/ml concentration of EGF. 
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5.2.6 Activation of downstream effector proteins by EGF  and heregulin-1 
in EGF signal transduction pathways in Hs578T cells. 
To investigate the activation of EGF downstream signal transduction pathway in 
Hs578T breast cancer cells, which express high levels of EGFR but no HER-2 
or HER-3, cells were withdrawn from the effects of EGF by culture in dextran-
coated charcoal treated serum (DCCS) medium for two days. Cells treated with 
50 ng/ml EGF or 50 ng/ml heregulin-1 for 15 minutes and proteins were 
extracted and lysed. Aliquots of proteins were analysed for phosphorylation of 
EGFR, AKT, and MAPK by western transfer (Figure 5.6).   
 
Figure 5.6: Activation of proteins involved in the EGF downstream signal transduction 
pathway in Hs578T cells. Hs578T cells were seeded both at 10 X 104 cells/ well in 1 ml of 
maintenance medium. Cells were allowed to attach by incubating them for 24 hours. Cells were 
removed from the maintenance medium, washed with 0.5 ml of PBS and medium were replaced 
with 1 ml of DCCS medium every day for two days. Medium was replaced with 1 ml of DCCS 
which is supplemented with 50 ng/ml EGF or 50 ng/ml heregulin-1 (HRG) for 15 minutes. After 
15 minutes of incubation, cells were lysed with 50 µl per well of RIPA buffer. Aliquots of 10 µg 
protein were electrophoresed on 12% denaturing polyacrylamide gel, followed by transfer to 
nitrocellulose membrane for 45 minutes at 100 mA. Membranes were incubated with 
phosphorylated EGFR (1:20,000 dilution), phosphorylated AKT (1:10,000 dilution), 
phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). Representative 
results are shown are from one experiment in triplicate.                     
 
Stimulation of Hs578T cells with 50 ng/ml EGF induced phosphorylation of 
EGFR. Reasonable amount of AKT and MAPK phosphorylation was detected in 
the presence of EGF, which suggest that EGF signal transduction pathway is 
functional in this cell line. Incubation of MDA-MB-231 cells with heregulin-1 did 
not stimulate phosphorylation of EGFR, which is consistent with the inability of 
the ligand to bind and activate EGFR. Moreover, heregulin-1 was unable to 
activate the downstream signal transduction proteins AKT and MAPK due to 
lack of the availability of its receptor. 
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In conclusion, stimulation of Hs578T cells with EGF but not heregulin-1 resulted 
in activation of EGFR mediated signalling pathways. This was demonstrated by 
activation of both PI3K-AKT and MAPK pathway after treatment with 50 ng/ml of 
EGF.  
5.2.7 Effect of EGF and heregulin-1 on anoikis of Hs578T cells 
The effect of EGF and HRG on PARP cleavage induced in Hs578T cells by 
growth as non-attached cells was investigated. Hs578T cells were cultured in 
non-attached conditions in serum-free medium in the presence and absence of 
50 ng/ml EGF or 50 ng/ml heregulin-1 for up to 24 hours. Proteins were 
extracted after 0, 4, 6, 8 and 24 hours and the degree of PARP cleavage was 
assessed by western transfer analysis (Figure 5.7).      
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 Figure 5.7: Effect of EGF and heregulin-1 on survival of Hs578T cells. Hs578T cells were 
cultured in phenol red-free Dulbecco’s Modified Eagle’s medium (DMEM) without serum (serum-
free medium) in non-attached condition. Cells were seeded in 12-well poly-HEMA coated plates 
at the density of 20 X 104 cells/ well in 2 ml of serum-free medium, in the presence and absence 
of 50 ng/ml EGF (A) or heregulin-1 (HRG) (B) and cultured for various length of time up to 24 
hours. Proteins was extracted and lysed with 50 μl of RIPA buffer after each specific time point. 
Aliquots of 10 μl protein were electrophoresed on 12% denatured gels and transferred to 
nitrocellulose membrane at 100 mA for 45 minutes. The membranes were incubated with 
cleaved PARP antibody (1:2000 dilution) and GAPDH (1:20,000 dilution). The illustrated figures 
are representative of bands from one experiment in triplicate that have been replicated at least 
two times. Densitometric scanning of X-ray films determined the amount of each protein by 
analysis with LabWork 4.0 software. The mean + SEM after normalisation to GAPDH 
expression are shown. Asterisks denotes statistically significantly less cleaved PARP in the 
present of EGF than in the absence of EGF in Hs578T cells (One way ANOVA, ****p<0.0001).  
 
In Hs578T cells, cleaved PARP was reduced markedly in the presence of 50 
ng/ml EGF compared with in the absence of EGF after 4 and 6 hours (Figure 
5.7 A). As shown in Figure 5.7 B, incubation of Hs578T cells with 50 ng/ml 
heregulin-1 did not induce reduction in the amount of cleaved PARP at any 
incubation time.  
Based on these results, reduction in cleaved PARP that observed in the 
presence of EGF in Hs578T cells can support the hypothesis that EGF inhibits 
anoikis in this cell line. Treatment of cells with 50 ng/ml heregulin-1 did not 
show any protective effect on survival of Hs578T cells, which is consistent with 
the previous finding that heregulin-1 does not stimulate the activation of 
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downstream signal transduction proteins AKT and MAPK pathways in Hs578T 
cells. 
5.2.8 Activation of proteins involved in the EGF signal transduction 
pathway by different EGF concentrations in Hs578T cells 
Although EGF at concentration of 50 ng/ml provided powerful protection against 
anoikis in Hs578T cells, the effect of various concentrations of EGF on 
downstream signal transduction pathway was tested on Hs578T cells, to 
investigate the effect of other EGF concentrations on activation of downstream 
signal transduction pathways.   
Hs578T cells were withdrawn from the effects of EGF by culture in dextran-
coated charcoal treated serum (DCCS) medium for two days. Cells treated with 
EGF at various concentrations up to 100 ng/ml for 15 minutes and proteins 
were extracted and lysed. Aliquots of protein were analysed for phosphorylation 
of the EGFR, AKT, and MAPK by western transfer (Figure 5.8).   
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 Figure 5.8: Activation of proteins involved in the EGF downstream signal transduction 
pathway in Hs578T cells. Hs578T cells were seeded both at 10 X 104 cells/ well in 1 ml of 
maintenance medium. Cells were allowed to attach by incubation for 24 hours. Cells were 
removed from the maintenance medium, washed with 0.5 ml of PBS and medium were replaced 
with 1 ml of DCCS medium every day for two days. Medium was replaced with 1 ml of DCCS 
which is supplemented with EGF at different concentrations of 0, 0.01, 1, 10, 50, 100 ng/ml for 
15 minutes. After 15 minutes of incubation, cells were lysed with 50µl per well of RIPA buffer 
plus inhibitors. Aliquots of 10 µg protein were electrophoresed on 12% denaturing 
polyacrylamide gel, followed by transferring to nitrocellulose membrane for 45 minutes at 100 
mA. Membranes were incubated with EGFR (1:20,000 dilution), phosphorylated EGFR 
(1:20,000 dilution), AKT (1:5000 dilution), phosphorylated AKT (1:5000 dilution), MAPK 
(1:10,000 dilution), phosphorylated MAPK (1:10,000 dilution) and GAPDH (1:20,000 dilution). 
Representative results are shown are from one experiment in triplicate. The amount of the 
phosphorylated receptor was determined by densitometric scanning of the X-ray films followed 
by analysis with Labwork 4.0 software. The mean + SEM after normalisation to GAPDH 
expression are shown. Asterisks denotes statistically significant increase in the phosphorylation 
of EGFR, AKT and MAPK with increasing EGF concentration (One way ANOVA, *p<0.05). 
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Stimulation with EGF induced a concentration dependent increase in 
phosphorylation of EGFR, detected from 0.01 ng/ml in Hs578T cells. The 
expression of EGFR was not altered following EGF stimulation. AKT 
phosphorylation was detected in the absence of EGF at very low levels and 
increased following stimulation with 0.01 ng/ml EGF or higher. Phosphorylation 
of MAPK was not observed in the absence of EGF and phosphorylation was 
detected after stimulation with EGF at concentration of 0.01 ng/ml and higher. 
Stimulation of triple-negative Hs578T cells with EGF resulted in activation of 
EGFR mediated signal transduction pathways. Phosphorylation of downstream 
effector proteins was detected after stimulation with lower concentrations of 
EGF than phosphorylation of the EGFR. One of the reasons for this might be 
amplification of the signal downstream of the receptor. Activation of EGFR 
pathways with low concentrations of EGF suggests that the Hs578T cell line is 
particularly sensitive to EGF. This sensitivity can be due to high level of EGFR 
expression. These results support the contention that cells with higher level of 
receptor expression are more sensitive for the activation of downstream effector 
proteins than cells with lower expression level of receptors.  
5.2.9 Effect of different EGF concentrations on anoikis of Hs578T cells 
To investigate the concentration dependence of the protective effect of EGF 
against anoikis in Hs578T cells, cells were cultured in non-attached conditions 
in serum-free medium in the presence and absence of 50 ng/ml EGF for up to 
24 hours. Proteins were extracted after 6 hours of incubation and the degree of 
PARP cleavage was assessed by western transfer analysis. The cell death was 
evaluated by measuring the level of PARP cleavage using western transfer 
analysis (Figure 5.9).      
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 Figure 5.9: Effect of various concentrations of EGF on anoikis in Hs578T cells. Hs578T 
cells were seeded in 12 well poly-HEMA coated plates at density of 20 X 104 cells/ well in 2 ml 
of serum-free medium, and incubated with different concentrations of EGF up to 50 ng/ml. 
Proteins were extracted after incubation of 6 hours with 50 μl per well of RIPA buffer. Aliquots of 
10µl protein were analysed by electrophoresis in 12% denatured gel and transferred for 45 
minutes at 100 mA. Membranes were incubated with antibody against cleaved PARP (1:2000 
dilution) and GAPDH (1:20,000 dilution). Illustrated images are representative of cleaved PARP 
from a triplicate experiment that have been repeated at least two times. Labwork 4.0 software 
used for densitometric analysis of the X-ray films and measurement were normalised with 
GAPDH. Error bars show mean + SEM, Asterisks represent that statistically significant less 
cleaved PARP in the presence of EGF compared with in the absence of EGF (One way 
ANOVA, p*<0.05). 
 
The amount of cleaved PARP detected was reduced in the presence of EGF in 
a concentration-dependent manner in Hs578T cells. There was a reduction in 
the amount of cleaved PARP in the presence of EGF at 1 ng/ml compared with 
in its absence, which was statistically significant. There was a positive 
association between the level of reduction in cleaved PARP and the increase in 
the concentration of EGF followed by complete inhibition of cleaved PARP at 50 
ng/ml concentration.  
Based on the results, EGF had a powerful survival effect on Hs578T cells and 
that the protective effect of EGF was detected at concentration of 1 ng/ml. This 
agrees with the previous finding that activation of EGFR in Hs578T cells was 
induced with EGF at concentrations of 1 ng/ml. The concentration dependent 
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reduction in PARP cleavage in the presence of EGF in Hs578T cells suggests 
that the survival effect of EGF is transmitted through the EGF receptor. 
 
5.2.10 Activation of downstream effector proteins in EGF signal 
transduction pathways by EGF and heregulin-1 in MDA-MB-231 
cells 
To investigate the activation of EGF downstream signal transduction pathway in 
MDA-MB-231 breast cancer cells which express high levels of EGFR and low 
levels of HER3 but not HER-2, cells were withdrawn from the effects of EGFs 
by culture in dextran-coated charcoal treated calf serum (DCCS) medium for 
two days. Cells were treated with 50 ng/ml EGF or 50 ng/ml heregulin-1 for 15 
minutes, cells were lysed and proteins were extracted. Aliquots of proteins were 
analysed for phosphorylation of EGFR, HER-3, AKT, and MAPK by western 
transfer (Figure 5.10).   
 
Figure 5.10: Activation of proteins involved in the EGF downstream signal transduction 
pathway in MDA-MB-231 cells. MDA-MB-231 cells were seeded at 10 X 104 cells/well in 1 ml 
of maintenance medium. Cells were allowed to attach by incubation for 24 hours. The 
maintenance medium was removed and the cells were washed with 0.5 ml of PBS and the 
medium replaced with 1 ml of DCCS medium every day for two days. Medium was replaced 
with 1 ml of DCCS supplemented with 50 ng/ml EGF or 50 ng/ml heregulin-1 (HRG) for 15 
minutes. After 15 minutes of incubation, cells were lysed with 50 µl per well of RIPA buffer. 
Aliquots of 10 µg protein were electrophoresed on a 12% denaturing polyacrylamide gel, 
followed by transfer to nitrocellulose membrane for 45 minutes at 100 mA. Membranes were 
incubated with phosphorylated EGFR (1:20,000 dilution), phosphorylated HER-3 (1:2000 
dilution), phosphorylated AKT (1:1000 dilution), phosphorylated MAPK (1:10,000 dilution) and 
GAPDH (1:20,000 dilution). Results shown are from one experiment in duplicate.   
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Dramatic phosphorylation of EGFR was stimulated with 50 ng/ml of EGF as 
might have been expected, because MDA-MB-231 cells express high level of 
EGFR (Figure 5.1). Incubation with EGF stimulated some phosphorylation of 
HER-3 suggests that EGFR activated by EGF has formed heterodimers with 
HER-3 as EGF does not interact with HER-3. There was no detectable 
activation of AKT after EGF stimulation which agrees with the supposition that 
phosphorylated EGFR does not activate the PI3K and AKT pathway. In 
contrast, dramatic activation of MAPK phosphorylation was evident after 15 
minutes of incubation with EGF.  
Incubation of MDA-MB-231 cells with heregulin-1 did not stimulate detectable 
phosphorylation of EGFR. A small amount of HER-3 phosphorylation was 
stimulated but phosphorylation of EGFR consequent to heterodimer formation 
with activated HER-3 was not detected. The amount of phosphorylated HER-3 
was not sufficient to activate detectable levels of phosphorylated AKT or MAPK. 
In conclusion, neither ligand was able to activate the PI3 kinase pathway in 
MDA-MB-231 cells. EGF but not heregulin-1 activated the MAPK pathway. 
5.2.11 Effect of EGF and heregulin-1 on anoikis of MDA-MB-231 cells 
The effect of EGF and heregulin-1 on survival of triple-negative MDA-MB-231 
breast cancer cells was investigated. MDA-MB-231 cells were cultured in non-
attached conditions in serum-free medium in the presence and absence of 50 
ng/ml EGF or 50 ng/ml heregulin-1 separately for up to 24 hours. Proteins were 
extracted after 0, 4, 6, 8 and 24 hours and the degree of PARP cleavage was 
assessed by western transfer analysis (Figure 5.11).      
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Figure 5.11: Effect of EGF and heregulin-1 on survival of MDA-MB-231 cells. MDA-MB-231 
cells were cultured in phenol red free Dulbecco’s Modified Eagle’s medium (DMEM) without 
serum (serum-free medium) in non-attached condition. Cells were seeded in 12-well poly-HEMA 
coated plates at the density of 20 X 104 cells/ well in 2 ml of serum-free medium, in the presence 
and absence of 50 ng/ml EGF (A) or 50 ng/ml heregulin (HRG) (B) and cultured for various 
length of time up to 24 hours. Protein was extracted and lysed with 50 μl of RIPA buffer after 
each specific time point. Aliquots of 10 μl protein were electrophoresed on 12% denatured gels 
and transferred to nitrocellulose membrane at 100 mA for 45 minutes. The membranes were 
incubated with cleaved PARP antibody (1:2000 dilution) and GAPDH (1:20,000 dilution). The 
illustrated images are representative of bands from one experiment in triplicate that have been 
replicated at least twice. Densitometric scanning of X-ray films determined the amount of each 
protein by analysis with LabWork 4.0 software. The mean + SEM after normalisation to GAPDH 
expression are shown. 
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As shown in the Figure 5.11, there was no reduction in the amount of cleaved 
PARP in presence of 50 ng/ml EGF at any incubation time in MDA-MB-231 
cells. Similarly, incubation of MDA-MB-231 cells with 50 ng/ml heregulin-1 did 
not reduce the amount of cleaved PARP at any incubation time. Based on these 
results, EGF does not have any protective effect against anoikis on MDA-MB-
231 despite the expression of EGFR in this cell line. The absence of a 
protective effect of EGF despite the strong activation of the MAPK pathway 
indicates that the MAPK pathway is not involved in protection of breast cancer 
cells from anoikis. These results are consistent with the AKT pathway being 
involved in protection of cells from anoikis, because AKT phosphorylation was 
not induced in response to stimulation with EGF, which had no survival effect in 
this cell line. The inability of heregulin-1 to protect MDA-MB-231 cells against 
anoikis is consistent with its inability to activate either the PI3 kinase or MAPK 
pathways. 
5.2.12 Activation of proteins involved in the EGF signal transduction 
pathway by different concentrations of EGF in triple-negative MDA-
MB-231 breast cancer cells 
To investigate whether other concentrations of EGF might be able to activate 
the PI3 kinase pathway in MDA-MB-231 and potentially have a role in protection 
of cells against anoikis, MDA-MB-231 cells were withdrawn from the effects of 
EGF by culture in dextran-coated charcoal treated calf serum (DCCS) medium 
for two days. Cells treated with EGF at various concentrations up to 100 ng/ml 
for 15 minutes, cells were lysed and proteins were extracted. Aliquots of 
proteins were analysed for phosphorylation of the EGFR, AKT, and MAPK by 
western transfer (Figure 5.12).    
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 Figure 5.12: Activation of proteins involved in the EGF downstream signal transduction 
pathway in MDA-MB-231 cells. MDA-MB-231 cells were seeded both at 10 X 104 cells/ well in 
1 ml of maintenance medium. Cells were allowed to attach by incubation for 24 hours. Cells 
were removed from the maintenance medium, washed with 0.5 ml of PBS and medium were 
replaced with 1 ml of DCCS medium every day for two days. Medium was replaced with 1 ml of 
DCCS supplemented with EGF at different concentrations of 0, 0.01, 1, 10, 50, 100 ng/ml for 15 
minutes. After 15 minutes of incubation, cells were lysed with 50µl per well of RIPA buffer plus 
inhibitors. Aliquots of 10 µg protein were electrophoresed on 12% denaturing polyacrylamide 
gel, followed by transfer to nitrocellulose membrane for 45 minutes at 100 mA. Membranes 
were incubated with EGFR (1:20,000 dilution), phosphorylated EGFR (1:20,000 dilution), AKT 
(1:5000 dilution), phosphorylated AKT (1:1000 dilution), MAPK (1:10,000 dilution), 
phosphorylated MAPK (1:10,000 dilution) and GAPDH (1:20,000 dilution). Representative 
results are shown are from one experiment in triplicate. Densitometric scanning of X-ray films 
determined the amount of each protein by analysis with LabWork 4.0 software. The mean + 
SEM after normalisation to GAPDH expression are shown. Asterisks denotes statistically 
significant increase in the phosphorylation of EGFR and MAPK with increasing EGF 
concentration (One way ANOVA, *p<0.05). 
         
Stimulation with EGF induced a concentration dependent increase in 
phosphorylation of EGFR, detected from 0.1 ng/ml in MDA-MB-231 cells. EGF 
did not affect the total level of EGFR after stimulation for 15 minutes. No 
phosphorylation of AKT was observed at any tested concentration of EGF in 
MDA-MB-231 cells. Phosphorylation of MAPK was not observed in the absence 
of EGF, MAPK phosphorylation was detected after stimulation with EGF at 
concentration of 1 ng/ml and higher.  
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Stimulation of triple-negative MDA-MB-231 breast cancer cells with EGF 
resulted in activation of EGFR mediated signalling pathways. This was 
demonstrated by phosphorylation of downstream proteins after treatment with 
certain concentrations of EGF. The results agree with the previous findings 
(section 5.2.10) that stimulation with EGF results in dramatic phosphorylation of 
EGFR and MAPK, whereas no detectable AKT phosphorylation was observed 
at any tested concentration and that MDA-MB-231 cells require high 
concentration of EGF to stimulate the maximum phosphorylation of EGFR and 
MAPK.  
Taken these data together, stimulation of MDA-MB-231 cells with EGF resulted 
in activation of EGFR mediated signal transduction pathways, confirming that 
some EGF-mediated signalling is functional in this cell line. The inability of EGF 
to protect MDA-MB-231 against anoikis might be due to non-activation of PI3K 
and AKT pathway in this cell line by EGF. Despite the strong activation of the 
MAPK pathway, MDA-MB-231 cell survival may be dependent upon activation 
of PI3K and AKT pathway, which means that EGF is unable to protect cells 
against anoikis.   
               
5.2.13 Effect of lapatinib on activation of both EGFR and HER-2 by EGF in 
SK-BR-3 cells 
Lapatinib is a dual tyrosine kinase inhibitor which targets both EGFR and HER-
2 pathways. It is used for treatment of HER-2 over-expressed breast tumours in 
both metastatic and adjuvant setting.  
In this experiment to investigate the effectiveness of lapatinib and establish the 
concentration at which the maximum inhibition occurs in SK-BR-3 cells that 
EGF had protective effect, cells were cultured in attached conditions in full 
maintenance medium and incubated with different concentrations of lapatinib up 
to 20 µM for 30 minutes. After 30 minutes of incubation, cells were stimulated 
with 50 ng/ml EGF for 15 minutes. Proteins were extracted after incubation for 
15 minutes and analysed by western transfer for phosphorylation of EGFR, 
HER-2, AKT, and MAPK (Figure 5.13). 
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 Figure 5.13: Effect of lapatinib on activation of both EGFR and HER-2 by EGF in SK-BR-3 
cells. SK-BR-3 cells were seeded into 12 well tissue culture plates at a density of 10 x 104 
cells/well in 1 ml of maintenance medium. Cells were incubated for 24 hours to allow 
attachment. Medium was aspirated and cells were washed with 0.5 ml of PBS. Medium was 
replaced daily with 1 ml/well of DCCS medium for two days. After two days of incubation, 
medium was replaced with DCCS supplemented with lapatinib at final concentrations of 0, 0.1, 
1, 10, 20 μM and cells were incubated with the lapatinib for 30 minutes. After 30 minutes 
treatment of cells with various concentrations of lapatinib, medium was replaced with the DCCS 
supplemented with 50 ng/ml of EGF and cells were stimulated for 15 minutes. Proteins were 
extracted with 50 μl of RIPA buffer. Aliquots of 10 μg protein were electrophoresed on a 
denaturing 12 % polyacrylamide gel and transferred to nitrocellulose membrane for 45 minutes 
at 100 mA. Membranes were incubated with phosphorylated EGFR (1:20,000 dilution), 
phosphorylated HER-2 (1:2000 dilution), phosphorylated AKT (1:15,000 dilution), 
phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). Representative 
results are from duplicate experiment. Labwork 4.0 software used for densitometric analysis of 
the X-ray films and measurement were normalised with GAPDH. Asterisks represent the 
statistically significant reduction in phosphorylation of EGFR, HER-2, AKT and MAPK in the 
presence of lapatinib compared with in the absence of lapatinib (One way ANOVA, * p<0.05).   
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Treatment of EGF stimulated cells with lapatinib resulted in a concentration 
dependent decrease in the phosphorylation of EGFR and HER-2, detected from 
a concentration of 0.1 μM lapatinib. There was an almost complete inhibition in 
phosphorylated AKT at concentrations of 1 μM and higher. Reduction in 
phosphorylation of MAPK was detected at concentrations of 1 μM, and 
complete inhibition was observed at higher concentrations.  
Stimulation of SK-BR-3 cells with various concentrations of lapatinib resulted in 
inhibition of activation of both downstream components Akt and MAPK, which 
suggest that lapatinib is an effective inhibitor of signal transduction induced by 
EGF. 
 
5.2.14 Inhibition of EGFR and HER-2 by lapatinib abrogates the protective 
effect of EGF against cell death in anoikis in SK-BR-3 cells 
Based on the previous result shown in section 5.2.13, lapatinib completely 
inhibited the phosphorylation of EGFR but not the downstream proteins in SK-
BR-3 cells at concentrations of 1 μM and complete inhibition of the downstream 
proteins was obtained at concentration of 10 μM. Hence the effect of lapatinib 
on the protective effect of EGF was investigated at two different concentrations 
of 1 μM (data not shown) and 10 μM. 
Cells were cultured in non-attached conditions in serum-free medium for 30 
minutes in the presence and absence of 1 μM and 10 μM lapatinib and in the 
presence and absence of 50 ng/ml EGF, proteins were extracted and analysed 
for cleaved PARP, phosphorylation of HER-2, EGFR, AKT and MAPK by using 
western transfer (Figure 5.14).  
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 Figure 5.14: The effect of inhibition of EGFR and HER-2 by lapatinib on the protective 
effect of EGF in SK-BR-3 cells. SK-BR-3 cells were seeded into 12 well poly-HEMA coated 
plates at 20 X 104 cells/well in 2 ml of serum free medium, in the presence 10 µM of lapatinib or 
vehicle (DMSO) and in the presence and absence of 50 ng/ml of EGF. Proteins were extracted 
after incubation of 6 hours from SK-BR-3 cells with 50 μl per well of RIPA buffer. Aliquots of 10 
µg protein were analysed by electrophoresis in 12% denatured gel and transferred for 45 
minutes at 100 mA. Membranes were incubated with antibody against phosphorylated EGFR 
(1:20,000 dilution), phosphorylated HER-2 (1:2000 dilution), cleaved PARP (1:2000 dilution), 
phosphorylated AKT (1:10,000 dilution), phosphorylated MAPK (1:20,000 dilution) and GAPDH 
(1:20,000 dilution). Illustrated images are representative of cleaved PARP from a triplicate 
experiment that have been repeated at least two times. Labwork 4.0 software used for 
densitometric analysis of the X-ray films and measurement were normalised with GAPDH. Error 
bars are + SEM. Asterisks denotes there was a statistically significant increase in the amount of 
cleaved PARP, complete inhibition in phosphorylation of EGFR, HER-2, AKT and MAPK in the 
presence of lapatinib compared with in the absence of lapatinib (One way ANOVA, 
****p<0.0001).   
 
As is shown in Figure 5.14, culture of SK-BR-3 cells in non-attached conditions 
in serum-free medium for 6 hours induced anoikis, which was inhibited in the 
presence of EGF at 50 ng/ml. In the presence of EGF, there was a statistically 
significant increase in the amount of cleaved PARP in the presence of 10 μM 
lapatinib. This was followed by complete inhibition of activation of downstream 
proteins AKT and MAPK in the presence of 10 μM lapatinib. Although in the 
absence of EGF, lapatinib at 1 μM concentration increased the cell death but 
was not enough to block the survival effect of EGF (data not shown). This 
observation agrees with the finding that higher concentration of lapatinib is 
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required as demonstrated to inhibit the downstream signal transduction 
PI3K/AKT and MAPK pathways in Figure 5.14.  
5.2.15 Effect of inhibition of EGFR with gefitinib on anti-anoikis effect of 
EGF in oestrogen receptor-negative breast cancer cells 
Gefitinib is a selective inhibitor of EGFR tyrosine kinase domain which inhibits 
EGFR autophosphorylation and downstream signal transduction; hence leading 
to inhibition in growth of EGFR overexpressed tumour cells (Thomas and 
Grandis 2004).  
To investigate the effectiveness of gefitinib and establish the concentration at 
which the maximum inhibition occurs in the cells that EGF had protective effect, 
Hs578T and SK-BR-3 cells were cultured in attached condition in full 
maintenance medium and incubated with different concentrations of gefitinib up 
to 20 µM for 30 minutes. After 30 minutes incubation, cells were stimulated with 
50 ng/ml of EGF for 15 minutes. Proteins were extracted and analysed by 
western transfer for phosphorylation of EGFR, AKT, and MAPK (Figure 5.15). 
 
 
 
156 
 
 Figure 5.15: Effect of gefitinib on activation of EGFR by EGF in Hs578T and SK-BR-3 
cells. Hs578T (A) and SK-BR-3 (B) cells were seeded into 12 well tissue culture plates at 
density of 10 x 104 cells/well and 20 X 104 cells/well in 1 ml of maintenance medium 
respectively. Cells were incubated for 24 hours to allow attachment. Medium was aspirated and 
cells were washed with 0.5 ml of PBS. Medium was replaced daily with 1 ml/well of DCCS 
medium for two days. After two days of incubation, medium was replaced with DCCS 
supplemented with gefitinib at final concentrations of 0, 0.1, 1, 10, 20 µM and cells were 
incubated with the inhibitor for 30 minutes. After 30 minutes treatment of cells with various 
concentrations of inhibitor, medium was replaced with the DCCS supplemented with 50 ng/ml of 
EGF and cells were stimulated for 15 minutes. Proteins were extracted with 50 μl of RIPA 
buffer. Aliquots of 10 μg proteins were electrophoresed on a denaturing 12 % polyacrylamide 
gel and transferred into nitrocellulose membrane for 45 minutes at 100 mA. Membranes were 
incubated with phosphorylated EGFR (1:20,000 dilution), phosphorylated AKT (1:10,000 
dilution), phosphorylated MAPK (1:20,000 dilution) and GAPDH (1:20,000 dilution). 
Representative bands are from duplicate experiment. Labwork 4.0 software used for 
densitometric analysis of the X-ray films and measurement were normalised with GAPDH. 
Asterisks represent the statistically significant reduction in phosphorylation of EGFR, AKT and 
MAPK in the presence of gefitinib compared with in the absence of gefitinib (One way ANOVA, * 
p<0.05).   
Following stimulation with 50 ng/ml of EGF in both Hs578T and SK-BR-3 cells, 
phosphorylation of EGFR was reduced in a concentration dependant fashion by 
increase in the concentration of gefitinib. In Hs578T cells, reduction in 
phosphorylation of EGFR was detected in the presence of gefitinib at 
concentration of 0.1 µM, followed by complete inhibition at concentration of 10 
µM and higher. Reduction in AKT phosphorylation was detected in the presence 
of 10 µM gefitinib and complete inhibition was observed at higher concentration 
in this cell line. Decreased phosphorylation of MAPK was detected at 
concentration of 1 µM and higher, and decreased more with increasing gefitinib 
concentration.  
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In SK-BR-3 cells, reduction in phosphorylation of EGFR was observed in the 
presence of 0.1 µM gefitinib and complete inhibition was detected at 
concentration of 1 µM and higher. Complete inhibition in the phosphorylation of 
AKT was observed at concentration of 1 µM and at higher concentrations in this 
cell line. Reduction in MAPK phosphorylation was detected at 0.1 µM, followed 
by complete inhibition at 1 µM and higher. 
Based on these results, the complete inhibition of EGFR and downstream signal 
transduction components in both cell lines at specific concentrations suggest 
the inhibitory effect of gefitinib against activation of EGFR signalling pathway, 
and that SK-BR-3 cells are more sensitive to gefitinib than Hs578T cells as 
complete inhibition of phosphorylated EGFR and AKT was detected at 
concentration of 1 µM, whereas complete inhibition in Hs578T cells observed at 
concentration of 20 µM. 
5.2.16 Inhibition of EGF receptor by gefitinib inhibitor on protective effect 
of EGF against anoikis in Hs578T and SK-BR-3 cells  
To confirm that the EGFR mediates the anti-anoikis effect of EGF, the effect of 
EGF in anoikis was evaluated in the presence and absence of gefitinib which is 
a specific inhibitor of the EGFR.  
Response to gefitinib has been linked to activating mutations in the EGFR gene 
in patients with lung adenocarcinoma. Hs578T and SK-BR-3 cells have been 
reported to have non-mutated EGFR gene based on the mutation analysis 
(Ikediobi, Davies et al. 2006). 
Hs578T and SK-BR-3 cells which express high level of EGFR were cultured in 
non-attached condition in serum-free medium in the presence and absence of 
gefitinib, and in the presence and absence of EGF. Proteins were extracted 
after incubation for 6 hours for both Hs578T and SK-BR-3 cells and were 
analysed for cleaved PARP, phosphorylation of EGFR, AKT and MAPK by 
using western transfer (Figure 5.16).   
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Figure 5.16: Effect of inhibition of EGFR with gefitinib on the anti-anoikis effect of EGF in 
Hs578T and SK-BR-3 cells. Hs578T and SK-BR-3 cells were seeded into 12 well poly-HEMA 
coated plates at 20 X 104 cells/well in 2ml of serum free medium, in the presence of 10 µM of 
gefitinib or vehicle (DMSO) for Hs578T cells or in the presence of 1µM gefitinib or vehicle 
(DMSO) for SK-BR-3 cells, and in the presence and absence of 50 ng/ml EGF. After incubation 
of 6 hours, proteins were extracted from both Hs578T and SK-BR-3 cells with 50 μl per well of 
RIPA buffer. Aliquots of 10 µg protein were separated by electrophoresis in denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose for 45 minutes at 100 mA. Membranes 
were incubated with antibody against phosphorylated EGFR (1:20,000 dilution), cleaved PARP 
(1:2000 dilution), phosphorylated AKT (1:10,000 dilution for Hs578T cells and 1:20,000 for SK-
BR-3 cells), phosphorylated MAPK (1:10,000 dilution for Hs578T cells and 1:20,000 for SK-BR-
3 cells) and GAPDH (1:20,000 dilution). Images shown are representative of cleaved PARP 
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from a triplicate experiment that have been repeated at least three times. Labwork 4.0 software 
used for densitometric analysis of the X-ray films and measurement were normalised with 
GAPDH. Error bars are + SEM. Asterisks denotes there was a statistically significant increase in 
the amount of cleaved PARP and complete inhibition in phosphorylation of EGFR, AKT in both 
cell lines along with full inhibition of MAPK phosphorylation in SK-BR-3 cells and significant 
reduction in phosphorylation of MAPK in Hs578T cells in the presence of gefitinib compared 
with in the absence of gefitinib (One way ANOVA, ***p=0.0001, ****p<0.0001).  
 
In Hs578T cells, stimulation with EGF in the absence of gefitinib induced 
strongly EGFR phosphorylation. In the presence of 10 µM gefitinib, no EGFR 
phosphorylation was detected in response to stimulation with EGF, compared 
with in the absence of gefitinib. Hs578T cells underwent anoikis following 
incubation in non-attached conditions in serum-free medium for 6 hours. In the 
presence of 50 ng/ml EGF anoikis was inhibited almost completely. The 
protective effect of EGF against anoikis was significantly reduced in the 
presence of gefitinib which was demonstrated by significant increase in the 
amount of cleaved PARP in the presence of gefitinib compared to the absence 
of gefitinib. The increase in phosphorylation of AKT in response to stimulation 
with EGF was completely inhibited in the presence of gefitinib. Increase in the 
amount of MAPK phosphorylation in response to stimulation with EGF was 
reduced markedly in the presence of gefitinib.   
In SK-BR-3 cells, stimulation with EGF in the absence of gefitinib induced 
phosphorylation of EGFR, whereas in the presence of 1μM gefitinib no EGFR 
phosphorylation was detected even after long exposure (Data not shown). In 
the presence of 50 ng/ml EGF anoikis was inhibited completely. The anti-
anoikis effect of EGF was significantly reduced in the presence of gefitinib 
(p<0.001). This was shown by significant increase in the amount of cleaved 
PARP. The increase in phosphorylation of both AKT and MAPK in response to 
stimulation with EGF was completely inhibited in the presence of gefitinib.   
The survival effect of EGF was completely inhibited with gefitinib, which can 
support the contention that the survival effect of EGF is mediated through the 
EGFR receptor.  
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5.2.17 Effect of EGF and heregulin-1 on migration of oestrogen receptor-
negative breast cancer cells 
5.2.17.1 Effect of EGF and heregulin-1 on migration of triple-negative 
MDA-MB-231 and Hs578T breast cancer cells   
One of the characteristics of malignancy and predisposition of metastasis is an 
increase in the motility of the cancerous cells. Hence, the effects of EGF and 
heregulin-1 on migration of two triple-negative MDA-MB-231 and Hs578T breast 
cancer cells were evaluated in an in vitro wound healing assay.   
Cells were plated at high density in 24 well plates, under which two parallel lines 
had been scored underneath each wells and left for 24 hours in order to form a 
confluent monolayer. Cells were washed and withdrawn from the effect of 
growth factors for 16 hours. After 16 hours, cells were wounded and incubated 
for 2 hours in 0.01% BSA and phenol red-free DMEM. After 2 hours, the first 
images of the wounded cells were captured in the absence or presence of EGF 
and heregulin-1 and represent as 0 hour. Images of the cells were captured 
every two hours up to 6 hours of incubation. The width of the each wound was 
measured 20 times with Image J software and the average was calculated 
(Figure 5.17). Cell migration was evaluated by measuring the distance of the 
edge of the wound towards the centre of the wound.   
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Figure 5.17: Effect of EGF and heregulin-1 on migration of triple-negative breast cancer 
cells. MDA-MB-231 (A) and Hs578T (B) cells were seeded at density of 40 X 104 cells/well into 
24 well plates that had scored on the under surface with two parallel lines across the middle of 
each well. Cells were withdrawn in phenol red-free DMEM medium supplemented with 10% 
charcoal-treated newborn calf serum as described in Materials and Methods section. Monolayer 
cells were wounded with a sterile 2 µl Gilson pipette tip through the centre of the well, 
perpendicular to the scored lines. Wounded cells were washed twice with 0.5 ml of phenol red-
free DMEM and incubated in phenol red-free DMEM supplemented with 0.01 % of BSA for two 
hours. After two hours of incubation, cells were washed again and incubated with phenol red-
free DMEM medium to remove any extra cell debris or detached cells and 0.01% BSA alone (
) or supplemented with 50 ng/ml of EGF( ) or in the presence of 50 ng/ml heregulin-1 
(HRG) ( )for various time points up to 6 hours. Image were captured at the beginning of the 
experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes there was a statistical significant increase in the 
cell migration in the presence of EGF compare with in the absence of EGF in both MDA-MB-231 
and Hs578T cells (One way ANOVA, ***p=0.0001,****p<0.0001). 
 
As illustrated in the Figure 5.17, addition of 50 ng/ml EGF stimulated the 
movement of both MDA-MB-231 and Hs578T cells 2.4 fold and 3 fold 
respectively. In MDA-MB-231 cells, there was a statistically significant increase 
in the migration of cells after 6 hours of incubation, whereas, significant 
increase in migration of Hs578T cells was observed after 2, 4 and 6 hours of 
incubation with 50 ng/ml EGF. Heregulin-1 did not stimulate the movement of 
the MDA-MB-231 or Hs578T cells at any time analysed, as no significant 
stimulation of cell movement was detected at any of the incubation time. 
Results suggest that EGF has potential migratory effect on both triple-negative 
breast cancer cell lines.  
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5.2.17.2 Effect of EGF and heregulin-1 on migration of HER-2 positive 
SKBR-3 breast cancer cells 
To examine the effectiveness of EGF and heregulin-1 on migration of HER-2 
positive SKBR-3 breast cancer cells, in vitro wound healing assay was initially 
conducted as described in section 5.2.17.1.  
Wounded SK-BR-3 cells were incubated in the presence and absence of 50 
ng/ml EGF and in the presence and absence of 50 ng/ml heregulin-1 at 0, 2, 4 
and 6 hours of incubation. Images of the cells were captured at each particular 
time. The width of the each wound was measured 20 times and the average of 
them was calculated. The cell migration was evaluated by measuring the 
distance of the edge of the wound towards the centre of the wound by using 
Image J software (Figure 5.18). 
   
 
Figure 5.18: Effect of EGF and heregulin-1 on migration of SK-BR-3 cells. SK-BR-3 cells 
were seeded at density of 40 X 104 cells/well into 24 well plates that had scored on the under 
surface with two parallel lines across the middle of each wells. Cells were withdrawn in phenol 
red-free DMEM medium supplemented with 10% charcoal-treated newborn calf serum as 
described in Materials and Methods section. Monolayer cells were wounded with a sterile 2 µl 
Gilson pipette tip through the centre of the well, perpendicular to the scored lines. Wounded 
cells were washed twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free 
DMEM supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells 
were washed again and incubated with phenol red-free DMEM medium and 0.01% BSA alone (
) or supplemented with 50 ng/ ml of EGF ( ) or in the presence of 50 ng/ ml heregulin-
1(HRG) ( ) for various time points up to 6 hours. Image were captured at the beginning of the 
experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes there was a statistically significant increase in 
the cell migration in the presence of EGF and heregulin-1 compare with in the absence of EGF 
or heregulin-1 in SK-BR-3 cells (One way ANOVA, **p<0.001, ****p<0.0001). 
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Addition of 50 ng/ml of EGF significantly enhanced migration of SK-BR-3 cells 
two fold after 6 and 8 hours of incubation. Addition of 50 ng/ml heregulin-1 
stimulated migration of cells more than three fold after 4 and 6 hours of 
incubation, which indicates that heregulin-1 has more migratory effect than EGF 
on SK-BR-3 cells.  
5.2.18 Effect of EGFR inhibitor on migration of triple-negative MDA-MB-
231 and Hs578T breast cancer cells  
In previous sections the potential migratory effect of EGF was evaluated on 
motility of oestrogen receptor-negative breast cancer cells. The migration 
stimulated was less than with IGF-1 but is comparable to that reported 
previously (Mezi, Todi et al. 2012). To investigate whether the migratory effect 
of EGF is inhibited by EGFR tyrosine kinase inhibitor, gefitinib in triple-negative 
breast cancer cells, wounded MDA-MB-231 and Hs578T cells were incubated in 
the presence and absence of 10 μM gefitinib and in the presence and absence 
of 50 ng/ml EGF at 0, 2, 4 and 6 hours of incubation. Images of the cells were 
captured at each particular time. The width of the each wound was measured 
20 times and the average of them was calculated. The cell migration was 
evaluated by measuring the distance of the edge of the wound towards the 
centre of the wound by using Image J software (Figure 5.19). 
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 Figure 5.19: Effect of inhibition of EGFR with gefitinib on migration of triple-negative 
breast cancer cells. MDA-MB-231 (A) and Hs578T (B) cells were seeded at density of 40 X 
104 cells/well into 24 well plates that had scored on the under surface with two parallel lines 
across the middle of each wells. Cells were withdrawn in phenol red-free DMEM medium 
supplemented with 10% charcoal-treated newborn calf serum as described in Materials and 
Methods section. Monolayer cells were wounded with a sterile 20-200 µl Gilson pipette tip 
through the centre of the well, perpendicular to the scored lines. Wounded cells were washed 
twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free DMEM 
supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells were 
washed again and incubated with phenol red-free DMEM medium and 0.01% BSA alone ( ) 
or supplemented with 50 ng/ ml of EGF ( ), or in the presence of 10 µM gefitinib and 50 ng/ml 
EGF ( ) for various time points up to 6 hours. Image were captured at the beginning of the 
experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes there was a statistically significant increase in 
the cell migration in the presence of EGF compare with in the absence of EGF and there was 
significant reduction in the migration of cells in the presence of the gefitinib cells in both MDA-
MB-231 and Hs578T cells (One way ANOVA, *p<0.05, ** P<0.001, *** p=0.0001, ****P<0.0001). 
 
As it was demonstrated previously, there was a statistically significant increase 
in migration of both MDA-MB-231 and Hs578T cells in the presence of 50 ng/ml 
EGF. Treatment of cells with 10 µM gefitinib significantly reduced migration of 
MDA-MB-231 cells after 6 hours and migration of Hs578T cells after 4 and 6 
hours of incubation. These results suggest that gefitinib has an inhibitory effect 
against migration of cells stimulated by EGF.  
 
 
 
 
 
    
 
     
  
165 
 
5.2.19 Effect of EGFR inhibitor on migration of SK-BR-3 cells 
The ability of gefitinib to inhibit migration of SK-BR-3 cells stimulated by EGF 
was tested by wounding healing assay. 
Wounded SK-BR-3 cells were incubated in the presence and absence of 10 μM 
gefitinib and in the presence and absence of 50 ng/ml EGF at 0, 2, 4 and 6 
hours of incubation. Images of the cells were captured at each particular time. 
The width of the each wound was measured 20 times and the average of them 
was calculated. The cell migration was evaluated by measuring the distance of 
the edge of the wound towards the centre by using Image J software (Figure 
5.20). 
 
Figure 5.20: Effect of inhibition of EGFR with gefitinib on migration of SK-BR-3 cells. SK-
BR-3 cells were seeded at density of 40 X 104 cells/well into 24 well plates that had scored on 
the under surface with two parallel lines across the middle of each wells. Cells were withdrawn 
in phenol red-free DMEM medium supplemented with 10% charcoal-treated newborn calf serum 
as described in Materials and Methods section. Monolayer cells were wounded with a sterile 2 
µl Gilson pipette tip through the centre of the well, perpendicular to the scored lines. Wounded 
cells were washed twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free 
DMEM supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells 
were washed again and incubated with phenol red-free DMEM medium and 0.01% BSA alone (
) or supplemented with 50 ng/ ml of EGF ( ), or in the presence of 10 µM gefitinib and 50 
ng/ ml EGF ( ) for various time points up to 6 hours. Image were captured at the beginning of 
the experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes there was a statistically significant increase in 
the cell migration in the presence of EGF compared with in the absence of EGF and there was 
significant reduction in the migration of cells in the presence of the gefitinib in SK-BR-3 cells 
compared with in the absence of gefitinib (One way ANOVA, ** P<0.001, ****P<0.0001). 
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Figure 5.20 shows the inhibitory effect of gefitinib on the migration response of 
SK-BR-3 cells to EGF. Treatment of SK-BR-3 cells with gefitinib reduced 
significantly EGF stimulated movement two folds at 4 and 6 hours of incubation, 
which can suggest that blocking the EGFR by gefitinib, inhibits the migratory 
effect of EGF.  
5.2.20 Effect of dual tyrosine kinase inhibitor of EGFR and HER-2 on 
migration of HER-2 positive SK-BR-3 cells 
The ability of dual tyrosine kinase inhibitor lapatinib on inhibition of SK-BR-3 cell 
stimulated with EGF was tested by using wound healing assay. 
Wounded SK-BR-3 cells were incubated in the presence and absence of 10 μM 
lapatinib and in the presence and absence of 50 ng/ml EGF for 0, 2, 4 and 6 
hours of incubation. Images of the cells were captured at each particular time. 
The width of the each wound was measured 10 times and the average of them 
was calculated. The cell migration was evaluated by measuring the distance of 
the edge of the wound towards the centre by using Image J software (Figure 
5.21). 
 
Figure 5.21: Effect of Lapatinib on migration of SK-BR-3 cells. SK-BR-3 cells were seeded 
at density of 40 X 104 cells/ well into 24 well plates that had scored on the under surface with 
two parallel lines across the middle of each wells. Cells were withdrawn in phenol red-free 
DMEM medium supplemented with 10% charcoal-treated newborn calf serum as described in 
Materials and Methods section. Monolayer cells were wounded with a sterile 2 µl Gilson pipette 
tip through the centre of the well, perpendicular to the scored lines. Wounded cells were 
washed twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free DMEM 
supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells were 
washed again and incubated with phenol red-free DMEM medium and 0.01% BSA alone ( ) 
or supplemented with 50 ng/ ml of EGF ( ), or in the presence of 10 µM lapatinib and 50 ng/ml 
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EGF ( ) for various time points up to 6 hours. Image were captured at the beginning of the 
experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes there was a statistically significant increase in 
the cell migration in the presence of EGF compared with in the absence of EGF, and significant 
reduction in migration of EGF stimulated cells in the presence of lapatinib compared with in the 
absence of lapatinib (One way ANOVA, *p<0.05, ** p<0.001, *** p=0.0001, ****P<0.0001).  
 
EGF significantly stimulated the migration of SK-BR-3 cells which is supporting 
the previous findings. There was a statistically significant two fold reduction in 
the presence of 10 µM lapatinib on stimulated cells with 50 ng/ml EGF at 4 and 
6 hours of incubation. Result suggests that blocking both EGFR and HER-2 
inhibit the migratory effect of EGF in SK-BR-3 cells. 
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5.3 Discussion  
As mentioned in the discussion of chapter 3, avoidance of anoikis and increase 
in cell motility are significant characteristics of malignant epithelial tumour cells. 
Deregulation of growth factor receptors expression is known as one of the 
anoikis-resistant mechanisms, which triggers activation of cell survival pathways 
and induces migration and invasion of cells (Wells 2000). Overexpression of 
EGFR and HER-2 has been reported in contribution of lung tumours metastasis 
through activation of MAPK signalling which leads to degradation of Bim and 
subsequently block the anoikis pathway (Sharma, Bell et al. 2007, Paoli, 
Giannoni et al. 2013). In 2003, Reginato et al illustrated in human mammary 
epithelial cells MCF-10A that when EGFR is overexpressed, it mediates ERK 
pathway activation which in turns blocks the anoikis process through 
suppression of Bim (Reginato, Mills et al. 2003). In another study, 
overexpression of HER-2 in human breast cancer was showed to supress Bim 
expression through activation of MAPK pathway which subsequently conferring 
anoikis insensitivity (Haenssen, Caldwell et al. 2010).   
Several studies addressed the involvement of EGF in induction of cell motility 
and invasion in various cancers (Price, Wilson et al. 1996, Shibata, Kawano et 
al. 1996, Wells 2000). Overexpression of EGFR and HER-2 reported to be 
related to the ability of the mammary carcinoma cells to invade and metastasis 
(Yamaguchi, Wyckoff et al. 2005, Palmieri, Bronder et al. 2007). In 2006, Garcia 
et al reported that treatment of MCF-7 breast cancer cells with EGF induced cell 
motility through activation of both AKT and ERK pathways (Garcia, Franklin et 
al. 2006). In breast cancer, the correlation between overexpression of EGF and 
its receptors with higher incidence of distant metastasis has been reported in 
several studies (Ikediobi, Davies et al. 2006, De Luca, Carotenuto et al. 2008, 
Giltnane, Moeder et al. 2009). Several in vitro mouse breast cancer model 
studies have been reported significant role of EGFR signalling inhibitors in 
reduction of bone and brain metastasis (Gril, Palmieri et al. 2008, Molli, Adam et 
al. 2008). 
In this chapter, the role of EGF-like ligands, namely: EGF and heregulin-1 in the 
survival and migration of oestrogen receptor-negative breast cancer cells was 
investigated. The first part of this chapter discussed the effect of EGF and 
heregulin-1 on survival of oestrogen receptor-negative breast cancer cells in 
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non-attached conditions. Amongst oestrogen non-responsive breast cancer 
cells studied in this chapter, SK-BR-3 cells, Hs578T and MDA-MB-231 
expressed high level of EGFR and downstream key components of EGFR 
signalling pathway was activated in response to stimulation with EGF in a 
concentration-dependent manner.  Stimulation with EGF powerfully suppressed 
anoikis in Hs578T and SK-BR-3 breast cancer cells cultured in non-attached 
conditions, as evidenced by inhibition of PARP cleavage in these cell lines. In 
contrast, EGF did not show a protective effect against anoikis on MDA-MB-231 
cells, which may be explained by the inability of EGF to induce 
autophosphorylation of EGFR and activation of the PI3K and AKT pathway in 
this cell line despite the activation of the MAPK pathway. These results suggest 
that survival signals need to be transmitted through PI3K and AKT but not the 
MAPK pathway.  
It has been reported that HER-2-HER-3 heterodimers are potent activators of 
PI3K pathways (Holbro et al, 2003; Chan et al, 2005). Frequent co-expression 
of HER-3 with HER-2 in breast cancer has been reported and contribution of 
HER-3 in HER-2-mediated breast carcinogenesis has speculated (Bieche, 
Onody et al. 2003, Witton, Reeves et al. 2003, Sassen, Rochon et al. 2008, 
Park, Jung et al. 2014). Treatment of cells with heregulin-1 showed powerful 
effect on suppression of anoikis in HER-2 positive SK-BR-3 cells, which 
supports the supposition that HER-2 and HER-3 formed heterodimers in 
response to stimulation with heregulin-1 and activated the downstream key 
component AKT and MAPK pathways. Following treatment of triple-negative 
MDA-MB-231 and Hs578T cells with heregulin-1 did not show a protective 
effect, which suggests that the survival signals must be through EGFR. The 
survival effect of EGF was found to be concentration-dependent in Hs578T and 
SK-BR-3 cells. In addition, interference with the function of both EGFR and 
HER-2 and also EGFR with tyrosine kinase inhibitors reduced the survival effect 
of EGF accompanied by complete inhibition of activation of two main 
downstream effector proteins, AKT and MAPK.  
The sensitivity of gefitinib in inhibition of growth in non-small lung cancer cell 
lines has been reported and that this sensitivity reported to be more associated 
with EGFR signal transduction pathway for mediation of cell proliferation and 
survival (Ono, Hirata et al. 2004). To our knowledge, effect of EGFR inhibitor 
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gefitinib and also dual tyrosine kinase inhibitor lapatinib on survival of 
anchorage-independent oestrogen receptor-negative breast cancer cells was 
not studied before. Hence, the effect of gefitinib and lapatinib was investigated 
on survival of oestrogen receptor-negative breast cancer cells in non-attached 
condition. In this chapter, gefitinib and lapatinib have been shown to play 
important role in abrogating the survival effect of EGF in non-attached 
oestrogen receptor-negative breast cancer cells. In SK-BR-3 cells, lapatinib 
demonstrated to play important role in the anti-anoikis effect of EGF, as 
observed by significant induction of cell death followed by block the two key 
downstream effector AKT and MAPK proteins. This result is agreed with other 
findings that lapatinib induces apoptosis and blocks activation of both 
downstream effectors AKT and MAPK in HER-2 positive BT-474 breast cancer 
cells (Xia, Mullin et al. 2002). 
Role of gefitinib in induction of apoptosis in SK-BR-3 has been reported 
(Normanno, Campiglio et al. 2002). Here, we have tested the effect of gefitinib 
on induction of anoikis in SK-BR-3 cells, and to see whether the survival effect 
is transmitted via EGFR and HER-2 hetero-dimerisation or through EGFR. 
Gefitinib significantly induced reduction in survival effect of EGF, as significant 
increase in the amount of cleaved PARP was observed. This was consistent 
with the previous finding that gefitinib induce apoptosis (Normanno, Campiglio 
et al. 2002). The increase in phosphorylation of both AKT and MAPK in 
response to stimulation with EGF was completely inhibited in the presence of 
gefitinib in SK-BR-3 cells. Induction of cell death by gefitinib can in part be 
explained due to complete inhibition of PI3K and AKT pathway. Interestingly, in 
SK-BR-3 cells, both lapatinib and gefitinib abrogated the EGF survival effect 
which was accompanied by complete inhibition of the AKT and MAPK 
pathways. The result confirms that the survival effect of EGF is transmitted 
through EGFR. In Hs578T cells in the presence of gefitinib, the survival effect of 
EGF was significantly reduced, which was shown by significant increase in the 
amount of cleaved PARP. In this cell line, phosphorylation of AKT was 
completely inhibited in the presence of gefitinib but MAPK phosphorylation was 
inhibited partially.  
The second part of this chapter demonstrated the migratory effect of EGF and 
heregulin-1 on oestrogen receptor-negative breast cancer cells with the 
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monolayer wound-healing assay. The migratory effect of EGF was observed in 
all three cell lines studied and was found to be higher in Hs578T and SK-BR-3 
than in MDA-MB-231 cells, as evidenced by significant increase in migration of 
all three cell lines. Stimulation with heregulin-1 resulted in an increase migration 
of SK-BR-3 cells, which can explained be due to hetero-dimerization of HER-2 
and HER-3. Heregulin-1 had no effect on motility of MDA-MB-231 or Hs578T 
cells, which is consistent with results of this chapter that heregulin-1 is not able 
to activate MAPK pathway in these cell lines, as activation of MAPK pathway 
reported to plays important role in migration of breast cancer cells (Garcia, 
Franklin et al. 2006).  
Treatment of MDA-MB-231, Hs578T and SK-BR-3 cells with gefitinib inhibited 
significantly the migratory effect of EGF. Gefitinib has shown more inhibitory 
effect in SK-BR-3 and Hs578T cells than in MDA-MB-231 cells. Treatment of 
SK-BR-3 cells with lapatinib resulted in significant inhibition of EGF stimulated 
migration. Interestingly, gefitinib and lapatinib has shown the similar significant 
inhibitory effect in SK-BR-3 (p<0.001). 
Further experiments could investigate the effect of lapatinib in the presence of 
heregulin-1 in survival and migration of HER-2 positive SK-BR-3 cells, to 
evaluate the inhibitory effect of this inhibitor on the effect of heregulin-1. 
In conclusion, these findings emphasise the activity of EGF signal transduction 
pathway in survival and migration of oestrogen receptor-negative breast cancer 
cells and that EGFs may contribute to the metastatic potential of breast cancer 
cells by activation of survival and migratory pathways. The inhibitory effect of 
both EGFR inhibitor and dual tyrosine kinase inhibitor against cell survival and 
migration might be useful as therapeutic targeted therapies.  
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Chapter 6. Expression of human epidermal growth factor 
receptors 1 and 2 in oestrogen receptor-negative breast 
tumours 
 
6.1 Introduction    
It is well known that aberration in tyrosine kinase activity of epidermal growth 
factor receptor family particularly, EGFR and HER-2 are considered as one of 
the significant reasons for development and progression of human cancer 
(Dhomen, Mariadason et al. 2012). Overexpression of EGFR and HER-2 has 
been reported frequently in breast tumours (Garcia, Vizoso et al. 2003, Memon, 
Sorensen et al. 2006). Overexpression of EGFR has been reported to be 
associated with aggressive phenotypes and poor clinical outcome in breast 
tumours and its over expression is correlated with increased proliferation of 
malignant cells and resistance to apoptosis (Rimawi, Shetty et al. 2010). 
Nickerson et al in 2010 reported the overexpression of EGFR in triple-negative 
breast cancer patients and its association with increase in metastasis 
(Wiseman, Makretsov et al. 2005, Foley, Nickerson et al. 2010). 
In 2005, Wiseman et al reported the high expression of EGFR, HER-2 and 
HER-3 in oestrogen receptor-positive breast tumours and their correlation with 
decreased disease survival of patients whose tumours express high levels of 
EGFR, HER-2 and HER-3 (Wiseman, Makretsov et al. 2005). Amplification of 
HER-2 has been reported in 15-30% of breast cancers and is associated with 
poor prognosis. Patients with lymph node metastasis are more likely to have 
HER-2 positive tumours than those that are node-negative. HER-2 amplification 
is observed more frequently in oestrogen receptor-negative breast cancers than 
in oestrogen receptor-positive breast cancers (Hynes and Stern 1994, Howe 
and Brown 2011). 
This chapter is focused on analyzing the expression of EGFR and its 
association with HER-2, expression of proliferation marker Ki-67, apoptotic 
marker, cleaved caspase-3 along with various clinico-pathological criteria on 
oestrogen receptor-negative breast tumours by immunohistochemistry.    
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6.2 Results 
6.2.1 Expression of EGFR in normal breast tissue 
EGFR expression was detected in all 7 normal breast tissues investigated by 
immunohistochemistry. In general, EGFR expression was weak to moderate 
with a mean histoscore of 123.43 and a median histoscore of 55. Immuno-
reaction was membranous in epithelial cells that line the acini (Figure 6.1). 
 
Figure 6.1: Expression of EGFR in normal breast tissue. Section from normal breast tissue 
with histoscore of 383 was analysed for expression of EGFR by immunohistochemistry. 
Membranous immuno-reaction of EGFR was detected in epithelial line of the acini. Photograph 
magnification is x200. 
 
6.2.2 Expression of EGFR in in situ carcinoma of the breast       
EGFR immuno-reaction was detected in 32 out of 37 carcinomas in situ 
(86.48%). The immuno-reaction of EGFR was membranous (Figure 6.2). In 
general, most of EGFR positive tumours showed weak to moderate expression 
of EGFR with a mean histoscore of 159 and a median histoscore of 72. 
However, 3 tumours were strongly immuno-reactive for EGFR with a maximum 
histoscore of 735.  
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 Figure 6.2: Expression of EGFR in in situ breast carcinoma. Section of (A) comedo and (B) 
solid type of carcinoma in situ with histoscores of 255 and 735 respectively were analysed by 
immunohistochemistry for expression of EGFR. The inset shows the membranous immuno-
reaction of EGFR in in situ neoplastic cells. Magnification is x200 for inset and x20 for the 
image.  
6.2.3 Expression of EGFR in invasive carcinoma of the breast 
All invasive breast tumours included in the study were analysed for EGFR 
expression in duplicate cores and the mean values were used for the statistical 
analyses. The consistency of expression between the duplicate cores was 
tested; there was a strong correlation between EGFR expression measured in 
the duplicate cores (Pearson correlation, p=0.001, Figure 6.3).  
 
Figure 6.3: Expression of EGFR in the duplicate cores of invasive tumours. Two cores (A 
and B) of one millimetre in diameter were taken from each tumour for construction of TMA 
blocks. EGFR immuno-reactive sections were analysed for EGFR independently. There was a 
strong correlation of EGFR expression between the two cores tested in each tumours 
(Pearson’s rho correlation p=0.001).  
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EGFR immuno-reaction was demonstrated in 77 tumours of the 79 invasive 
lesions investigated (97%). In general, the majority of EGFR positive tumour 
cells were moderately immuno-reactive with a mean histoscore of 202 and 
median histoscore of 115. However, 6 tumours were strongly positive for 
expression of EGFR with a maximum histoscore of 856. The immuno-reaction 
for EGFR was membranous (Figure 6.4).  
 
Figure 6.4: Expression of EGFR in invasive breast cancer. Sections of invasive breast 
carcinomas with histoscore of 578 were tested for EGFR expression by immunohistochemistry. 
Specific membranous immuno-reaction was demonstrated in the neoplastic cells. 
Representative arrows indicate the malignant epithelial cells with EGFR expression absent 
(blue), weakly positive (yellow), moderately positive (green) and strongly positive (red). Specific 
membranous immuno-reaction was demonstrated. Magnification is x20 and x200 for insets. 
 
6.2.4 EGFR expression and presence of lymph node metastasis 
To explore the possible role of EGFR in breast cancer cell metastasis, the 
expression of EGFR was tested in the primary tumours and their corresponding 
tumour cells with axillary lymph node metastases in 26 patients. There was a 
significant correlation between the expression of EGFR in the primary tumour 
cells and tumour cells with metastatic lymph node deposits (Pearson’s rho 
correlation, p=0.030, Figure 6.5). There is a significant difference in the 
expression levels of EGFR in primary tumours and metastatic counterparts. 
EGFR is expressed at higher levels in primary tumours than the corresponding 
metastatic tumour cells (Wilcoxon signed ranking test, p=0.02).  
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Figure 6.5: EGFR expression in primary breast tumour cells and metastatic tumour cells 
in lymph nodes. EGFR expression was analysed by immunohistochemistry in both primary (A) 
and metastatic (B) tumour cells of the same patients in 26 tumours. There was a significant 
association between EGFR expression in primary and metastatic tumour cells (p=0.030) (C). 
Magnification is x200. 
 
The association of EGFR expression with the number of axillary lymph node 
metastasis were investigated. There was no significant correlation between 
EGFR expression and the number of axillary lymph node metastasis 
(Spearman’s rho correlation, p=0.236).  
6.2.5 Expression of EGFR in various breast lesions 
Expression of EGFR was investigated in normal breast tissues and various 
types of breast carcinomas (Figure 6.6). Amongst different types of breast 
lesions, EGFR was mostly expressed in invasive breast tumours.   
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Figure 6.6: Expression level of EGFR in different breast lesions. Expression of EGFR in 
normal breast tissues, in situ carcinomas, invasive carcinomas and metastatic breast tumours 
(LN metastasis). The horizontal bars represent the median values, the boxes represent the 50th 
percentiles, whiskers represent the range of data, the dots refer to outlier values.   
6.2.6 EGFR expression and clinico-pathological criteria 
The relationship between EGFR expression and clinical and pathological 
features of breast tumours was investigated. There was no significant 
correlation between EGFR expression and age of patients (Pearson’s rho 
correlation, p=0.840, Figure 6.7).  
The data illustrated in figure 6.7 suggests that there may be a trimodal 
distribution of EGFR expression. The association between age and EGFR 
expression in each of the identified EGFR subgroups (0-200, 200-400 and 
>400) was evaluated. There was no significant association between EGFR 
expression and patient’s age in any of the EGFR subgroups (Pearson rho 
correlation p=0.118, p=0.477 and p=0.344). 
 
Figure 6.7: Association of EGFR expression with patient age.  EGFR expression was not 
associated significantly with age of patients, p=0.840). 
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There was no correlation between EGFR expression and size of the tumour 
(Pearson’s rho correlation, p=0.997) or grade of tumour (Spearman’s rho 
correlation, p=0.350). There was no significant difference in expression level of 
EGFR in lower and high grade tumours (Mann-Whitney test, p=0.585, Figure 
6.8). This implies that EGFR expression is independent of the size of the 
tumours and tumour grade. 
 
Figure 6.8: Association of EGFR expression with tumour grade. EGFR expression showed 
no significant association with the histological grades of invasive tumours (p>0.05). The 
horizontal bars represent the median values, the boxes represent the 50th percentiles and the 
whiskers represent the range of data. 
6.2.7 Association between expression of EGFR and expression of Ki-67 
protein in malignant breast tumours  
To investigate the role of EGFR in proliferation of breast tumour cells, 
association between EGFR expression and expression of the proliferation 
markers Ki-67 was investigated. The statistical analysis was tested on 142 
cases which include in situ carcinoma, invasive carcinoma and lymph node 
metastasis tumour cells. The results show that there was no significant 
correlation between the expression of EGFR and Ki-67 in all the breast lesions 
analysed (Pearson correlation, p=0.058). 
6.2.7.1 Association between expression of EGFR and expression of 
Ki-67 in in situ breast carcinoma 
Expression of EGFR and Ki-67 was investigated in 37 in situ breast carcinomas, 
of which 6 tumours positive for EGFR were negative for Ki-67 and 5 tumours 
that expressed Ki-67 were negative for expression of EGFR (Figure 6.9).  
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 Figure 6.9: EGFR expression and expression of Ki-67 in in situ breast cancer. Sections 
from comedo type of in situ breast carcinomas were tested for EGFR (A, C) and Ki-67 (B, D) 
expression by immunohistochemistry. Magnification is x200.  
The association between expression of EGFR and Ki-67 were investigated in in 
situ breast carcinomas. There was no correlation between expression of EGFR 
and Ki-67 in in situ tumours (Pearson correlation, p-value=0.752, Figure 6.10).  
 
Figure 6.10: Association of EGFR expression and expression of Ki-67 in in situ breast 
carcinoma. EGFR and Ki-67 expression were compared in 37 in situ breast carcinomas. There 
was no association between EGFR expression and expression of Ki-67 in in situ breast 
carcinomas (p=0.752).  
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6.2.7.2 Association between expression of EGFR and expression of 
Ki-67 in invasive breast tumours 
To investigate whether EGFR is associated with proliferation of invasive breast 
tumours, the expression of Ki-67 and EGFR was measured in invasive breast 
tumours. Out of 79 invasive tumours, 77 were positive for both expression of 
EGFR and Ki-67. There was a significant correlation between EGFR expression 
and Ki-67 expression in invasive breast carcinoma investigated (Pearson’s rho 
correlation, p=0.024, Figure 6.11).  
 
 
Figure 6.11: Association of EGFR expression and expression of Ki-67 in invasive breast 
cancers. EGFR (A) expression and Ki-67 (B) expression were analysed by 
immunohistochemistry. Significant association was detected between EGFR and Ki-67 
expression(C) (p=0.024). 
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6.2.7.3 Association between expression of EGFR and Ki-67 in breast 
tumour cells with involved lymph nodes metastasis 
The association between expression of EGFR and Ki-67 in 26 breast tumour 
cells with axillary lymph nodes was investigated (Figure 6.12).  
 
Figure 6.12: EGFR expression and expression of Ki-67 in breast tumour cells with 
involved lymph nodes. Expression of EGFR (A, C) and Ki-67 (B, D) was analysed in tumours 
involved with axillary lymph nodes metastatic tumour cells by immunohistochemistry. 
Magnification is x40.  
There was no association between EGFR expression and expression of Ki-67 in 
tumour cells with involved axillary lymph nodes metastatic deposits (Pearson’s 
rho correlation, p= 0.654, Figure 6.13). 
 
Figure 6.13: Association of EGFR expression and expression of Ki-67 in breast tumour 
cells with involved lymph nodes. EGFR histoscores were shown against Ki-67 histoscores in 
26 breast tumour cells with involved lymph nodes. There was no association between EGFR 
expression and Ki-67 (p=0.654).  
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6.2.8 EGFR expression and HER-2 protein expression  
The association between the expression of EGFR and HER-2 was investigated. 
Expression of HER-2 has been evaluated on 142 cases which include in situ 
carcinomas, invasive carcinomas and lymph node metastasis tumours. EGFR 
was expressed in 110 out of 142 tumours and there was no significant 
correlation between the expression of EGFR and HER-2 expression in all the 
breast lesions analysed (Pearson’s rho correlation, p= 0.988).  
 
Figure 6.14: Expression of EGFR and HER-2 in in in situ breast carcinomas. Parallel 
sections of solid ductal carcinoma in situ (A and B) comdeo carcinoma in situ (C and D) were 
analysed by immunohistochemistry for expression of EGFR (A, C) and HER-2 (B, D). 
Magnification is x20. 
Out of 37 in situ breast carcinoma, 28 tumours were positive for HER-2. There 
was no correlation between expression of EGFR and HER-2 in in situ breast 
carcinoma (Pearson’ rho correlation, P=0.136, Figure 6.15).  
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Figure 6.15: Association of EGFR expression with HER-2 expression in in situ breast 
carcinomas. EGFR histoscores were shown against HER-2 histoscores in 37 in situ breast 
carcinomas and no significant correlation was detected (p=0.136).  
Expression of HER-2 and EGFR was investigated in invasive breast tumours. 
Out of 79 invasive tumours, 43 tumours were positive for expression of HER-2 
with mean histoscore of 143.65 (figure 6.16). 
 
Figure 6.16: Expression of EGFR and HER-2 in invasive breast tumours. Parallel sections 
of invasive breast tumour were analysed by immunohistochemistry for expression of EGFR (A, 
C) and HER-2 (B, D) Magnification is x200. 
The association between expression of EGFR and HER-2 was investigated in 
79 invasive breast tumours. There was a significant inverse association 
between expression of EGFR and HER-2 expression in invasive breast tumours 
(Pearson’s rho correlation, p=0.044, Figure 6.17). 
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Figure 6.17: Association between expression of EGFR and HER-2 in invasive breast 
tumours. Expression of EGFR compared with the expression of HER-2 in 79 invasive breast 
tumours (p=0.044). 
Out of 26 tumour cells with involved lymph node metastatic deposites, 15 
tumour cells were positive for expression of HER-2 with mean histosocre of 
199.46 (Figure 6.18).  
 
Figure 6.18: Expression of EGFR and HER-2 in breast tumour cells with involved lymph 
nodes. Parallel sections breast tumour cells with axillary lymph node deposits were analysed by 
immunohistochemistry for expression of EGFR (A, C) and HER-2 (B, D). Magnification is x20. 
Association between expression of EGFR and HER-2 expression was 
investigated in breast tumour cells with involved lymph nodes and significant 
inverse correlation was detected (Pearson’s rho correlation, p=0.045, Figure 
6.19). 
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Figure 6.19: Association of EGFR expression with HER-2 expression in breast tumour 
cells with involved lymph nodes. The expression between EGFR and HER-2 was compared 
in 26 tumour cells that metastasized to axillary lymph nodes. Expression of EGFR was inversely 
associated with expression of HER-2 in breast tumour cells with involved lymph nodes 
(p=0.045). 
 
6.2.9 EGFR and expression of cleaved caspase-3 protein 
Based on the previous findings of this study, mediation of the survival effect of 
EGF through EGFR in oestrogen receptor-negative breast cancer cells was 
demonstrated. The association between EGFR expression and expression of 
cleaved caspase-3 was tested. The expression of cleaved caspase-3 in 79 
invasive breast tumours was evaluated. Amongst the 78 EGFR positive 
tumours, 71 were negative for cleaved caspase-3 and only 7 were positive for 
cleaved caspase-3. One EGFR negative tumour was negative for cleaved 
caspase-3 (cross tabulation). There were no significant difference between 
expression levels of EGFR and cleaved caspase-3 (Mann-Whitney test, p= 
0.966, Figure 6.20).  
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Figure 6.20: EGFR and expression of cleaved caspase-3 in invasive breast tumours. 
Seventy one tumours out of 78 EGFR positive tumours were negative for cleaved caspase-3 
and 7 tumours were positive for cleaved caspase-3. The cut off point for positive cleaved 
caspase-3 histoscore was >10.  The whiskers represent the range of data, the boxes represent 
the 50th percentiles, the horizontal bars represent the median values and the dots refer to 
outlier values. 
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6.3 Discussion 
Immunohistochemical expression of EGFR was demonstrated in all 7 cases of 
normal breast tissue, in a high proportion of in situ breast carcinoma (86.48%) 
with mean histoscore of 160 and in 78.5% of invasive breast cancers 
investigated. The mean expression level of EGFR in invasive breast tumours 
was 202.  
In 2005, Wiseman et al demonstrated that expression of EGFR was 
independent from patient’s lymph node status (Wiseman, Makretsov et al. 
2005). In the current study, the possibility of correlation between EGFR 
expression and number of lymph node metastasis was investigated and no 
significant association was found (Pearson’s rho correlation, p=0.236). This 
result would agree with the previous findings that EGFR expression is not 
related to the lymph node status of the patient. There was a significant 
association between EGFR expression in primary breast tumours with their 
metastatic counterparts (Pearson’s rho correlation, p=0.03). However, primary 
tumour cells expressed EGFR at higher levels than corresponding metastatic 
tumour cells of the same patients (Wilcoxon signed ranking test, p=0.02).   
Riwambi et al (2010) reported the high proliferation of EGFR expressing breast 
tumour cells in a large cohort of malignant breast tumours including oestrogen 
receptor-positive and negative breast tumours (Rimawi, Shetty et al. 2010). In 
current study, the association between EGFR expression and expression of 
proliferation marker Ki-67 was tested. There was a significant correlation 
between EGFR expression and Ki-67 expression in invasive breast tumours 
(p=0.046). This result agrees with the contention that EGFR-positive tumours 
have higher proliferative rate than other breast tumours (Rimawi, Shetty et al. 
2010).  
The association between EGFR expression and the other clinico-pathological 
parameters was considered. Witton et al in 2003 reported a significant 
correlation between EGFR expression and tumour grade (Moulder, Yakes et al. 
2001). Similarly, Wiseman et al also reported the significant correlation between 
expression of EGFR and HER-2 with grade of tumours in cohort of breast 
tumours but no association with size of the tumour was found (Wiseman, 
Makretsov et al. 2005). In the present study, EGFR expression did not exhibit 
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significant association with size of tumours (p=0.997), which would agree with 
the conclusion of the previous study. Unlike the previous study of EGFR on 
breast carcinoma, expression of EGFR was not associated with tumour grade 
(p=0.350) or age of the patient (p=0.840). There was no significant differences 
in the expression level of EGFR in low and high grade tumours (p=0.940). 
The present study demonstrated a significant inverse correlation between 
EGFR and HER-2 expression in invasive and metastatic HER-2 positive breast 
tumour cells (p=0.044 and p=0.045 respectively). This is the first time that an 
inverse correlation has been observed. In 2001, Esteva et al reported a positive 
correlation between co expression of EGFR and HER-2 in breast tumours 
(Esteva, Hortobagyi et al. 2001). Conversely, another study reported no 
significant association between EGFR and HER-2 in HER-2 positive breast 
tumours (Wiseman, Makretsov et al. 2005). 
Based on findings described in this thesis, EGFR mediated the survival effect of 
EGF in oestrogen receptor-negative breast cancer cells. It has been 
demonstrated that overexpression of EGFR in invasive breast tumours is 
associated with their resistance to apoptosis (Rimawi, Shetty et al. 2010). 
Hence, the correlation between expression of EGFR and expression of cleaved 
caspase-3 was tested on oestrogen receptor-negative breast tumours. Most of 
the EGFR positive tumour cells were negative for cleaved caspase-3. However, 
only 7 tumours were positive for both EGFR expression and cleaved caspase-3. 
This supports the contention that EGFR plays an important role in mediation of 
cell survival in oestrogen receptor-negative breast tumour cells (Rimawi, Shetty 
et al. 2010).   
In conclusion, EGFR and HER-2 are expressed at moderate levels in oestrogen 
receptor-negative neoplastic breast tissues. The results suggest that EGFR 
plays a significant role in mediation of survival and proliferation but not 
metastasis of oestrogen receptor-negative breast tumour cells. 
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Chapter 7. The effect of combined IGF-1 and EGF in oestrogen 
receptor-negative breast cancer 
 
7.1 Introduction 
Insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) stimulate 
migration of oestrogen receptor-negative breast cancer cells through interaction 
via type I IGF receptor and EGFR respectively as discussed in chapters 3 and 
5.  
Activation of IGF-IR and EGFR play important role in initiation and progression 
of breast cancer. Several studies addressed the possibility that interaction 
between IGF-IR and EGFR is important in EGFR-targeted therapy resistance in 
breast cancer (Camirand, Zakikhani et al. 2005, Jones, Gee et al. 2006, Jin and 
Esteva 2008, van der Veeken, Oliveira et al. 2009). It has been reported that 
increased IGF-IR signalling plays a significant role in breast cancer resistance 
to anti-EGFR therapy and that one of the mechanisms of resistance to anti-
EGFR therapy is the direct interaction between IGF-IR and EGFR (Camirand, 
Zakikhani et al. 2005, Jones, Gee et al. 2006). Studies reported that in breast 
cancer association between IGF-IR and EGFR activity synergistically induce 
cellular proliferation (Hijazi, Thompson et al. 2000, Tsai, Shamon-Taylor et al. 
2003, Ahmad, Farnie et al. 2004, Hirsch, Shen et al. 2006).   
 In this chapter, the effect of both IGF-1 and EGF in combination on migration of 
oestrogen receptor-negative breast cancer cells was investigated and the 
effects of the combined treatment with inhibitors against IGF-IR and EGFR 
tested on cell migration of these cells. 
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7.2 Results 
7.2.1 Effect of both combinations of IGF-1 and EGF on migration of 
oestrogen receptor-negative breast cancer cells 
7.2.1.1 Effect of combination of IGF-1 and EGF on migration of triple-
negative MDA-MB-231 and Hs578T breast cancer cells  
The results of the previous chapters indicated the significant migratory effect of 
IGF-1 and EGF on their own in each MDA-MB-231, Hs578T cell lines. The 
ability of IGF-1 and EGF in combination to stimulate cell migration was 
compared to the effect of either ligand on its own. 
Scratched monolayer MDA-MB-231, Hs578T cells were incubated in the 
presence and absence of 50 ng/ml IGF-1 or 50 ng/ml EGF or both IGF-1 and 
EGF for 0, 2, 4 and 6 hours. Images of the cells were captured at each 
particular time. The width of the each wound was measured 20 times and the 
average of them was calculated. The cell migration was evaluated by 
measuring the distance of the edge of the wound towards the centre of the 
wound with Image J software (Figure 7.1). 
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 Figure 7.1: Effect of IGF-1 and EGF in combination on migration of MDA-MB-231 and 
Hs578T cells. MDA-MB-231 (A) and Hs578T (D) cells were seeded at density of 40 X 104 
cells/well into 24 well plates that had scored on the under surface with two parallel lines across 
the middle of each wells. Cells were withdrawn in phenol-red free DMEM medium supplemented 
with 10% charcoal-treated new born calf serum as described in Materials and Methods section. 
Monolayer cells were wounded with a sterile 20-200 µl Gilson pipette tip through the centre of 
the well, perpendicular to the scored lines. Wounded cells were washed twice with 0.5 ml of 
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phenol red-free DMEM and incubated in phenol red-free DMEM supplemented with 0.01 % of 
BSA for two hours. After two hours of incubation, cells were washed again and incubated with 
0.01% BSA alone ( ) or with 50 ng/ml IGF-1 ( ), 50ng/ml EGF ( ) or in the presence of 50 
ng/ml IGF-1 and 50 ng/ml EGF in combination ( ) for various time points up to 6 hours. 
Image were captured at the beginning of the experiment (time 0) and after each two hours of 
treatment up to 6 hours. Three separate measurements in three different wells were made for 
each treatment condition. The distance between the wounds was measured using Image J 
software programme. The demonstrated values are the mean + SEM. Asterisks denotes 
statistically significant increase in migration of cells in the presence of IGF-1 or EGF compared 
with in the absence of IGF or EGF and that IGF-1 and EGF in combination markedly increase 
more cell movement compared to each ligand alone in both MDA-MB-231 and Hs578T cells (B, 
E) (One way ANOVA, **p<0.001, ***p=0.0001, ****p<0.0001). Similar results were obtained in 
three independent experiments. Results are shown as the fold increase in migration stimulated 
by IGF-1 in the absence and presence of EGF (C, F). The mean of + SEM, are shown. The 
interactions were statistically significant (**p<0.001, ***p=0.0001 by two way ANOVA with log 
transformation).     
As shown in the Figure 7.1, movement of MDA-MB-231 cells in response to 
stimulation with 50 ng/ml IGF-1 increased significantly at 4 and 6 hours of 
incubation by 2 and 3 fold respectively. EGF stimulated significantly the 
movement of the MDA-MB-231 cells at 6 hours of incubation by 2 fold, in which 
the cell movement was lower than the respond of the cells to stimulation with 
50 ng/ml IGF-1. The combination of 50 ng/ml IGF-1 and 50 ng/ml EGF 
enhanced synergistically more movement of MDA-MB-231 cells at 2, 4 and 6 
hours of incubation by 3, 4 and 5 fold respectively. This result indicates that 
IGF-1 and EGF in combination stimulate significantly more migration in MDA-
MB-231 cells compared to the migratory effect of either ligand on its own 
(p<0.0001 by one way ANOVA).   
In Hs578T cells, 50 ng/ml IGF-1 stimulated significantly migration of the cells at 
4 and 6 hours of incubation by 1.4 and 2 fold respectively. In response to 50 
ng/ml EGF, the movement of Hs578T cells was stimulated after 2, 4 and 6 
hours by 1, 2 and 3 fold respectively, which was more than in response to 50 
ng/ml IGF-1. The combination of 50 ng/ml IGF-1 and 50 ng/ml EGF increased 
more migration of the cells than either ligand on its own (p<0.0001 by one way 
ANOVA).  
The results shown that the combination of IGF-1 and EGF triggers more 
migration of triple-negative breast cancer cells than the combination of the two 
stimuli alone. These two ligands have a synergistic effect on migration of MDA-
MB-231 cells (p=0.0001 by two way ANOVA). Combination of IGF-1 and EGF 
resulted in higher migration in Hs578Tcells compared to MDA-MB-231 cells.  
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7.2.1.2 Combination effect of IGF-1 and EGF on migration of HER-2 
positive SK-BR-3 breast cancer cells 
Previously in this study, migratory effect of either IGF-1 or EGF in SK-BR-3 cells 
was demonstrated. Here, the effect of IGF-1 and EGF in combination was 
investigated on migration of SK-BR-3 cells (Figure 7.2). 
 
Figure 7.2: Effect of IGF-1 and EGF in combination on migration of SK-BR-3 cells. SK-BR-
3 cells were seeded at density of 40 X 104 cells/well into 24 well plates that had scored on the 
under surface with two parallel lines across the middle of each wells. Cells were withdrawn in 
phenol free DMEM medium supplemented with 10% charcoal-treated new born calf serum as 
described in Materials and Methods section. Monolayer cells were wounded with a sterile 20-
200 µl Gilson pipette tip through the centre of the well, perpendicular to the scored lines. 
Wounded cells were washed twice with 0.5 ml of phenol red-free DMEM and incubated in 
phenol red-free DMEM supplemented with 0.01 % of BSA for two hours. After two hours of 
incubation, cells were washed again and incubated with 0.01% BSA alone ( ) or with 50 ng/ml 
IGF-1 ( ), 50ng/ml EGF ( ) or in the presence of 50 ng/ml IGF-1 and 50ng/ml EGF in 
combination ( ) for various time points up to 6 hours. Image were captured at the beginning of 
the experiment (time 0) and after each two hours of treatment up to 6 hours. Three separate 
measurements in three different wells were made for each treatment condition. The distance 
between the wounds was measured using Image J software programme. The demonstrated 
values are the mean + SEM. Asterisks denotes statistically significant increase in migration of 
cells in the presence of IGF-1 or EGF compared with in the absence of IGF or EGF. IGF-1 and 
EGF in combination markedly increased higher migration of the cells compared to each ligand 
alone in SK-BR-3 cells (One way ANOVA, ** p<0.01, ***p=0.0001, ****p<0.0001). Similar results 
were obtained in three independent experiments.  
 
 
 
    
 
 
195 
 
Stimulation of SK-BR-3 cells with 50 ng/ml EGF increased the cell migration 
significantly 1.5, 2 and 3 fold at 2, 4  and 6 hours of incubation, which was 
higher than migration of the cells stimulated with 50 ng/ml IGF-1. The 
combination of 50 ng/ml IGF-1 and 50 ng/ml EGF induced higher cell movement 
at 2, 4 and 6 hours of incubation by 3, 3.5 and 4 fold respectively. 
Results indicate that the combination of IGF-1 and EGF induced a migratory 
response higher than two stimuli used alone in SK-BR-3 cells.  
7.2.2 Effect of combination of IGF-IR and EGFR inhibitors on migration of 
triple-negative breast cancer cells  
As demonstrated previously, inhibitory effect of CP-751, 871, an antibody 
against type I IGF receptor and gefitinib, an EGFR tyrosine kinase inhibitor on 
migration of MDA-MB-231 and Hs578T cells were demonstrated individually. In 
this chapter, ability of IGF-IR and EGFR inhibitor in combination on inhibition of 
migration of MDA-MB-231, Hs578T cells investigated.    
Wounded MDA-MB-231 and Hs578T cells were incubated in the presence and 
absence of 50 ng/ml IGF-1 or 50 ng/ml EGF or in combination. In addition, cells 
were treated with 10 μM gefitinib or 10 μg/ml CP-751, 871 or in combination, in 
the presence of 50 ng/ml IGF-1 or 50 ng/ml EGF or in combination at 0, 2, 4 
and 6 hours of incubation. Images of the cells were captured at each particular 
time. The width of each wound was measured 20 times and the average of 
them was calculated. The cell migration was evaluated by measuring the 
distance of the edge of the wound towards the centre by using Image J software 
(Figure 7.3). 
As shown in the Figure 7.3, treatment of MDA-MB-231 cells with CP-751, 871 
or gefitinib induced significant reduction of migration of cells in response to IGF-
1 or EGF respectively. The combination of inhibitors resulted in reduction of 
MDA-MB-231 cell movement in response to both IGF-1 and EGF, but the 
reduction was not significantly higher compared to treatment of cells with either 
inhibitor alone. 
Treatment of Hs578T cells with CP-751, 871 or gefitinib significantly reduced 
the migration of cells in response to IGF-1 or EGF respectively after 6 hours of 
incubation. Treatment of cells with combination of both CP-751, 871 and 
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gefitinib resulted in reduction of cell movement in response to IGF-1 and EGF 
by three fold after 2 hours of incubation and more than six fold after 4 and 6 
hours of incubation. The combination of both inhibitors significantly induced 
higher reduction in cell movement compared to treatment of cells with either 
inhibitor alone as illustrated in Figure 7.3.  
These results suggest that combination of CP-751, 871 and gefitinib triggered 
higher inhibitory effect on migration of cells compared with the either inhibitor 
used alone in Hs578T but not in MDA-MB-231 cells.   
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 Figure 7.3: Effect of IGF-IR and EGFR inhibitors in combination on migration of MDA-MB-
231 and Hs578T cells. MDA-MB-231 (A) and Hs578T (B) cells were seeded at density of 40 X 
104 cells/well into 24 well plates that had scored on the under surface with two parallel lines 
across the middle of each wells. Cells were withdrawn in phenol red-free DMEM medium 
supplemented with 10% charcoal-treated new born calf serum as described in Materials and 
Methods section. Monolayer cells were wounded with a sterile 20-200 µl Gilson pipette tip 
through the centre of the well, perpendicular to the scored lines. Wounded cells were washed 
twice with 0.5 ml of phenol red-free DMEM and incubated in phenol red-free DMEM 
supplemented with 0.01 % of BSA for two hours. After two hours of incubation, cells were 
washed again and incubated with 0.01% BSA alone ( ) or 50 ng/ml IGF-1 ( ) or 50 ng/ml of 
EGF ( ) or IGF-1 and EGF in combination ( ) in the presence of 10 μg/ml CP-751, 871 and 
50 ng/ml IGF-1 ( ), or in the presence of 10 μg/ml CP-751, 871 and 50 ng/ml IGF-1 in 
combination with 10 μM of gefitinib and 50 ng/ml  EGF ( )for various time points up to 6 hours. 
Image were captured at the beginning of the experiment (time 0) and after each two hours of 
treatment up to 6 hours. Three separate measurements in three different wells were made for 
each treatment condition. The distance between the wounds was measured using Image J 
software programme. The demonstrated values are the mean + SEM. Asterisks denotes the 
signiifcant decrease in motility of cells in the presence of CP-751, 871 or gefitinib compared with 
in the absence of either CP-751, 871 or gefitinib. Combination of both inihbitors markedly 
decreased the migration of the cells more than each inhibitor alone in Hs578T cells but not 
MDA-MB-231 cells. Similar results were obtained in three independent experiments (One way 
ANOVA, *p <0.05, *** P=0.0001, ****P<0.0001).   
 
7.2.3 Effect of combination of IGF-IR and EGFR inhibitors on migration of 
HER-2 positive SK-BR-3 breast cancer cells  
Previously in this study, the inhibitory effect of CP-751, 871 or gefitinib was 
investigated on migration of SK-BR-3 cells. Here, inhibitory effect of both 
inhibitors in combination was studied on migration of SK-BR-3 cells stimulated 
with both IGF-1 and EGF (Figure 7.4).  
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Treatment of SK-BR-3 cells with CP-751, 871 or gefitinib resulted in significant 
decrease in the migration of cells, which was demonstrated earlier in this study. 
The effect of combination of inhibitors in reduction of cell movement stimulated 
with both IGF-1 and EGF was almost three fold after 2 hours and more than five 
fold after 4 and 6 hours of incubation. The effect of combined inhibitors did not 
induced significantly higher reduction in SK-BR-3 cell movement compared to 
the treatment of cells with each inhibitor alone. 
 
 
Figure 7.4: Effect of IGF-IR and EGFR inhibitors in combination on migration of SK-BR-3 
cells. SK-BR-3 cells were seeded at density of 40 X 104 cells/well into 24 well plates that had 
scored on the under surface with two parallel lines across the middle of each wells. Cells were 
withdrawn in phenol red-free DMEM medium supplemented with 10% charcoal-treated new 
born calf serum as described in Materials and Methods section. Monolayer cells were wounded 
with a sterile 20-200 µl Gilson pipette tip through the centre of the well, perpendicular to the 
scored lines. Wounded cells were washed twice with 0.5 ml of phenol red-free DMEM and 
incubated in phenol red-free DMEM supplemented with 0.01 % of BSA for two hours. After two 
hours of incubation, cells were washed again and incubated with 0.01% BSA alone ( ) or 50 
ng/ml IGF-1 ( ) or 50 ng/ml of EGF ( ) or IGF-1 and EGF in combination (  ) in the 
presence of 10 μg/ml CP-751, 871 and 50 ng/ml IGF-1 ( ), or in the presence of 10 μg/ml CP-
751,871 and 50 ng/ml IGF-1 in combination with 10 μM of gefitinib and 50 ng/ml  EGF ( )for 
various time points up to 6 hours. Image were captured at the beginning of the experiment (time 
0) and after each two hours of treatment up to 6 hours. Three separate measurements in three 
different wells were made for each treatment condition. The distance between the wounds was 
measured using Image J software programme. The demonstrated values are the mean + SEM. 
Asterisks denotes the significant decrease in motility of cells in the presence of CP-751, 871 or 
gefitinib compared with in the absence of either CP-751, 871 or gefitinib (B). Combination of 
both inihbitors decreased the migration of the cells (A) but did not induce significantly higher 
redcution in cell motility compared to either inhibitor alone (C). Similar results were obtained in 
three independent experiments (One way ANOVA, **p<0.001, *** P=0.0001, ****P<0.0001).   
 
 
 
    
 
 
   
  
 
 
   
  
 
 
   
  
199 
 
7.2.4 Association of IGF-IR and EGFR in malignant breast lesions 
The association between expression of IGF-IR and EGFR in both in situ and 
invasive breast carcinoma was investigated. The expression of IGF-IR and 
EGFR was compared in 37 in situ breast carcinomas (Figure 7.5).  
 
Figure 7.5: Expression of IGF-IR and EGFR in in situ carcinoma of the breast. Sections of 
comedo types of ductal carcinoma in situ were analysed for IGF-IR (A, C) and EGFR (B, D) 
expression by immunohistochemistry. Magnification x200. 
 
Both IGF-IR and EGFR expressed in 29 in situ breast carcinomas. The 
association between expression of IGF-IR and EGFR expression was 
investigated in in situ carcinoma of the breast. The expression of IGF-IR was 
not significantly associated with the expression of EGFR in in situ breast 
carcinoma (Pearson’s rho correlation, p=0.501, Figure 7.6).  
 
Figure 7.6: Association of IGF-IR and EGFR expression in in situ carcinoma of the breast. 
IGF-IR histoscores are shown against EGFR histoscores in 37 in situ lesions. No significant 
correlation was detected (Pearson correlation, p=0.501). 
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The expression of IGF-IR and EGFR was compared in 79 invasive breast 
tumours (Figure 7.7). Both IGF-IR and EGFR were detectable in 73 tumours 
(92%).  
 
Figure 7.7: Expression of IGF-IR and EGFR expression in invasive breast cancer. Parallel 
section of invasive breast tumour (A, B) and metastasized breast tumour cells to axillary lymph 
nodes (C, D) were analysed for IGF-IR (A, C) and EGFR (B, D) expression by 
immunohistochemistry. Immuno-reaction is membranous. Magnification x20. 
 
The relationship between IGF-IR and EGFR expression was investigated in 79 
invasive breast tumours. There was a significant association between IGF-IR 
expression and expression of EGFR in invasive breast cancer (Pearson 
correlation rho, p=0.002, Figure 7.8 A). There was no significant association 
between the expression of IGF-IR and EGFR in breast cancer cells that had 
metastasized to axillary lymph node (Pearson correlation, p=0.879, Figure 7.8 
B). 
 
Figure 7.8: Association of IGF-IR and EGFR expression in malignant breast lesions.  IGF-
IR histoscores are shown against EGFR histoscores for 79 invasive breast cancers (A) and 26 
lesions of axillary lymph node metastatic deposits (B). Expression of IGF-IR is significantly 
correlated with expression of EGFR in invasive breast cancers (Pearson correlation, p=0.002).      
201 
 
    
7.2.5 IGF-IR expression and HER-2 protein expression     
The association between expression of IGF-IR and expression of HER-2 in in 
situ, invasive and lesions of axillary lymph node deposits was investigated. 
There was no association between expression of IGF-IR and HER-2 expression 
in overall tumours (Pearson’s rho correlation, p=0.531).  
Association between IGF-IR expression and expression of HER-2 was 
investigated in 37 in situ breast carcinomas. There was no association between 
IGF-IR expression and expression of HER-2 in in situ breast carcinomas 
(Pearson’s rho correlation, p= 0.590, Figure 7.9). 
 
 
 
 
Figure 7.9: Association of IGF-IR expression with HER-2 expression in in situ breast 
carcinomas. IGF-IR expression (A, C) and HER-2 expression (B, D) were analysed in in situ 
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breast carcinoma by immunohistochemistry.  IGF-IR expression showed no significant 
association with expression of HER-2 in in situ breast carcinomas (E), (p=0.590). 
Expression of IGF-IR and HER-2 was investigated in 79 invasive breast 
tumours. There was no association between expression of IGF-IR and HER-2 
expression in invasive breast tumours (Pearson’s rho correlation, p=0.498, 
Figure 7.10). 
 
 
Figure 7.10: Expression of IGF-IR and HER-2 expression in invasive breast cancer. 
Sections of invasive breast tumours were analysed for IGF-IR (A, C) and HER-2 (B, D) 
expression in by immunohistochemistry. Magnification x20. No correlation was found between 
expression of IGF-IR and HER-2 in 79 cases of invasive breast tumours (E) (Pearson’s rho 
correlation p=0.498). 
 
Association between expression of IGF-IR and HER-2 expression was 
investigated in 26 breast tumour cells with the involved lymph node and no 
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significant correlation was detected between expression of IGF-IR and HER-2 
expression (Pearson’s rho correlation, p=0.174, Figure 7.11). 
 
 
 
Figure 7.11: Association of IGF-IR expression with HER-2 expression in breast tumour 
cells in the involved lymph node. IGF-IR expression (A, C) and HER-2 expression (B, D) 
were analysed in breast carcinoma with metastatic deposit by immunohistochemistry. IGF-IR 
expression showed no significant association with expression of HER-2 in metastatic breast 
tumour cells (E) (p=0.174). 
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 7.3 Discussion 
The effect of the combination of IGF-1 and EGF on migration of oestrogen 
receptor-negative breast cancer cells were studied in this chapter. 
One study compared the effect of IGF-1 and EGF on migration of MDA-MB-231 
breast cancer cells and reported that migratory effect of IGF-1 was more than 
the migratory effect of EGF (Mezi, Todi et al. 2012). Results of the current study 
regarding the effect of each IGF-1 and EGF ligand on migration of MDA-MB-
231 cell line, as discussed in previous chapters are in agreement with the 
findings of previous group, who observed that IGF-1 had more migratory effect 
than EGF in MDA-MB-231 cells (Mezi, Todi et al. 2012). However, this group 
did not test the effect of combination of IGF-1 and EGF on migration of MDA-
MB-231 cells. No previous study has tested the effect of the combination of 
IGF-1 and EGF on the migration of oestrogen receptor-negative breast cancer 
cells.  
In the current study, the effect of the combination of IGF-1 and EGF on 
migration of MDA-MB-231, Hs578T and SK-BR-3 cells was investigated. 
Although IGF-1 and EGF each alone stimulated significantly the migration of 
oestrogen receptor-negative breast cancer cells, the combination of both 
ligands stimulated higher migration of breast cancer cells than either motogen 
alone. Additionally, the inhibitors against IGF-IR and EGFR abolished IGF-1 
and EGF-mediated migration. The migratory effect of the IGF-1 and EGF in 
combination was inhibited more significantly using combination of both anti-IGF-
IR and anti-EGFR inhibitors compared to inhibitory effect of either inhibitor 
alone only in Hs578T cells. But, the combination of inhibitors did not show 
significantly higher inhibitory effect on movement of MDA-MB-231 or SK-BR-3 
cells. This result is agreed with the findings of previous study that IGF-IR and 
EGFR inhibitors in combination are more effective on inhibition growth of 
colorectal cancer cells (Thomas and Grandis 2004).  
The correlation between expression of IGF-IR and EGFR in both in situ and 
invasive breast carcinoma was investigated. There was no significant 
correlation detected in in situ breast carcinomas, whereas, a strong significant 
association was found between expression of IGF-IR and EGFR in invasive 
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breast carcinomas (p=0.002). In addition, correlation between expression of 
IGF-IR and HER-2 was studied. There was no significant association between 
expression of IGF-IR and HER-2 expression in in situ, invasive or metastatic 
HER-2 positive breast tumours (p>0.05). This result is not in agreement with the 
conclusion of previous report that IGF-IR expression was associated with HER-
2 negativity (Yerushalmi, Gelmon et al. 2012).  
Taken these data together, combination of IGF-1 and EGF demonstrated more 
effect on migration of oestrogen receptor-negative breast cancer cells than 
either ligand alone. Hence, targeting both IGF-IR and EGFR signal transduction 
pathway might be a valuable therapeutic approach, especially as both receptors 
are expressed in the same tumours. 
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 Chapter 8. Expression of trefoil proteins (TFF1 and TFF3) in 
oestrogen receptor-negative breast cancer 
 
8.1  Introduction 
Trefoil proteins are small secretory proteins that are expressed in epithelial cells 
of gastrointestinal mucosa and other mucus secreting mucosae. TFF1 is 
synthesised mainly in the stomach and colon, while TFF3 is expressed in the 
goblet cells of small and large intestines (May, Semple et al. 2004, Westley, 
Griffin et al. 2005). The main functions of trefoil proteins are mucosal protection 
and repair through interaction with mucins and induction of cellular migration for 
the process of restitution. Overexpression of trefoil proteins is reported in 
several human solid tumours including breast cancer. Studies show that 
amongst the three trefoil proteins, TFF1 and TFF3 are expressed at high level 
in breast tumours whereas TFF2 is generally not expressed (Poulsom, Hanby et 
al. 1997, May, Semple et al. 2004). In addition, both TFF1 and TFF3, in 
particular TFF1 is identified as oestrogen-responsive genes which are most 
frequently expressed in breast tumours. It has been reported that 
overexpression of TFF3 induce the oestrogen-independent growth in breast 
cancer cells (Kannan, Kang et al. 2010). TFF3 expression at mRNA level has 
been reported in HER-2 positive BT-474 and MDA-MB 361 breast cancer cell 
lines, but not in HER-2 positive SK-BR-3 cells (Wilson, Roberts et al. 2002). In a 
recent study, expression of TFF3 reported to be higher in HER-2 positive breast 
tumours (Yue, Xiang et al. 2013).  
Expression of TFF1 and TFF3 in oestrogen-responsive breast tumour has been 
studied and the involvement of TFF3 in progression and dissemination of 
oestrogen responsive breast tumours is reported (Ahmed, Griffiths et al. 2012). 
However, immunohistochemical expression of TFF3 protein and its association 
with IGF-IR, EGFR, HER-2 and proliferation marker, Ki-67 in oestrogen 
receptor-negative breast cancer tissues has not been reported. There are no 
reports that describe expression of TFF1 and TFF3 by immunofluorescence in 
oestrogen receptor-positive and negative breast cancer cells. 
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In this chapter, the expression of TFF1 and TFF3 proteins in a series of 
oestrogen non-responsive breast tumours were investigated by 
immunohistochemistry, also expression of TFF1 and TFF3 proteins in different 
breast cancer cell lines were analysed by immunofluorescence and western 
transfer analysis.   
8.2 Result 
8.2.1 Expression of TFF1 and TFF3 in in situ carcinoma of the breast 
Expression of TFF1 and TFF3 was studied in all 37 in situ breast carcinomas. 
Out of 37 cases, TFF1 expression was not detected in any of the in situ cases, 
but TFF3 expression was detected in 7 tumours (8.8%). The expression was 
cytoplasmic and the majority of the positive tumour cells expressed TFF3 at 
weak or moderate levels with mean histoscore of 106 and median histoscore of 
90, respectively (Figure 8.1). However, out of 7 tumours, one tumour was 
strongly immuno-reactive for TFF3. There is a significant correlation in the 
expression levels in between the duplicate cores (Pearson’s rho correlation, 
p<0.01). 
 
Figure 8.1: Expression of TFF1 and TFF3 in in situ breast carcinoma. Parallel sections of 
solid in situ carcinoma having histoscore of 4 (left side) and 213 (right side) were analysed in 
oestrogen receptor-negative breast tumours by immunohistochemistry for expression of TFF1 
(A) and TFF3 (B) antibody. Magnification is x20. 
 
8.2.2 Expression of trefoil proteins in invasive carcinoma of the breast 
Consistency of TFF1 and TFF3 expression in duplicate cores was tested. It has 
been observed that there is a significant correlation in expression levels of 
duplicate cores (Pearson correlation, p<0.01). This implies that further analysis 
can be performed and therefore mean values are taken into consideration. 
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Out of the 79 investigated invasive lesions, TFF3 immuno-reaction was 
detected in 6 tumours (7.5%). TFF1 was expressed at very low levels, therefore 
evaluation of TFF1 for further analysis was not been considered. Most of the 
TFF3 positive tumours were either weak or moderately immuno-reactive with 
mean histoscore of 232 and median histoscore of 245, respectively (Figure 8.2). 
However, 3 tumours were strongly immuno-reactive for TFF3 with maximum 
histoscore of 583. The immuno-reaction was cytoplasmic.  
 
Figure 8.2: Expression of TFF1 and TFF3 in invasive breast carcinoma. Sections of an 
invasive breast carcinoma were analysed in oestrogen receptor-negative breast tumours by 
immunohistochemistry for expression of TFF1 (A) and TFF3 (B) with histoscore of 15 and 583, 
respectively. Magnification is x20 and for inset is x200. 
 
8.2.3 TFF3 expression and presence of lymph node metastasis     
To investigate whether TFF3 has role in further progression of breast cancer, 
expression of TFF3 was tested in the primary tumours and their corresponding 
axillary lymph node metastases in 26 patients. There was no correlation 
between expression of TFF3 in primary tumour cells and tumour cells with 
involved lymph node (Pearson’s rho correlation, p=0.134, Figure 8.3).    
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 Figure 8.3: TFF3 expression in primary breast tumours and tumour cells in involved 
lymph node. TFF3 expression was analysed by immunohistochemistry in both primary (A) and 
metastatic (B) tumour cells from the same patients in 26 tumours having histoscore of 0 and 
517, respectively. TFF3 histoscores in the primary tumour cells of 26 patients are shown against 
its histoscore in the same tumour cells that metastasized to axillary lymph nodes (C). 
 
The association between expression of TFF3 and number of axillary lymph 
node metastasis was tested. There was no association between expression of 
TFF3 and number of axillary lymph node metastasis (Spearman’s rho 
correlation, p=0.640, Figure 8.3). Out of 26 tumour cells for which involved 
lymph node was identified; TFF3 was detected only in 5 tumours. There was no 
significant difference between the expression level of TFF3 in primary tumours 
with detected axillary lymph nodes and tumours without detectable axillary 
lymph nodes (Mann-Whitney test, p=0.932). 
 
8.2.4 Association between TFF3 expression and expression of IGF-IR and 
EGFR 
To evaluate the relationship between the expression of TFF3, IGF-IR and 
EGFR, their association has been tested in 79 invasive breast tumours (Figure 
8.4). There was no association between expression of TFF3 and IGF-IR 
expression (Pearson’s rho correlation, p=0.921). There was no association 
between expression of TFF3 and EGFR expression (Pearson’s rho correlation, 
p=0.938). 
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Figure 8.4: Association between expression of TFF3 and IGF-IR and EGFR expression in 
invasive breast tumours. TFF3 expression (A) and expression of IGF-IR (B) and EGFR (C) 
was analysed in invasive breast tumours by immunohistochemistry. No correlation between 
TFF3 expression and expression of IGF-IR (p=0.921) or EGFR (p=0.938) was detected (D, E).  
 
8.2.5 Association between HER-2 expression and expression of TFF3 
Few literatures have reported the relationship between expression of TFF3 and 
HER-2. In one immunohistochemical study, it has been reported that HER-2 
positive breast tumours have expressed high level of TFF3. In the in vitro part of 
the same study, inhibition of HER-2 shown to significantly down regulate TFF3 
expression in HER-2 overexpressed SK-BR-3 breast cancer cells (Yue, Xiang 
et al. 2013). In another study, expression of TFF3 reported to be up regulated in 
HER-2 positive breast cancer cell lines  (Wilson, Roberts et al. 2002). Here, the 
association between expression of TFF3 and HER-2 in in situ breast 
carcinomas, invasive tumours and breast tumour cells with involved axillary 
lymph nodes was investigated. 
Expression levels of TFF3 and HER-2 was been compared in 37 in situ breast 
carcinomas. There was no association between TFF3 expression and 
expression of HER-2 in in situ breast carcinomas (Pearson correlation, p= 0.46, 
Figure 8.5). 
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 Figure 8.5: Association of TFF3 expression with HER-2 expression in in situ breast 
carcinomas. TFF3 expression (A) and HER-2 expression (B) were analysed in in situ breast 
carcinoma by immunohistochemistry. TFF3 expression showed no significant association with 
expression of HER-2 (p=0.46). 
Expression of TFF3 and HER-2 was investigated in 79 invasive tumours. Out of 
6 TFF3 positive tumours, 5 tumours were positive for expression of HER-2.  
Association between expression of TFF3 and HER-2 was investigated in 
invasive tumours. There was a significant association between expression of 
TFF3 and HER-2 expression (Pearson’s rho correlation, p=0.02, Figure 8.6 C).     
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 Figure 8.6: Association between expression of TFF3 and HER-2 expression in invasive 
breast tumours. TFF3 expression (A) and HER-2 expression (B) were analysed in invasive 
breast tumours by immunohistochemistry. TFF3 histoscores are shown against HER-2 
histoscores in the 79 invasive tumours. The correlation between TFF3 expression and HER-2 
expression was significant (p=0.02).   
  
Association between expression of TFF3 and HER-2 was investigated in 26 
breast tumour cells in involved axillary lymph nodes. There was no significant 
correlation detected between expression of TFF3 and HER-2 expression 
(Pearson’s rho correlation, p-value=0.662, Figure 8.7). 
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 Figure 8.7: Association of TFF3 expression with HER-2 expression in breast tumour cells 
in involved lymph node. Sections of breast tumours with metastatic lymph node deposits were 
analysed for expression of TFF3 (A) and HER-2 (B) by immunohistochemistry. TFF3 expression 
showed no significant association with expression of HER-2 in metastatic breast tumour cells 
(C) (p=0.662). 
 
8.2.6 Association between expression of TFF3 and Ki-67 protein 
Association between expression of TFF3 and expression of proliferation marker, 
Ki-67 was investigated in breast tumours including in situ carcinomas, invasive 
tumours and tumour cells with involved lymph nodes. 
Expression of TFF3 and Ki-67 was analysed in 37 in situ carcinoma of the 
breast. There was no significant association between expression of TFF3 and 
Ki-67 expression (Pearson’s rho correlation, p=0.789, Figure 8.8 C). However, 
TFF3 positive tumours were expressed Ki-67 at low level (Figure 8.8 C).  
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 Figure 8.8: Association of TFF3 expression with Ki-67 expression in in situ breast 
carcinomas. TFF3 expression (A) and Ki-67 expression (B) were analysed in in situ breast 
carcinoma by immunohistochemistry. TFF3 expression showed no significant association with 
expression of Ki-67 in in situ breast carcinomas (p=0.789). 
 
Expression of TFF3 and Ki-67 was compared in 79 invasive breast tumours. 
Majority of Ki-67 positive tumours were negative for expression of TFF3. 
However, 5 tumours positive for expression of TFF3 also expressed Ki-67 at 
weak and moderate level. There was no significant association between 
expression of TFF3 and Ki-67 expression in invasive breast tumours (Pearson’s 
rho correlation, p=0.839, Figure 8.9).  
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 Figure 8.9: Association of TFF3 expression and expression of Ki-67 in invasive breast 
tumours. Parallel sections of invasive breast tumours were analysed for expression of TFF3 (A) 
and Ki-67 (B) by immunohistochemistry. There was no association between expression of TFF3 
and expression of Ki-67 (p=0.839).  
 
Expression of TFF3 and Ki-67 was analysed in 26 breast tumour cells with 
metastatic lymph node deposits. There was no significant correlation between 
expression of TFF3 and Ki-67 expression in tumour cells with involved lymph 
node (Pearson’s rho correlation, p=0.183, Figure 8.10 C). 
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 Figure 8.10: Association of TFF3 expression with Ki-67 expression in breast tumour cells 
in involved axillary lymph nodes. Expression of TFF3 (A) compared with expression of Ki-67 
(B) in 26 breast tumours with involved lymph nodes by immunohistochemistry. TFF3 expression 
showed no significant association with expression of Ki-67 in tumour cells with metastatic 
deposits (p=0.183). 
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8.2.7 Expression of TFF1 and TFF3 in oestrogen receptor-positive and 
negative breast cancer cell lines 
Expression of TFF1 and TFF3 was evaluated by western transfer analysis in 
different breast cancer cell lines (Figure 8.11). In MCF-7 cells, TFF1 protein was 
detected but not TFF3 protein. BT-474 cells expressed both TFF1 and TFF3 at 
reasonable amount. EFM-19 cells did not show expression of TFF1 or TFF3. 
Expression of TFF1 and TFF3 was not detected in any of the oestrogen 
receptor-negative SK-BR-3, Hs578T and MDA-MB-231 breast cancer cells. 
Expression of TFF1 and TFF3 was observed in HCC-1419 cells, which is 
agreed with the previous findings. TFF1 expressed at higher level than TFF3 in 
HCC-2218 cell. Different results in the expression level of TFF1 and TFF3 in 
EFM-19 cells might be due to different sensitivities of the antibodies that have 
been used in western and immunofluorescence experiments. 
 
Figure 8.11: Expression of TFF1 and TFF3 in different breast cancer cell lines by western 
transfer analysis.  MCF-7, BT-474, EFM-19, SK-BR-3, Hs578T, MDA-MB-231, HCC-1419 and 
HCC-1418 cells were cultured to approximately 80% confluence and their protein extracted with 
1 ml of RIPA buffer per 75 cm2 tissue culture flask as described in Material and Methods 
Section. Aliquots containing 20 μg of extracted protein were electrophoresed on a 12% 
denaturing polyacrylamide gel and transferred in to PVDF membrane at 100 mA for 10 minutes. 
Membrane was incubated with (A) TFF1 (1 in 10 dilution), (B) TFF3 (1 in 20 dilution) and 
GAPDH (1 in 20,000 dilution).  Densitometric scanning of X-ray films determined the amount of 
each protein by analysis with LabWork 4.0 software. The mean + SEM after normalisation to 
GAPDH expression are shown. 
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8.2.8 Cellular localization of TFF1 and TFF3 expression in oestrogen 
receptor-positive and negative breast cancer cell lines 
Expression of TFF1 and TFF3 was analysed by immunofluorescence in 
oestrogen receptor-positive, HER-2 negative MCF-7 cells, and HER-2 positive 
EFM-19 and BT-474 cells. The expression of TFF1 and TFF3 were also 
analysed in oestrogen receptor-negative but HER-2 positive HCC-1419 and SK-
BR-3 cell lines. 
In MCF-7 cells, expression of TFF1 was detected, but there were no detectable 
expression of TFF3 in this cell line. In EFM-19 cells, TFF1 expression was not 
detected, but expression of TFF3 was detected. In HCC-1419 and BT-474 cells, 
expression of both TFF1 and TFF3 was detected. Neither TFF1 nor TFF3 
expression was detected in SK-BR-3 cells. Expression of both TFF1 and TFF3 
was cytoplasmic. As illustrated in Figure 8.12 and Figure 8.13, the vesicular 
expression of both TFF1 and TFF3 makes them distinct from nuclear 
expression.  
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8.3 Discussion  
Both TFF1 and TFF3, particularly TFF1 are oestrogen-responsive genes in 
breast cancer cells (Masiakowski, Breathnach et al. 1982, May and Westley 
1997, May and Westley 1997). In contrast to the reduction in TFF1 expression 
in gastric tumours, TFF1 expression is not reduced in breast tumours and its 
expression in breast cancer cells is under the control of oestrogen. The exact 
role of trefoil proteins in tumourigenesis is controversial. Different biological 
roles have been assigned to trefoil proteins including tumour suppressive and 
tumour promoting depending partly upon the tissue. TFF1 and TFF3 can help 
tumour cell dissemination by stimulating the migration of breast cancer cells 
(May and Westley 1997). Over expression of TFF3 has been reported to 
enhance the cellular proliferation, survival and migration and anchorage-
independent growth of the oestrogen receptor-positive breast cancer cells 
(Kannan, Kang et al. 2010). In a recent immunohistochemical study, the 
involvement of TFF3 in progression and dissemination of oestrogen receptor-
positive breast tumours was reported (Ahmed, Griffiths et al. 2012).  
Expression of TFF1 was investigated in a series of oestrogen receptor-negative 
breast tumours. TFF1 expression was detected at very low level in few cases 
where majority of breast tumours were negative for expression of TFF1, which 
is consistent with the conclusion that TFF1 is oestrogen-responsive element 
and its expression is under control of oestrogen (Masiakowski, Breathnach et al. 
1982, May and Westley 1997, May and Westley 1997). Hence, further analysis 
has not considered.  
TFF3 expression was detected in 7 in situ breast carcinomas with mean 
histoscore of 106 and 6 invasive breast tumours with mean histoscore of 232. 
The majority of TFF3 positive tumours were weakly to moderately cytoplasmic 
immuno-reactive. In the present study, the association between TFF3 
expression in primary tumour cells and the related metastatic cells in the lymph 
nodes was investigated. There was no correlation between expression of TFF3 
in primary tumour cells with their corresponding metastatic cells in the lymph 
nodes (p=0.134). The association between TFF3 and proliferation marker, Ki-67 
was evaluated. There was no significant association between their expressions 
in any tested tumour type. TFF3 positive tumours were expressed Ki-67 at low 
level.  
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No correlation between expression of TFF3 and expression of EGFR or IGF-IR 
was found (p>0.05). There was a significant correlation between TFF3 
expression and expression of HER-2 in invasive breast tumours (p= 0.02). This 
result would agree with the recent finding that TFF3 expression is higher in 
HER-2 positive breast tumours (Yue, Xiang et al. 2013). There was no 
significant correlation between TFF3 and HER-2 expression in in situ 
carcinomas (p=0.466) or breast tumours with involved axillary lymph nodes 
(p=0.662).  
Cellular localization of TFF1 and TFF3 demonstrated by immunofluorescence 
on different oestrogen receptor-positive and oestrogen receptor-negative breast 
cancer cells. Cytoplasmic with vesicular expression of TFF1 was detected in 
oestrogen receptor-positive MCF-7 and BT-474 cells and oestrogen receptor-
negative HCC-1419 cells, whereas, TFF3 expression was detected in EFM-19, 
BT-474 and HCC-1419 cells and also shown to be cytoplasmic and vesicular. 
TFF1 or TFF3 expression was not detected in HER-2 positive SK-BR-3 cells. 
Cytoplasmic expression of TFF3 would agree the immunohistochemical findings 
of this study that TFF3 expression is tend to be cytoplasmic in oestrogen 
receptor-negative breast tumours. 
Expression of TFF1 and TFF3 was evaluated by western transfer analysis in 
different types of breast cancer cell lines. MCF-7 and HCC-1419 cells showed 
the similar expression results as observed in immunofluorescence. TFF1 
expression was observed in MCF-7 cells but not TFF3, and in HCC-1419 
expression of both TFF1 and TFF3 was detected.  Expression of TFF1 or TFF3 
was not observed in EFM-19 cells by western transfer, whereas, TFF3 
expression was detected in EFM-19 by immunofluorescence. One possibility for 
this discordance might be different sensitivities of TFF3 antibodies that have 
used for detection of TFF3 expression by western transfer and 
immunofluorescence.  
In 2002, Wilson et al investigated the association between TFF3 and HER-2 
expression in series of HER-2 positive and negative breast cancer cell lines. 
TFF3 expression was not found in any of the HER-2 negative breast cancer 
cells but was found to express at high level in two of three HER-2 positive BT-
474 and MDA-MB-361 cells. Expression of TFF3 was not detected in HER-2 
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positive SK-BR-3 cells. The study has concluded that TFF3 is up regulates in 
HER-2 positive breast cancer cells. However, one of the limitations in their 
study is that they did not consider the oestrogen receptor status of the tested 
cell lines and did not demonstrated an association between TFF3 and HER-2 
expression in primary tumour cells (Wilson, Roberts et al. 2002). Conversely, 
recently Yue et al reported the expression of TFF3 in HER-2 positive SK-BR-3 
cells and that silencing HER-2 induced downregulation of TFF3. In the same 
study, the high expression of TFF3 was reported in a cohort of HER-2 positive 
breast cancer patients (Yue, Xiang et al. 2013). In contrast to Yue et al study, 
but in agreement with Wilson et al findings, expression of TFF3 was not 
detected in SK-BR-3 cells by western transfer analysis or immunofluorescence, 
in the present study (Wilson, Roberts et al. 2002).  
In conclusion, TFF3 but not TFF1 is expressed in oestrogen receptor-negative 
breast tumours and there is a significant association between TFF3 and HER-2 
in oestrogen receptor-negative tumours which suggests that expression of TFF3 
is not always under the control of oestrogen and might be regulated by other 
factors in oestrogen receptor-negative breast tumours. 
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Chapter 9. General discussion 
The purpose of the current study was to investigate the role of insulin-like 
growth factor 1 and epidermal growth factors in the survival and migration of 
oestrogen receptor-negative breast cancer cells. An additional aim was to 
evaluate the expression level of the type I IGF receptor, EGFR, HER-2, TFF1, 
TFF3 and their association with biomarkers of proliferation and survival in 
oestrogen receptor-negative primary breast tumours and their associated 
metastases.  
Studies have addressed the contribution of IGFs in the development, survival 
and invasion of different cancers, including breast cancer. In 2010, Key et al 
has reported that higher level of serum IGF-1 is associated with an increased 
risk of breast cancer (Key, Appleby et al. 2010). In 2011, Davison et al 
demonstrated the protective effect of IGF-1 on staurosporine-induced apoptosis 
in attached triple-negative breast cancer cell lines (Davison, de Blacquiere et al. 
2011). Ravid et al (2005) reported that IGF-1 prevents reduction in a number of 
viable MCF-7 cells cultured in non-attached condition through maintaining 
mitochondrial activity, which was assessed with an MTT assay. However, the 
study did not investigate directly if the cells had died or not, the mode of cell 
death or the mechanism by which IGF-1 inhibits the cell death (Ravid, Maor et 
al. 2005). There have been no studies specifically on the protective effect of 
IGF-1 against anoikis in oestrogen receptor-negative breast cancer cells. The 
current in vitro data show that IGF-1 has a powerful effect on the prevention of 
anoikis in non-attached condition in triple-negative breast cancer cells. This was 
demonstrated by the induction of PARP cleavage and activation of casapase-3 
as a result of loss of attachment in triple-negative breast cancer cells, which 
was consistent with the induction of anoikis. 
In 2011, Davison et al demonstrated that IGF-IR and insulin receptor are 
expressed at relatively high levels in triple-negative breast cancer cell lines 
(Davison, de Blacquiere et al. 2011). Hence, it was interesting to compare the 
effect of an inhibitor that targets both IGF-IR and insulin receptor with an 
antibody that targets only IGF-IR in triple-negative breast cancer cells. 
Targeting both IGF-IR and the insulin receptor was reported to be more 
effective in inhibition of growth in triple-negative breast cancer cells than 
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targeting type I IGF receptor alone (Law, Habibi et al. 2008). In 2011, Beate et 
al reported the sensitivity of triple-negative breast cancer cell lines to small dual 
tyrosine kinase inhibitor of type I IGF receptor and the insulin receptor BMS-
754807. In the same study, Beate et al demonstrated that treatment of triple-
negative tumour grafts with the anti-IGF-IR and the insulin receptor inhibits the 
growth of tumour grafts and when combined with cytotoxic agents result in 
complete tumour regression (Litzenburger, Creighton et al. 2011). In the current 
study, survival effects of IGF-1 were inhibited by BMS-754807 in triple-negative 
breast cancer cells. This was followed by complete inhibition of downstream 
PI3K and AKT pathway and noticeable reduction in activation of MAPK in these 
cell lines. This result supports the contention that dual tyrosine kinase inhibitor 
are effective in inhibition of anti-anoikis effect of IGF-1 in triple-negative breast 
cancer cells.   
Sachdev et al (2009) reported that blocking the type I IGF receptor signal 
transduction pathway increases the anoikis, as measured the trypan blue 
exclusion in a metastatic variant of MDA-MB-435 breast cancer cells (Sachdev, 
Zhang et al. 2009). Interference of the IGF-IR activity with inhibitory antibody 
CP-751,871 reduced significantly the survival effect of IGF-1 in triple-negative 
breast cancer cells but showed partial inhibition in activation of PI3K and AKT in 
Hs578T cells. Taken together, these results indicate that dual tyrosine kinase 
inhibitor is more effective in inhibition of downstream PI3K and AKT pathway in 
triple-negative breast cancer cells than type I IGF receptor inhibitor. This 
conclusion is in agreement with previous report that targeting both the type I 
IGF receptor and the insulin receptor might be more efficient in inhibition of 
growth in triple-negative breast cancer cells (Law, Habibi et al. 2008).  
In the present study, IGF-1 was required to prevent anoikis in triple-negative 
breast cancer cells and loss of IGF-1 survival signals could not compensated 
with other serum components in the culture medium. This result indicates that 
IGF-1 plays significant role in preventing anoikis in triple-negative breast cancer 
cells.   
Studies have reported the role of IGF-1 as a potent inducer of migration in 
different types of human cancer cells. In 2010, Metalli et al demonstrated the 
migratory effect of IGF-1 in head and neck cancer cells in which the IGF-1-
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induced motility effect could be inhibited through using anti-IGF-IR antibody 
(Metalli, Lovat et al. 2010). Similarly, it was reported that in pancreatic cancer, 
IGF-1 stimulated the migration of seven different pancreatic cancer cells 
(Tomizawa, Shinozaki et al. 2010). In the current in vitro study using monolayer 
wound-healing migration assay, IGF-1 induced migration of oestrogen receptor-
negative breast cancer cells, which is in agreement with the published reports 
(Bartucci, Morelli et al. 2001, de Blaquière, May et al. 2009). The migratory 
effect of IGF-1 was found to be higher in two triple-negative breast cancer cells 
compared to HER-2 positive breast cancer cells.   
Sachdev et al (2009) reported that disruption of type I IGF receptor results in 
inhibition of invasion of lung cancer cells. Other study reported the growth 
inhibitory effect of dual tyrosine kinase inhibitor on triple-negative breast 
tumourgraft (Litzenburger, Creighton et al. 2011). Migratory effect of IGF-1 was 
significantly inhibited by treatment of the cells with anti-IGF-IR inhibitor, which is 
in agreement with the previous findings (Doerr and Jones 1996, Sachdev, 
Zhang et al. 2009), but greater inhibitory effect was observed in all oestrogen 
receptor-negative breast cancer cells by treating them with the dual tyrosine 
kinase inhibitor of IGF-IR and the insulin receptor.  
In this study, the expression level of IGF-IR in series of oestrogen receptor-
negative primary breast tumours and their associated metastases was 
investigated; also association between IGF-IR expression with biomarkers of 
proliferation and survival in breast tumours was evaluated. IGF-IR expression 
was detected at high percentage of in situ and invasive breast carcinomas. 
Expression of IGF-IR was detected also in normal breast tissues. There was no 
association between expression of IGF-IR and tumour size or grade. This 
finding is in agreement with previous studies which showed that expression of 
IGF-IR is not associated with tumour size or grade in oestrogen receptor-
positive and negative breast tumours (Koda, Sulkowski et al. 2003). 
In the current study, data demonstrated that there was a correlation between 
IGF-IR expression in primary tumours with the corresponding metastatic tumour 
cells of the same patients. The expression of IGF-IR was found to be higher in 
primary tumours than the corresponding metastatic tumours, which is consistent 
with the previous findings that expression of IGF-IR was more frequent in 
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primary breast tumours than lymph node metastasis (Koda, Sulkowski et al. 
2003). Further evaluation could investigate the expression of IGF-IR in a greater 
number of oestrogen receptor-negative primary tumours and their associated 
tumour cells metastasized to the lymph nodes.   
Data from this study indicates that IGF-IR expression is important in 
proliferation of invasive breast tumour cells as an association with Ki-67 
proliferation marker was observed. These data are in agreement with a previous 
in vitro study that IGF-IR mediates the proliferation of triple-negative breast 
cancer cells (Davison, de Blacquiere et al. 2011).  
The expression of IGF-IR was associated with biomarker of survival in 
oestrogen receptor-negative tumours. In the majority of the IGF-IR positive 
tumour cells, cell death was not observed as no cleaved caspase-3 was 
detected. This result is consistent with the previous in vitro finding of this study 
regarding mediation of cell survival through IGF-IR. Although another study 
reported that activated IGF-IR and insulin receptor has a higher correlation with 
survival of breast tumours (Law, Habibi et al. 2008). Further analysis could 
attempt to evaluate the expression of phosphorylated IGF-IR and insulin 
receptor in primary and their associated metastases tumour cells and compare 
the expression of both total and activated IGF-IR in these tumour cells and their 
relationship with survival outcome.  
In the present study, the effects of EGF and heregulin-1 were examined on 
survival of oestrogen receptor-negative MDA-MB-231 and Hs578T breast 
cancer cells. EGF but not heregulin-1 demonstrated a powerful protective effect 
against anoikis in Hs578T cells. Although neither EGF nor heregulin-1 showed 
anti-anoikis effect in one of the triple-negative MDA-MB-231 breast cancer cells, 
which may because EGF does not induce autophosphorylation of EGFR and 
activation of the PI3K and AKT pathway in this cell line as demonstrated in the 
result chapter 5. 
The anti-anoikis effect of EGF is mediated through the EGFR based on the 
results discussed in chapter 5 that showed the same effect of dual tyrosine 
kinase inhibitor of EGFR and HER-2, lapatinib and an inhibitor of only EGFR, 
gefitinib on survival of HER-2 positive breast cancer cells. These observations 
confirm that the survival effect of EGF is transmitted through EGFR. Inhibition of 
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either EGFR or both EGFR and HER-2 hetero-dimers effectively reduced the 
survival effect of EGF which was followed by complete inhibition of downstream 
effectors PI3K/Akt and MAPK pathways in HER-2 positive cells.   
EGF showed a powerful migratory effect on oestrogen receptor-negative breast 
cancer cells, which is in agreement with previous published reports that EGF 
induces migration in breast cancer cells (Price, Tiganis et al. 1999, Garcia, 
Franklin et al. 2006). It has been reported that heregulin-1 induces migration 
and invasion in HER-2 positive breast cancer cells by induction of epithelial-
mesenchymal transition through activation of PI3K and AKT pathway (Cheng, 
Zha et al. 2009). In the current study, stimulation with heregulin-1 resulted in a 
significant increase in migration of SK-BR-3 cells, possibly due to formation of 
HER-2 and HER-3 heterodimers. This result is consistent with the previously 
mentioned findings that heregulin-1 induced migration and invasion of SK-BR-3 
cells (Cheng, Zha et al. 2009). Heregulin-1 did not have a significant effect on 
the motility of triple-negative breast cancer cells, even though one of them, 
MDA-MB-231 cells expresses detectable levels of HER-3. One of the 
possibilities might be due to inability of heregulin-1 in activation of MAPK 
pathway as discussed in result chapter 5.  
In vivo mouse mammary cancer model studies have been reported significant 
role of EGFR signalling inhibitors in reduction of bone and brain metastasis 
(Gril, Palmieri et al. 2008, Molli, Adam et al. 2008). In the current study, 
treatment of triple-negative breast cancer cells with anti-EGFR inhibitor resulted 
in inhibition of the migratory effect of EGF in these cell lines. Treatment of HER-
2 positive breast cancer cells with either dual tyrosine kinase inhibitor or EGFR 
inhibitor showed similar inhibitory effects on migration of these cells. 
A very recent study reported the involvement of new mechanism in lapatinib 
resistant HER-2 positive breast cancer cells, which is heregulin-mediated 
EGFR-HER-3 signalling axis and that HER-2 positive breast cancer cells are no 
longer depend on HER-2-HER-3 signalling axis (Xia, Petricoin et al. 2013). This 
group claimed that the reason for HER-2 positive breast cells to become 
resistant to lapatinib is due to incomplete inhibition of EGFR by lapatinib which 
leads to transactivation of HER-3 with EGFR, in which lapatinib is not able to 
inhibit, as HER-3 which is a cognate receptor of heregulin is up regulated in 
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lapatinib resistant HER-2 positive breast cancer cell models. Further 
experiments could attempt to investigate the effect of lapatinib in the presence 
of heregulin-1 on survival and migration of HER-2 positive SK-BR-3 cells, to 
evaluate the inhibitory effect of this inhibitor on the effect of heregulin-1. 
EGFR expression was evaluated in a series of oestrogen receptor-negative 
breast primary tumours and their associated tumour cells with involved lymph 
nodes. EGFR expression was detected in normal breast tissues and in a high 
percentage in in situ and invasive breast carcinomas. Wiseman et al (2005) 
reported the association between EGFR with tumour grade in breast tumours 
but did not find a significant association between EGFR and size of the tumour 
(Wiseman, Makretsov et al. 2005). In the present study, no association was 
found between expression of EGFR and tumour size, which is in agreement 
with the previous study. Unlike the mentioned study from the other group, no 
association between EGFR expression and tumour grade or age of the patients 
was detected.  
In 2005, Wiseman et al reported the expression of EGFR regardless of patient’s 
lymph node status (Wiseman, Makretsov et al. 2005). Similarly, in the current 
study, no significant association was found between expression of EGFR and 
number of lymph node metastasis. There was a significant correlation between 
expression of EGFR in primary tumours with the corresponding metastatic 
tumour cells of the same patients. However, primary tumour cells expressed 
EGFR at higher levels than corresponding metastatic tumour cells of the same 
patients. 
In 2010, Riwambi et al reported the high proliferative rate of EGFR expressing 
tumours compared to EGFR-negative tumours in a large cohort of oestrogen 
receptor-positive and negative malignant breast tumour cells (Rimawi, Shetty et 
al. 2010). The significant association between EGFR expression and 
expression of Ki-67 in invasive breast carcinomas that has been shown in this 
study could be explained by the ability of EGFR in promoting the proliferation of 
invasive oestrogen receptor-negative breast tumour cells. This finding agrees 
with the previous mentioned findings from other groups (Rimawi, Shetty et al. 
2010). According to the discussed findings in the in vitro part of the current 
study, EGFR mediates survival of oestrogen receptor-negative breast cancer 
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cells. Immunohistochemical data showed that high expression of EGFR is not 
associated with expression of apoptotic protein cleaved caspase-3. In the 
majority of EGFR positive tumours, cleaved caspase-3 was not detected. This 
result is in agreement with the previous finding that EGFR may be responsible 
for mediation of survival in oestrogen receptor-negative breast tumours. 
In one study a significant effect of both IGF-1 and EGF on migration of MDA-
MB-231 breast cancer cells was compared and reported the stronger migratory 
effect of IGF-1 compared to the migratory effect of EGF (Mezi, Todi et al. 2012). 
Results of the current study regarding the effect of each IGF-1 and EGF ligand 
on migration of MDA-MB-231 cell line which has already been discussed 
separately are in agreement with the findings of previous group, who observed 
that IGF-1 had more migratory effect than EGF in MDA-MB-231 cells but this 
group did not test the effect of combination of IGF-1 and EGF on migration of 
MDA-MB-231 cells. No previous study tested the effect of the combination of 
IGF-1 and EGF on the migration of oestrogen receptor-negative breast cancer 
cells. Although IGF-1 and EGF each alone stimulated significantly the migration 
of oestrogen receptor-negative breast cancer cells, the combination of both 
ligands stimulated higher migration of breast cancer cells than either mitogen 
alone. Additionally, in one of the triple-negative breast cancer cells, Hs578T 
cells, the migratory effect of the combination of IGF-1 and EGF was inhibited 
more significantly using combination of both anti-IGF-IR and anti-EGFR 
inhibitors compared to inhibitory effect of either inhibitor alone.  
Further experiment could investigate the effect of IGF-1 and EGF in 
combination on survival of oestrogen receptor-negative breast cancer cells and 
evaluate the combined effect of anti-IGF-IR and anti-EGFR inhibitors on anoikis 
to further support the importance of interaction between IGF-IR and EGFR in 
cell survival.  
A significant association was found between expression of IGF-IR and EGFR in 
invasive breast tumours. There was no significant association between 
expression of IGF-IR and HER-2 in invasive HER-2 positive breast tumours. 
However, there was a significant inverse correlation between EGFR and HER-2 
expression in both invasive and metastatic HER-2 positive breast tumours.  
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Expression of TFF1 and TFF3 has been reported in breast tumour cells and 
their expression is identified to be regulated by oestrogen (May and Westley 
1997, Ahmed, Griffiths et al. 2012). Expression of both TFF1 and TFF3 was 
investigated in oestrogen receptor-positive and negative breast cancer cell lines 
and in series of oestrogen receptor-negative breast tumours. 
TFF1 and TFF3 expression were evaluated at protein level by western transfer 
analysis. TFF3 expression was observed in two oestrogen receptor-negative 
cells which are positive for HER-2. Expression of TFF3 was not detected in 
HER-2 positive SK-BR-3 cells, which is agreed with the previous finding that 
TFF3 mRNA was not detected in SK-BR-3 cells (Wilson, Roberts et al. 2002).  
In 2012, Ahmed et al reported the expression of TFF3 in normal oestrogen 
receptor-positive breast epithelial cells (Ahmed, Griffiths et al. 2012). In the 
current study expression of TFF1 and TFF3 was not detected in normal breast 
tissues. TFF1 expression was detected at low levels in a few breast tumours but 
the majority of oestrogen receptor-negative tumours were negative for 
expression of TFF1, which agrees with the previous published reports that TFF1 
is an oestrogen-inducible gene and is expressed in oestrogen receptor-positive 
breast tumours (May and Westley 1997). Therefore, in this study investigation 
of TFF1 was not considered further. 
Interestingly, TFF3 expression was observed in weak to moderate level in in 
situ breast carcinoma and in moderate to strong level in invasive breast 
tumours. TFF3 expression was not correlated with proliferation of oestrogen 
receptor-negative breast tumours, as no association was found between TFF3 
expression and expression of proliferation marker Ki-67. TFF3 positive tumours 
expressed Ki-67 at low level, which agrees with the previous observation that 
TFF3 positive tumours express low mitotic index and act against cell division in 
malignant epithelial breast tumour (Ahmed, Griffiths et al. 2012).  Expression of 
TFF3 was reported to be higher in HER-2 positive breast tumours than other 
tumour types (Yue, Xiang et al. 2013). Data from the current study 
demonstrated the significant association between expression of TFF3 and 
expression of HER-2 in invasive breast tumours, which is agreed with a recent 
report that TFF3 expression is high in HER-2 positive breast tumours (Yue, 
Xiang et al. 2013). There was no association of TFF3 expression with 
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expression of EGFR or IGF-IR in invasive breast tumours. Followed these 
investigations, cellular localization of TFF1 and TFF3 investigated in oestrogen 
receptor-positive and negative breast cancer cell lines by immunofluorescence 
to confirm the cytoplasmic expression of these proteins as it was observed by 
immunohistochemistry.       
In conclusion, both IGF-1 and EGF have a powerful survival and migratory 
effect in oestrogen receptor-negative breast cancer cells and their receptors 
show significant association with biomarkers of survival and proliferation in 
oestrogen receptor-negative breast tumours. Combination of both IGF-1 and 
EGF mitogens stimulate migration of oestrogen receptor-negative breast cancer 
cells, which is more effective than the stimulation achieved by either mitogen 
alone. Thus the inhibition of both IGF-IR and EGFR signal transduction pathway 
would be predictive to increase the effectiveness of therapies in oestrogen 
receptor-negative particularly triple-negative breast cancers.  
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